PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 21949158-9 2012 Together, these results suggest that PKC is likely to be involved in LL absorption, and the ability of PMA/ionomycin to block the terbutaline-induced increase in J(v) suggests that the downstream target of PKC is ENaC. Terbutaline 130-141 sodium channel epithelial 1 subunit gamma Rattus norvegicus 213-217 21870426-4 2011 After silencing beta-arrestin 2 expression in CD4+ T lymphocytes from asthmatic mice by RNA interference (RNAi), the interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) levels in CD4+ T lymphocyte culture supernatants with or without terbutaline stimulation were determined. Terbutaline 236-247 arrestin, beta 2 Mus musculus 16-31 21901530-13 2011 The cells will respond to the beta-adrenergic receptor agonist terbutaline resulting in reduced TNF-alpha and increased IL-10 and IL-6 production following CEA activation. Terbutaline 63-74 tumor necrosis factor Homo sapiens 96-105 21901530-13 2011 The cells will respond to the beta-adrenergic receptor agonist terbutaline resulting in reduced TNF-alpha and increased IL-10 and IL-6 production following CEA activation. Terbutaline 63-74 interleukin 10 Homo sapiens 120-125 21901530-13 2011 The cells will respond to the beta-adrenergic receptor agonist terbutaline resulting in reduced TNF-alpha and increased IL-10 and IL-6 production following CEA activation. Terbutaline 63-74 interleukin 6 Homo sapiens 130-134 21901530-13 2011 The cells will respond to the beta-adrenergic receptor agonist terbutaline resulting in reduced TNF-alpha and increased IL-10 and IL-6 production following CEA activation. Terbutaline 63-74 CEA cell adhesion molecule 3 Homo sapiens 156-159 21874331-1 2011 This study aims to investigate the association between prenatal exposure to terbutaline and other beta2 adrenergic receptor (B2AR) agonists and autism spectrum disorders (ASDs). Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 98-123 21874331-1 2011 This study aims to investigate the association between prenatal exposure to terbutaline and other beta2 adrenergic receptor (B2AR) agonists and autism spectrum disorders (ASDs). Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 125-129 21562317-13 2011 These results indicate that prolonged alveolar hypoxia and treatment with terbutaline impaired beta2AR signaling in alveolar epithelia and in whole lungs, and this signaling was not further impaired by hypoxia. Terbutaline 74-85 adrenoceptor beta 2 Rattus norvegicus 95-102 21562317-14 2011 Despite impaired beta2AR signaling, treatment with terbutaline for 4 days prevented the inhibition of alveolar reabsorption caused by in vivo hypoxia. Terbutaline 51-62 adrenoceptor beta 2 Rattus norvegicus 17-24 21234673-7 2011 The beta(2)-AR-selective agonist terbutaline and the endogenous neurotransmitter norepinephrine decreased VEGF production by MB-231, but increased VEGF production by MB-231BR. Terbutaline 33-44 vascular endothelial growth factor A Homo sapiens 106-110 21234673-7 2011 The beta(2)-AR-selective agonist terbutaline and the endogenous neurotransmitter norepinephrine decreased VEGF production by MB-231, but increased VEGF production by MB-231BR. Terbutaline 33-44 vascular endothelial growth factor A Homo sapiens 147-151 21960094-7 2011 One patient had a significant elevation in cTnI concentration (peak level of 3.79 ng/mL) with electrocardiogram (ECG) changes of myocardial injury that normalized upon discontinuation of terbutaline. Terbutaline 187-198 troponin I3, cardiac type Homo sapiens 43-47 21752065-3 2011 Clenbuterol is lipophilic and may enter into the intracellular compartment, and because of this, it is likely that clenbuterol will have different effects to classical beta(2)-adrenoceptor agonists such as terbutaline. Terbutaline 206-217 adrenoceptor beta 2 Rattus norvegicus 168-188 21870426-7 2011 beta-arrestin 2 RNAi decreased IL-4 (43.16%) and GATA3 (protein 77.21%, mRNA 62.98%) expression after terbutaline stimulation. Terbutaline 102-113 arrestin, beta 2 Mus musculus 0-15 21870426-7 2011 beta-arrestin 2 RNAi decreased IL-4 (43.16%) and GATA3 (protein 77.21%, mRNA 62.98%) expression after terbutaline stimulation. Terbutaline 102-113 interleukin 4 Mus musculus 31-35 21870426-7 2011 beta-arrestin 2 RNAi decreased IL-4 (43.16%) and GATA3 (protein 77.21%, mRNA 62.98%) expression after terbutaline stimulation. Terbutaline 102-113 GATA binding protein 3 Mus musculus 49-54 21870426-8 2011 Cell-surface beta2AR of CD4+ T lymphocytes decreased (15.27%) after terbutaline treatment, but recovered after beta-arrestin 2 RNAi down-modulation. Terbutaline 68-79 adrenergic receptor, beta 2 Mus musculus 13-20 21870426-8 2011 Cell-surface beta2AR of CD4+ T lymphocytes decreased (15.27%) after terbutaline treatment, but recovered after beta-arrestin 2 RNAi down-modulation. Terbutaline 68-79 CD4 antigen Mus musculus 24-27 21352833-8 2011 Our data show that a chronic treatment with the beta(2)-AR agonist terbutaline at low antiallodynic dose does not affect cardiovascular parameters, whereas the mixed beta(1)/beta(2)-AR agonist isoproterenol induces cardiac hypertrophy. Terbutaline 67-78 adrenergic receptor, beta 2 Mus musculus 48-58 21329664-8 2011 Exposing Panc-1 cells to the beta2 adrenergic receptor agonist, terbutaline, increased the miR-132 and miR-212 expression by 2- to 4-fold. Terbutaline 64-75 adrenoceptor beta 2 Homo sapiens 29-54 21602169-1 2011 Bet 1: The effectiveness of oral terbutaline in treatment of priapism. Terbutaline 33-44 Bet1 golgi vesicular membrane trafficking protein Homo sapiens 0-5 21329664-8 2011 Exposing Panc-1 cells to the beta2 adrenergic receptor agonist, terbutaline, increased the miR-132 and miR-212 expression by 2- to 4-fold. Terbutaline 64-75 microRNA 132 Homo sapiens 91-98 21329664-8 2011 Exposing Panc-1 cells to the beta2 adrenergic receptor agonist, terbutaline, increased the miR-132 and miR-212 expression by 2- to 4-fold. Terbutaline 64-75 microRNA 212 Homo sapiens 103-110 21361697-7 2011 Analysis of the trajectory lengths revealed two different binding durations with tau(1) = 77 +- 1 ms and tau(2) = 388 +- 11 ms. Agonistic stimulation of the beta(2)AR-Alexa-NA complexes with 1 muM terbutaline caused immobilization of almost 50% of the receptors within 35 min. Terbutaline 197-208 adrenoceptor beta 2 Homo sapiens 157-166 21385652-0 2011 Polymorphisms of the beta2-adrenergic receptor correlated to nocturnal asthma and the response of terbutaline nebulizer. Terbutaline 98-109 adrenoceptor beta 2 Homo sapiens 21-46 20674738-5 2011 Treatment with TERB induced a dose-dependent inhibition of cellular CaN activity, along with a reduction in IL-2 and IFN-gamma production, and T cell proliferation. Terbutaline 15-19 interleukin 2 Rattus norvegicus 108-112 21385652-6 2011 RESULTS: The polymorphisms of beta(2)-AR 27 but not 16 or 164 were significantly associated with the response to terbutaline nebulizer (p<0.05). Terbutaline 113-124 adrenoceptor beta 2 Homo sapiens 30-40 21385652-11 2011 CONCLUSION: These findings suggest that polymorphisms of beta(2)-AR 16 are related to nocturnal asthma and polymorphisms of beta(2)-AR 27 are associated with the variable responses to the inhaled terbutaline in children with nocturnal and nonnocturnal asthma. Terbutaline 196-207 adrenoceptor beta 2 Homo sapiens 57-67 21385652-11 2011 CONCLUSION: These findings suggest that polymorphisms of beta(2)-AR 16 are related to nocturnal asthma and polymorphisms of beta(2)-AR 27 are associated with the variable responses to the inhaled terbutaline in children with nocturnal and nonnocturnal asthma. Terbutaline 196-207 adrenoceptor beta 2 Homo sapiens 124-134 20674738-5 2011 Treatment with TERB induced a dose-dependent inhibition of cellular CaN activity, along with a reduction in IL-2 and IFN-gamma production, and T cell proliferation. Terbutaline 15-19 interferon gamma Rattus norvegicus 117-126 20674738-9 2011 Disruption of the interaction between PKA and A-kinase anchoring protein (AKAP) by the inhibitor peptide St-Ht31 fully blocked TERB-induced CaN inhibition, demonstrating that PKA-AKAP interaction is essential for the beta2-AR-mediated CaN inhibition. Terbutaline 127-131 A-kinase anchoring protein 11 Rattus norvegicus 46-72 20674738-9 2011 Disruption of the interaction between PKA and A-kinase anchoring protein (AKAP) by the inhibitor peptide St-Ht31 fully blocked TERB-induced CaN inhibition, demonstrating that PKA-AKAP interaction is essential for the beta2-AR-mediated CaN inhibition. Terbutaline 127-131 A-kinase anchoring protein 11 Rattus norvegicus 74-78 20674738-9 2011 Disruption of the interaction between PKA and A-kinase anchoring protein (AKAP) by the inhibitor peptide St-Ht31 fully blocked TERB-induced CaN inhibition, demonstrating that PKA-AKAP interaction is essential for the beta2-AR-mediated CaN inhibition. Terbutaline 127-131 A-kinase anchoring protein 11 Rattus norvegicus 179-183 20837485-6 2010 A similar partial beta(2)AR activation signal was revealed for the synthetic agonists fenoterol and terbutaline. Terbutaline 100-111 adrenoceptor beta 2 Homo sapiens 18-27 19965982-11 2010 Terbutaline insensitivity was also reversed by postinfection nebulization with neutralizing anti-KC or anti-CXCR2 antibodies and could be replicated in normal, uninfected mice by nebulization with recombinant KC. Terbutaline 0-11 chemokine (C-X-C motif) receptor 2 Mus musculus 108-113 20221745-9 2010 Terbutaline significantly (1) prevented delayed hypotension and reduced hepatic and renal dysfunction, (2) diminished plasma IL-1beta and nitrite/nitrate, lung iNOS expression, tissue O(2) (-) level and the infiltration of neutrophils in the lung and the liver, and (3) improved the 18-h survival rate. Terbutaline 0-11 interleukin 1 beta Rattus norvegicus 125-133 20221745-9 2010 Terbutaline significantly (1) prevented delayed hypotension and reduced hepatic and renal dysfunction, (2) diminished plasma IL-1beta and nitrite/nitrate, lung iNOS expression, tissue O(2) (-) level and the infiltration of neutrophils in the lung and the liver, and (3) improved the 18-h survival rate. Terbutaline 0-11 nitric oxide synthase 2 Rattus norvegicus 160-164 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 101-112 adrenoceptor beta 2 Homo sapiens 30-35 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 101-112 adrenoceptor beta 2 Homo sapiens 87-92 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 114-118 adrenoceptor beta 2 Homo sapiens 30-35 20519311-3 2010 We tested the hypothesis that ADRB2 gene variation would influence the SVR response to ADRB2 agonist terbutaline (Terb) during ganglionic blockade. Terbutaline 114-118 adrenoceptor beta 2 Homo sapiens 87-92 20523006-5 2010 From roughly quantitative stereoselective glucuronidation study of racemic beta-blocker analogues by UGT1A9, propranolol had a high ratio of the ratios of S- to R-isomer glucuronide (S-G/R-G), about 4.3, the ratios of terbutaline, atenolol and esomolol were 3.3, 3.1 and 2.8 respectively, sotalol and propafenone were 2.3 and 2.0. Terbutaline 218-229 testis expressed 101 Homo sapiens 183-190 20012638-1 2010 Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 77-97 20012638-1 2010 Terbutaline (Bricanyl) and its prodrug Bambuterol (Bambec) are highly potent beta(2)-adrenoceptor agonists often used in asthma patients. Terbutaline 13-21 adrenoceptor beta 2 Homo sapiens 77-97 20501369-8 2010 Terbutaline increases the absorption of alveolar fluid primarily by increasing sodium transport of ENaC and CNG on ATI and AT II cells. Terbutaline 0-11 sodium channel epithelial 1 subunit gamma Rattus norvegicus 99-103 20054151-11 2010 24h treatment with terbutaline increased the capacity of Na(+)/K(+)-ATPase and ENaC as measured after permeabilization with amphotericin. Terbutaline 19-30 sodium channel epithelial 1 subunit gamma Rattus norvegicus 79-83 20233198-0 2010 The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma. Terbutaline 14-25 insulin Homo sapiens 70-77 20233198-4 2010 RESULTS: Prior administration of terbutaline led to a 44% increase in absorption of insulin over 6 h for the Rev+ group compared with no prior administration of bronchodilator [ratio (95% confidence interval) 1.44 (1.13, 1.82), P= 0.004], whereas no effect was seen for the Rev- or the whole group. Terbutaline 33-44 insulin Homo sapiens 84-91 19857486-7 2010 beta(2)-adrenoceptor agonists, salbutanol and terbutaline inhibited AGE-2- and AGE-3-induced adhesion expression and cytokine production, but alpha(1)-, alpha(2)- and beta(1)-adrenoceptor agonist had no effect, indicating that the stimulation of beta(2)-adrenoceptor might improve AGEs-initiated complications in diabetes. Terbutaline 46-57 adrenoceptor beta 2 Homo sapiens 246-266 19684287-5 2009 Two antagonists (propranolol, alprenolol) and 2 agonists (metaproterenol, terbutaline) for beta(2)AR were investigated in a displacement assay using europium(III)-labeled pindolol ligand. Terbutaline 74-85 adrenoceptor beta 2 Homo sapiens 91-100 20355173-1 2009 Terbutaline is a fast-acting beta(2)-adrenergic agonist used in the treatment of obstructive pulmonary diseases. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-35 19525101-8 2009 Interestingly, aminophylline and terbutaline could not only down-regulate the ingestion of apoptotic eosinophils by A549 cells in a time- and dose-dependent manner, but also decrease IL-6 and IL-8 secretion by A549 cells induced by LPS. Terbutaline 33-44 interleukin 6 Homo sapiens 183-187 19525101-8 2009 Interestingly, aminophylline and terbutaline could not only down-regulate the ingestion of apoptotic eosinophils by A549 cells in a time- and dose-dependent manner, but also decrease IL-6 and IL-8 secretion by A549 cells induced by LPS. Terbutaline 33-44 C-X-C motif chemokine ligand 8 Homo sapiens 192-196 19525101-9 2009 CONCLUSIONS: The present study showed that all of the investigated anti-asthmatic drugs including dexamethasone, aminophylline and terbutaline play an anti-inflammatory effect by decreasing the release of IL-6 and IL-8 induced by LPS. Terbutaline 131-142 interleukin 6 Homo sapiens 205-209 19525101-9 2009 CONCLUSIONS: The present study showed that all of the investigated anti-asthmatic drugs including dexamethasone, aminophylline and terbutaline play an anti-inflammatory effect by decreasing the release of IL-6 and IL-8 induced by LPS. Terbutaline 131-142 C-X-C motif chemokine ligand 8 Homo sapiens 214-218 19429833-7 2009 Propranolol (1 microM) inhibited the rise in NO induced by isoproterenol or the beta(2)-adrenoceptor agonists salbutamol, terbutaline, or fenoterol. Terbutaline 122-133 adrenoceptor beta 2 Rattus norvegicus 80-100 19462961-1 2009 Phenolic beta(2)-adrenoreceptor agonists salbutamol, fenoterol, and terbutaline relax smooth muscle cells that relieve acute airway bronchospasm associated with asthma. Terbutaline 68-79 adrenoceptor beta 2 Homo sapiens 9-31 19460695-0 2009 [Role of epithelial sodium channel alpha subunit in terbutaline-induced transient enhancement of pulmonary edema clearance in adult rats with acute lung injury]. Terbutaline 52-63 sodium channel epithelial 1 subunit alpha Rattus norvegicus 9-48 19460695-1 2009 OBJECTIVE: To explore the association of epithelial sodium channel alpha subunit (alphaENaC) with terbutaline-induced transient enhancement of pulmonary edema clearance in adult rats with acute lung injury (ALI). Terbutaline 98-109 sodium channel epithelial 1 subunit alpha Rattus norvegicus 41-80 18952242-1 2009 The objective of this study was to assess the short-term efficacy and safety of terbutaline, a beta2-adrenergic agonist, in patients with myasthenia gravis (MG) in a randomized, double-blind, placebo-controlled, crossover study. Terbutaline 80-91 AA2 Homo sapiens 93-100 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 interleukin 2 Homo sapiens 99-103 18814973-11 2008 Importantly, administration of the beta-2 adrenergic receptor agonist terbutaline also caused social withdrawal while administration of the beta-2 adrenergic receptor antagonist butoxamine blocked NE-induced social withdrawal. Terbutaline 70-81 adrenergic receptor, beta 2 Mus musculus 35-61 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 CD4 molecule Homo sapiens 142-145 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 CD4 molecule Homo sapiens 160-163 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 CD8a molecule Homo sapiens 164-167 18761816-5 2008 The results showed that additional inhalation of budesonide and terbutaline could upregulate serum IL-2 levels, the percentages of CD3+ T and CD4+ T cells, and CD4/CD8 ratio, and decrease eosinophils and serum CRP level more efficiently than conventional treatment in patients with AECOPD. Terbutaline 64-75 C-reactive protein Homo sapiens 210-213 17986640-12 2008 The beta2-agonist, terbutaline, caused a marked concentration-dependent increase of muscle lactate and blood flow (P < 0.0001). Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 18097649-12 2008 Terbutaline in the instilled solution and PEEP lessened alveolar 99mTc-albumin leakage and pulmonary 111In-transferrin uptake due to high-volume ventilation, whereas terbutaline given intra-peritoneally only lessened 111In-transferrin uptake. Terbutaline 0-11 transferrin Rattus norvegicus 107-118 18097649-12 2008 Terbutaline in the instilled solution and PEEP lessened alveolar 99mTc-albumin leakage and pulmonary 111In-transferrin uptake due to high-volume ventilation, whereas terbutaline given intra-peritoneally only lessened 111In-transferrin uptake. Terbutaline 0-11 transferrin Rattus norvegicus 223-234 18024719-7 2008 The beta2-agonist terbutaline significantly increased AFC in WT but not in m/m mice. Terbutaline 18-29 hemoglobin, beta adult minor chain Mus musculus 4-9 18396760-0 2007 [The influence of terbutaline on VEGF gene expression in rat astrocytes after norepinephrine and burn serum induction]. Terbutaline 18-29 vascular endothelial growth factor A Rattus norvegicus 33-37 18389792-5 2007 On the other hand, on sensitized rat after antigen challenge, theophylline pretreatment reduced Ang II inhibition of terbutaline--induced relaxation of bronchial rings precontracted with ACh, increasing both EC50 and E(max) of terbutaline effects with 22.04 +/- 3.48% and 19.48 +/- 1.67%, respectively. Terbutaline 117-128 angiotensinogen Rattus norvegicus 96-102 18389792-5 2007 On the other hand, on sensitized rat after antigen challenge, theophylline pretreatment reduced Ang II inhibition of terbutaline--induced relaxation of bronchial rings precontracted with ACh, increasing both EC50 and E(max) of terbutaline effects with 22.04 +/- 3.48% and 19.48 +/- 1.67%, respectively. Terbutaline 227-238 angiotensinogen Rattus norvegicus 96-102 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Terbutaline 72-83 vascular endothelial growth factor A Rattus norvegicus 106-140 18396760-1 2007 OBJECTIVE: To investigate the influence of adrenoreceptor beta-agonists terbutaline on gene expression of vascular endothelial growth factor (VEGF) in rat astrocyte after induction by norepinephrine (NE) and burn serum. Terbutaline 72-83 vascular endothelial growth factor A Rattus norvegicus 142-146 18396760-10 2007 CONCLUSION: Terbutaline can increase gene expression of VEGF in rat astrocytes after induction by NE and burn serum. Terbutaline 12-23 vascular endothelial growth factor A Rattus norvegicus 56-60 16603198-8 2006 RESULTS: Terbutaline significantly improved twitch characteristics and force-frequency relationship of the diaphragm in the CLP group (P<0.01). Terbutaline 9-20 coactosin-like F-actin binding protein 1 Rattus norvegicus 124-127 17177114-8 2007 For the Bricanyl Turbohaler, increasing FIR from 120 to 600 l min(-1) s(-1) for a constant peak flow rate (PFR) of 60 l min(-1) increased the mean Terbutaline FPF from 18.2% to 45.5%. Terbutaline 147-158 CD59 molecule (CD59 blood group) Homo sapiens 62-68 17177114-8 2007 For the Bricanyl Turbohaler, increasing FIR from 120 to 600 l min(-1) s(-1) for a constant peak flow rate (PFR) of 60 l min(-1) increased the mean Terbutaline FPF from 18.2% to 45.5%. Terbutaline 147-158 CD59 molecule (CD59 blood group) Homo sapiens 120-126 16603198-10 2006 However, incubation with ryanodine completely abolished the inotropic effect of terbutaline in the CLP group. Terbutaline 80-91 coactosin-like F-actin binding protein 1 Rattus norvegicus 99-102 17569809-4 2007 METHODS: Among 55 subjects, cardiac contractile response to the beta2-adrenergic receptor agonist terbutaline was assessed from the peak myocardial velocity of systolic shortening (Sm) in 18 subjects with the Ile-164 variant and 37 matched controls. Terbutaline 98-109 adrenoceptor beta 2 Homo sapiens 64-89 17400887-3 2007 Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 15-33 17112600-3 2007 METHODS: We analyzed the in vitro effects of the beta-adrenergic agonist terbutaline and the glucocorticoid agonist dexamethasone on TNF-alpha and IL-10 production by LPS-stimulated monocytes in whole cell blood cultures in patients with inflammatory bowel diseases in remission (N=10), diarrhoea-predominant irritable bowel syndrome (IBS, N=12), patients with a recent gastroenteritis (post-infectious group, N=10), and healthy controls (N=15). Terbutaline 73-84 tumor necrosis factor Homo sapiens 133-142 17112600-3 2007 METHODS: We analyzed the in vitro effects of the beta-adrenergic agonist terbutaline and the glucocorticoid agonist dexamethasone on TNF-alpha and IL-10 production by LPS-stimulated monocytes in whole cell blood cultures in patients with inflammatory bowel diseases in remission (N=10), diarrhoea-predominant irritable bowel syndrome (IBS, N=12), patients with a recent gastroenteritis (post-infectious group, N=10), and healthy controls (N=15). Terbutaline 73-84 interleukin 10 Homo sapiens 147-152 17112600-4 2007 RESULTS: In response to terbutaline, there was a significant increase in IL-10 production (concentration effect: p<0.05), which was diminished in IBD (group effect: p<0.01), comparable in IBS and controls, but enhanced in the post-infectious group (group x concentration effect: p<0.05). Terbutaline 24-35 interleukin 10 Homo sapiens 73-78 17112600-5 2007 In contrast, terbutaline resulted in a concentration-dependent suppression of TNF-alpha production, which was comparable in all groups. Terbutaline 13-24 tumor necrosis factor Homo sapiens 78-87 17211154-2 2007 The renal functional responses to the systemic injection of the beta2-AR agonist terbutaline in Wistar rats over-expressing renal beta2-AR were compared with those of nontreated rats. Terbutaline 81-92 adrenoceptor beta 2 Homo sapiens 64-72 17211154-2 2007 The renal functional responses to the systemic injection of the beta2-AR agonist terbutaline in Wistar rats over-expressing renal beta2-AR were compared with those of nontreated rats. Terbutaline 81-92 adrenoceptor beta 2 Homo sapiens 130-138 17211154-4 2007 The animal study showed that the suppression of glomerular function by terbutaline was associated with a reduction in systemic blood pressure and over-expression of renal beta2-ARs. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 171-176 17211154-5 2007 Moreover, in rats over-expressing renal beta2-ARs, administration of terbutaline resulted in a high mortality rate after a lipopolysaccharide challenge. Terbutaline 69-80 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 40-45 17127497-0 2006 Terbutaline inhibits corticotropin-releasing hormone (CRH) expression in human trophoblast cells. Terbutaline 0-11 corticotropin releasing hormone Homo sapiens 21-52 17127497-0 2006 Terbutaline inhibits corticotropin-releasing hormone (CRH) expression in human trophoblast cells. Terbutaline 0-11 corticotropin releasing hormone Homo sapiens 54-57 17127497-5 2006 RESULTS: Exposure of the trophoblasts to terbutaline (10(-8) M) inhibited the expression of the CRH gene as depicted by Northern blot analysis. Terbutaline 41-52 corticotropin releasing hormone Homo sapiens 96-99 17127497-7 2006 CONCLUSION: The beta-adrenergic agonist terbutaline inhibits the expression of CRH in human trophoblasts. Terbutaline 40-51 corticotropin releasing hormone Homo sapiens 79-82 17375502-8 2006 A week following cessation of the dexamethasone and terbutaline, her insulin requirements dramatically decreased. Terbutaline 52-63 insulin Homo sapiens 69-76 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Terbutaline 188-199 insulin Homo sapiens 54-61 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Terbutaline 188-199 insulin Homo sapiens 146-153 17375502-9 2006 We conclude that in pregnant patients with underlying insulin resistance and strong family history of diabetes, the use of agents that antagonize insulin action, such as dexamethasone and terbutaline, can result in massive insulin resistance. Terbutaline 188-199 insulin Homo sapiens 146-153 16648137-4 2006 Broxaterol and terbutaline are agonists at beta(2)- and beta(3)-receptors; however, they act as antagonists at the beta(1)-subtype. Terbutaline 15-26 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 43-51 16546120-4 2006 Ambroxol of 100 microM diminished the terbutaline (a beta2-adrenergic agonist)-stimulated Cl-/HCO3(-)-dependent secretion without any decreases in the conductance of cystic fibrosis transmembrane conductance regulator (CFTR) channel locating on the apical membrane. Terbutaline 38-49 CF transmembrane conductance regulator Homo sapiens 219-223 16051698-8 2005 Both salbutamol and terbutaline behaved as partial agonists of beta-gal complementation. Terbutaline 20-31 galactosidase, beta 1 Mus musculus 63-71 16448568-8 2006 Our data support the existence of differences between these six genotypes both in the shape of the dose response relationship of the beta2-adrenoceptor agonist fenoterol as well as in the propensity to develop tolerance for these effects by pre-treatment with terbutaline. Terbutaline 260-271 adrenoceptor beta 2 Homo sapiens 133-151 15998544-3 2005 The selective beta2-AR agonists salbutamol and terbutaline induced a similar inhibitory pattern of IL-18 and IL-12 production. Terbutaline 47-58 adrenoceptor beta 2 Homo sapiens 14-22 15998544-3 2005 The selective beta2-AR agonists salbutamol and terbutaline induced a similar inhibitory pattern of IL-18 and IL-12 production. Terbutaline 47-58 interleukin 18 Homo sapiens 99-104 15536076-3 2005 When AQP5-expressing mouse lung epithelial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 response was observed. Terbutaline 103-114 aquaporin 5 Mus musculus 5-9 16417856-7 2005 Prenatal overstimulation of the beta2-adrenergic receptor by terbutaline or by increased signaling of genetic polymorphisms of the beta2-adrenergic receptor that have diminished desensitization can affect cellular responses and developmental programs in the fetal brain, leading to autism. Terbutaline 61-72 adrenoceptor beta 2 Homo sapiens 32-57 16024912-5 2005 The Met/Met genotype was associated with a marked increase of 1.5 log units in the lipolytic sensitivity to the beta2-adrenoceptor agonist terbutaline (P=0.0008) as compared with the Thr/Thr and Thr/Met genotypes. Terbutaline 139-150 adrenoceptor beta 2 Homo sapiens 112-130 16153394-9 2005 Long-term terbutaline treatment desensitizes venous beta2-AR in a haplotype-dependent manner, with haplotype A (Arg16Gln27Thr164) showing greater desensitization than haplotype B (Gly16Gln27Thr164), which shows greater desensitization than haplotype C (Gly16Glu27Thr164). Terbutaline 10-21 adrenoceptor beta 2 Homo sapiens 52-60 15681398-4 2005 In vitro experiments showed that inhibition of endogenous serine proteases by apical aprotinin 1) decreased ENaC-mediated currents in primary cultures of rat and mouse alveolar epithelial cells without affecting the abundance nor the electrophoretic migration pattern of biotinylated alpha- and beta-ENaC expressed at the cell surface and 2) suppressed the increase in amiloride-sensitive short-circuit current induced by the beta2-agonist terbutaline. Terbutaline 440-451 sodium channel epithelial 1 subunit gamma Rattus norvegicus 108-112 15798957-0 2005 Influence of sex and beta2 adrenergic receptor haplotype on resting and terbutaline-stimulated whole body lipolysis. Terbutaline 72-83 adrenoceptor beta 2 Homo sapiens 21-46 15536076-3 2005 When AQP5-expressing mouse lung epithelial cells were treated with cAMP or the beta-adrenergic agonist terbutaline, a biphasic AQP5 response was observed. Terbutaline 103-114 aquaporin 5 Mus musculus 127-131 15536076-7 2005 The beta-adrenergic agonist terbutaline produced changes in AQP5 abundance in mouse trachea and lung, consistent with our findings in cultured epithelial cells. Terbutaline 28-39 aquaporin 5 Mus musculus 60-64 15655528-6 2005 Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively. Terbutaline 148-159 adrenoceptor beta 2 Homo sapiens 6-24 15655528-6 2005 Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively. Terbutaline 148-159 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 6-11 15494187-6 2004 The NGF increase was suppressed by treatment of rats with the selective tachykinin NK1 receptor antagonist SR140333 (0.1 mg/kg), and by the beta adrenergic agonist terbutaline (0.3 mg/kg). Terbutaline 164-175 nerve growth factor Rattus norvegicus 4-7 15715182-4 2005 Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action. Terbutaline 78-89 adrenoceptor beta 2 Homo sapiens 12-30 15715182-4 2005 Traditional beta2-adrenoceptor agonists (beta2-agonists), such as salbutamol, terbutaline and fenoterol, were characterised by a rapid onset but relatively short duration of action. Terbutaline 78-89 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 12-17 15645294-6 2005 The aim of this study was to detect the effects of the beta(2)-AR agonist terbutaline on nonpregnant and late-pregnant (day 18, 20, 21 or 22) cervices isolated from Sprague-Dawley rats. Terbutaline 74-85 adrenoceptor beta 2 Rattus norvegicus 55-65 15494187-8 2004 Terbutaline also inhibited the increase in NGF caused by intraplantar injection of the NK1 receptor agonist substance P (SP), but did not significantly affect that caused by carrageenan. Terbutaline 0-11 nerve growth factor Rattus norvegicus 43-46 15494187-8 2004 Terbutaline also inhibited the increase in NGF caused by intraplantar injection of the NK1 receptor agonist substance P (SP), but did not significantly affect that caused by carrageenan. Terbutaline 0-11 tachykinin receptor 1 Rattus norvegicus 87-99 15311061-4 2004 All beta2-adrenoceptor agonists tested (salbutamol, procaterol and terbutaline) attenuated the KCl induced contraction. Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 4-22 15373934-5 2004 RESULTS: Formoterol and terbutaline had significant beta2-adrenergic effects on most outcomes. Terbutaline 24-35 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 52-57 15458278-3 2004 The selective beta2-AR agonists salbutamol and terbutaline induced a similar co-stimulatory molecule expression pattern. Terbutaline 47-58 adrenoceptor beta 2 Homo sapiens 14-22 15449725-0 2004 Interaction of human butyrylcholinesterase variants with bambuterol and terbutaline. Terbutaline 72-83 butyrylcholinesterase Homo sapiens 21-42 15229461-0 2004 Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes. Terbutaline 34-45 adrenoceptor beta 2 Homo sapiens 49-74 15229461-1 2004 OBJECTIVE: Our objective was to determine whether beta(2)-adrenergic receptor polymorphisms influence terbutaline-stimulated changes in glucose, insulin, and potassium concentrations in healthy adults. Terbutaline 102-113 insulin Homo sapiens 145-152 15201362-5 2004 Infusion of the beta(2) agonist terbutaline was used to decrease plasma (and interstitial) K(+). Terbutaline 32-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 16-22 15159029-6 2004 Peak up-regulation occurred after 30 min with a decline at 1 h. We examined the effects of the specific beta2-adrenergic receptor agonist terbutaline on cytokine production by CEA stimulated rat Kupffer cells. Terbutaline 138-149 adrenoceptor beta 2 Rattus norvegicus 104-129 15159029-6 2004 Peak up-regulation occurred after 30 min with a decline at 1 h. We examined the effects of the specific beta2-adrenergic receptor agonist terbutaline on cytokine production by CEA stimulated rat Kupffer cells. Terbutaline 138-149 carcinoembryonic antigen gene family 4 Rattus norvegicus 176-179 15159029-7 2004 Pre-treatment of Kupffer cells with terbutaline followed by CEA caused a significant increase in IL-6 and IL-10 production, but a significant reduction in TNF-alpha production (>3 fold). Terbutaline 36-47 interleukin 6 Rattus norvegicus 97-101 15159029-7 2004 Pre-treatment of Kupffer cells with terbutaline followed by CEA caused a significant increase in IL-6 and IL-10 production, but a significant reduction in TNF-alpha production (>3 fold). Terbutaline 36-47 interleukin 10 Rattus norvegicus 106-111 15159029-7 2004 Pre-treatment of Kupffer cells with terbutaline followed by CEA caused a significant increase in IL-6 and IL-10 production, but a significant reduction in TNF-alpha production (>3 fold). Terbutaline 36-47 tumor necrosis factor Rattus norvegicus 155-164 15159029-12 2004 Control of TNF-alpha production is negatively affected by terbutaline, while that of IL-6 and IL-10 is positively controlled suggesting that very different beta-adrenergic receptor signaling pathways are involved. Terbutaline 58-69 tumor necrosis factor Rattus norvegicus 11-20 15145612-3 2004 The selective beta 2-AR agonists, salbutamol and terbutaline, induced a similar pattern of cytokine production, indicating that the effect of these AR agonists on cytokine production was through beta 2-AR stimulation. Terbutaline 49-60 adrenoceptor beta 2 Homo sapiens 14-23 15145612-3 2004 The selective beta 2-AR agonists, salbutamol and terbutaline, induced a similar pattern of cytokine production, indicating that the effect of these AR agonists on cytokine production was through beta 2-AR stimulation. Terbutaline 49-60 adrenoceptor beta 2 Homo sapiens 195-204 15145612-5 2004 While endogenous IL-18 produced by salbutamol and terbutaline reached a sufficient concentration to induce IL-12 production, these beta 2-AR agonists did not induce the production of IL-12 at all. Terbutaline 50-61 interleukin 18 Homo sapiens 17-22 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 17-22 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 14982976-9 2004 Terbutaline is a beta2-adrenergic agonist that may mediate its effects via direct beta2-receptor stimulation, baroreceptor-mediated increases in sympathetic tone, or via presynaptic beta2-stimulation. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 15449725-3 2004 Both bambuterol and terbutaline inhibit BChE, but their affinities differ in human serum BChE variants (U, A, F, K and S) due to their positive charge. Terbutaline 20-31 butyrylcholinesterase Homo sapiens 40-44 15449725-5 2004 Terbutaline showed competitive reversible inhibition for all BChE variants. Terbutaline 0-11 butyrylcholinesterase Homo sapiens 61-65 15449725-9 2004 The affinity of all studied BChE variants for terbutaline was low, which suggests that terbutaline originating from bambuterol hydrolysis should not affect the hydrolysis of bambuterol by BChE. Terbutaline 46-57 butyrylcholinesterase Homo sapiens 28-32 15449725-9 2004 The affinity of all studied BChE variants for terbutaline was low, which suggests that terbutaline originating from bambuterol hydrolysis should not affect the hydrolysis of bambuterol by BChE. Terbutaline 87-98 butyrylcholinesterase Homo sapiens 28-32 14998686-9 2004 Indices of cholinergic synaptic activity [hemicholinium-3 and m(2)-muscarinic acetylcholine receptor binding] showed impairment after exposure to either terbutaline or CPF but the effects were more severe when the treatments were combined. Terbutaline 153-164 cholinergic receptor, muscarinic 2 Rattus norvegicus 62-100 14565945-3 2004 Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin. Terbutaline 87-98 surfactant associated protein B Mus musculus 34-59 14565945-3 2004 Secretion of phosphatidylcholine, surfactant protein (SP)-B and SP-C was stimulated by terbutaline, 5"-N-ethylcarboxyamidoadenosine (NECA), ATP, UTP, TPA, and ionomycin. Terbutaline 87-98 sparse coat Mus musculus 64-68 14565945-6 2004 Secretion of SP-B and SP-C was increased sevenfold by terbutaline and threefold by ATP, effects similar to those in rat type II cells. Terbutaline 54-65 surfactant protein B Rattus norvegicus 13-17 14565945-6 2004 Secretion of SP-B and SP-C was increased sevenfold by terbutaline and threefold by ATP, effects similar to those in rat type II cells. Terbutaline 54-65 surfactant protein C Rattus norvegicus 22-26 14565945-7 2004 The response to terbutaline was significantly decreased in type II cells from beta(2)-adrenergic receptor null mice. Terbutaline 16-27 adrenergic receptor, beta 2 Mus musculus 78-105 14709345-1 2004 Terbutaline, a selective beta(2)-adrenoceptor (beta(2)AR) agonist, is widely used as a tocolytic to arrest preterm labor but recent studies indicate that excessive betaAR stimulation can alter the expression and function of other neurotransmitter receptors that are essential to fetal/neonatal development. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 25-45 14610225-1 2004 Beta(2)-adrenoceptor agonists, especially terbutaline, are widely used to arrest preterm labor, but they also cross the placenta to stimulate fetal beta-adrenoceptors that control neural cell differentiation. Terbutaline 42-53 adrenoceptor beta 2 Homo sapiens 0-20 14610225-3 2004 Terbutaline administered on postnatal days PN2 to 5 elicited neurochemical changes indicative of neuronal injury and reactive gliosis: immediate increases in glial fibrillary acidic protein and subsequent induction of the 68-kDa neurofilament protein. Terbutaline 0-11 amyloid beta precursor protein Homo sapiens 43-46 14610225-5 2004 In the cerebellum, PN2 to 5 terbutaline treatment reduced the number of Purkinje cells and elicited thinning of the granular and molecular layers. Terbutaline 28-39 amyloid beta precursor protein Homo sapiens 19-22 14709345-1 2004 Terbutaline, a selective beta(2)-adrenoceptor (beta(2)AR) agonist, is widely used as a tocolytic to arrest preterm labor but recent studies indicate that excessive betaAR stimulation can alter the expression and function of other neurotransmitter receptors that are essential to fetal/neonatal development. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 47-56 14607276-7 2004 Western blot analysis using anti-actin and anti-annexin II antibodies showed a transient increase of G-actin and annexin II in the Triton X-100 soluble fraction of terbutaline-stimulated type II cells. Terbutaline 164-175 annexin A2 Homo sapiens 48-58 14607276-7 2004 Western blot analysis using anti-actin and anti-annexin II antibodies showed a transient increase of G-actin and annexin II in the Triton X-100 soluble fraction of terbutaline-stimulated type II cells. Terbutaline 164-175 annexin A2 Homo sapiens 113-123 14745978-1 2003 BACKGROUND: Beta(2)-Adrenoceptor (betaAR) agonists, such as terbutaline, are widely used to arrest preterm labor. Terbutaline 60-71 adrenoceptor beta 2 Homo sapiens 12-32 14745978-1 2003 BACKGROUND: Beta(2)-Adrenoceptor (betaAR) agonists, such as terbutaline, are widely used to arrest preterm labor. Terbutaline 60-71 adrenoceptor beta 2 Homo sapiens 34-40 12759717-4 2003 Atropine enhanced HR-increasing effects of all three beta-AR agonists and exercise; increases were larger for beta2-AR (terbutaline, adrenaline) mediated effects than for beta1-AR (exercise) mediated effects. Terbutaline 120-131 adrenoceptor beta 2 Homo sapiens 110-118 12869379-4 2003 Compared with WT beta2AR subjects, Thr164Ile subjects exhibited a blunted terbutaline-induced maximum increase in HR (WT 32 +/- 4 beats/min, Thr164Ile 19 +/- 3 beats/min, P < 0.05) and contractility (WT -54 +/- 2 ms, Thr164Ile -37 +/- 6 ms, P < 0.05). Terbutaline 74-85 adenosine A2a receptor Homo sapiens 17-24 12869379-5 2003 Two-week oral terbutaline treatment desensitized cardiac beta2AR responses to terbutaline infusion (increase in HR: WT 10 +/- 2 beats/min, Thr164Ile 8 +/- 4 beats/min; increase in contractility: WT -22 +/- 5 ms Thr164Ile: -17 +/- 6 ms); however, the extent of desensitization was larger in WT than Thr164Ile beta2AR subjects. Terbutaline 14-25 adenosine A2a receptor Homo sapiens 57-64 12869379-5 2003 Two-week oral terbutaline treatment desensitized cardiac beta2AR responses to terbutaline infusion (increase in HR: WT 10 +/- 2 beats/min, Thr164Ile 8 +/- 4 beats/min; increase in contractility: WT -22 +/- 5 ms Thr164Ile: -17 +/- 6 ms); however, the extent of desensitization was larger in WT than Thr164Ile beta2AR subjects. Terbutaline 14-25 adenosine A2a receptor Homo sapiens 308-315 12869379-5 2003 Two-week oral terbutaline treatment desensitized cardiac beta2AR responses to terbutaline infusion (increase in HR: WT 10 +/- 2 beats/min, Thr164Ile 8 +/- 4 beats/min; increase in contractility: WT -22 +/- 5 ms Thr164Ile: -17 +/- 6 ms); however, the extent of desensitization was larger in WT than Thr164Ile beta2AR subjects. Terbutaline 78-89 adenosine A2a receptor Homo sapiens 57-64 12869379-5 2003 Two-week oral terbutaline treatment desensitized cardiac beta2AR responses to terbutaline infusion (increase in HR: WT 10 +/- 2 beats/min, Thr164Ile 8 +/- 4 beats/min; increase in contractility: WT -22 +/- 5 ms Thr164Ile: -17 +/- 6 ms); however, the extent of desensitization was larger in WT than Thr164Ile beta2AR subjects. Terbutaline 78-89 adenosine A2a receptor Homo sapiens 308-315 14504664-14 2003 In comparison, intradermally injected terbutaline significantly reduced allergen-induced histamine release, PGD(2) synthesis, and skin reactions. Terbutaline 38-49 phosphoglycerate dehydrogenase Homo sapiens 108-111 12826277-5 2003 Exposure of cells to Stx2 for 24hr increased the DNA fragmentation to 11.6+/-0.9%, compared to 3.3+/-0.2% in control cells (P<0.05) but was decreased to approximately 5-7% (P<0.05) in the presence of terbutaline. Terbutaline 206-217 syntaxin 2 Homo sapiens 21-25 12826277-6 2003 Furthermore, Stx2-stimulated apoptosis, detected by TUNEL, annexin V and mitochondrial potential, was inhibited by terbutaline (P<0.05) which was prevented by cAMP-PKA inhibitors and a beta(2)-adrenoceptor antagonist. Terbutaline 115-126 syntaxin 2 Homo sapiens 13-17 12826277-6 2003 Furthermore, Stx2-stimulated apoptosis, detected by TUNEL, annexin V and mitochondrial potential, was inhibited by terbutaline (P<0.05) which was prevented by cAMP-PKA inhibitors and a beta(2)-adrenoceptor antagonist. Terbutaline 115-126 annexin A5 Homo sapiens 59-68 12826277-6 2003 Furthermore, Stx2-stimulated apoptosis, detected by TUNEL, annexin V and mitochondrial potential, was inhibited by terbutaline (P<0.05) which was prevented by cAMP-PKA inhibitors and a beta(2)-adrenoceptor antagonist. Terbutaline 115-126 adrenoceptor beta 2 Homo sapiens 188-208 12826277-7 2003 However, inhibition of Stx2-mediated caspase activity by terbutaline was partially blocked by cAMP-PKA inhibitors. Terbutaline 57-68 syntaxin 2 Homo sapiens 23-27 12826277-8 2003 On the other hand, p38MAPK inhibition by terbutaline prevented Stx2-induced apoptosis and caspase activity through a cAMP-independent pathway via beta(2)-adrenoceptor. Terbutaline 41-52 syntaxin 2 Homo sapiens 63-67 12826277-8 2003 On the other hand, p38MAPK inhibition by terbutaline prevented Stx2-induced apoptosis and caspase activity through a cAMP-independent pathway via beta(2)-adrenoceptor. Terbutaline 41-52 adrenoceptor beta 2 Homo sapiens 146-166 14698854-5 2004 RESULTS: Terbutaline and UK-14304 significantly suppressed TNF-alpha production by MF. Terbutaline 9-20 tumor necrosis factor Rattus norvegicus 59-68 14698854-7 2004 Terbutaline significantly suppressed IFN-gamma and TNF-alpha production by splenocytes. Terbutaline 0-11 interferon gamma Rattus norvegicus 37-46 14698854-7 2004 Terbutaline significantly suppressed IFN-gamma and TNF-alpha production by splenocytes. Terbutaline 0-11 tumor necrosis factor Rattus norvegicus 51-60 14698854-8 2004 EAE acute phase and remission animals showed reduced terbutaline-induced inhibition of IFN-gamma production. Terbutaline 53-64 interferon gamma Rattus norvegicus 87-96 12966369-4 2003 In time-course studies, however, in groups A and C lymphocyte beta(2)AR showed significant (P <.05, repeated-measures ANOVA) down-regulation as early as 24 hours after the first terbutaline intake, whereas in group B significant (P <.05, repeated-measures ANOVA) beta(2)AR decreases were observed only 72 hours after the first terbutaline intake. Terbutaline 181-192 adrenoceptor beta 2 Homo sapiens 62-71 12966369-4 2003 In time-course studies, however, in groups A and C lymphocyte beta(2)AR showed significant (P <.05, repeated-measures ANOVA) down-regulation as early as 24 hours after the first terbutaline intake, whereas in group B significant (P <.05, repeated-measures ANOVA) beta(2)AR decreases were observed only 72 hours after the first terbutaline intake. Terbutaline 333-344 adrenoceptor beta 2 Homo sapiens 62-71 12630530-5 2003 Overproduction of TNF-alpha and NO* (produced by inducible NO synthase [iNOS] examined by Western blot analysis in the lung and the liver) is inhibited by treatment of LPS rats with terbutaline. Terbutaline 182-193 tumor necrosis factor Rattus norvegicus 18-27 12795776-16 2003 A similar pattern of responses with the different beta-blocker treatments was observed for the effects on insulin concentrations during the terbutaline infusion. Terbutaline 140-151 insulin Homo sapiens 106-113 12603345-6 2003 The aim of the present study was to investigate the uterus relaxant effect of the beta2-adrenoceptor agonists (terbutaline, ritodrin) applied together with the subtype-selective alpha1A-adrenoceptor antagonists (WB 4101, 5-methylurapidil) in an in vitro rat model. Terbutaline 111-122 adrenoceptor beta 2 Rattus norvegicus 82-100 12630530-5 2003 Overproduction of TNF-alpha and NO* (produced by inducible NO synthase [iNOS] examined by Western blot analysis in the lung and the liver) is inhibited by treatment of LPS rats with terbutaline. Terbutaline 182-193 nitric oxide synthase 2 Rattus norvegicus 49-70 12630530-7 2003 Terbutaline also improves the liver (assessed by aspartate aminotransferase, alanine aminotransferase, total bilirubin, and albumin/globulin) and kidney (assessed by creatinine and uric acid) dysfunction induced by endotoxin. Terbutaline 0-11 glutamic-oxaloacetic transaminase 2 Rattus norvegicus 49-75 12630530-8 2003 These findings suggest that the amelioration of circulatory failure and organs injury by terbutaline is associated with its suppression in TNF-alpha, O2*- and NO (via iNOS) production in animals with endotoxic shock. Terbutaline 89-100 tumor necrosis factor Rattus norvegicus 139-148 12569076-1 2003 1 The principal aim of the present study was to determine whether long-term treatment of human lung mast cells (HLMC) with the clinically-relevant beta(2)-adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of beta(2)-adrenoceptor-mediated responses in these cells. Terbutaline 193-204 adrenoceptor beta 2 Homo sapiens 147-167 12569076-1 2003 1 The principal aim of the present study was to determine whether long-term treatment of human lung mast cells (HLMC) with the clinically-relevant beta(2)-adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of beta(2)-adrenoceptor-mediated responses in these cells. Terbutaline 193-204 adrenoceptor beta 2 Homo sapiens 234-254 12569076-2 2003 2 The non-selective beta-adrenoceptor agonist, isoprenaline, and the selective beta(2)-adrenoceptor agonists, salbutamol and terbutaline, inhibited the IgE-mediated release of histamine from HLMC. Terbutaline 125-136 adrenoceptor beta 2 Homo sapiens 79-99 12569076-2 2003 2 The non-selective beta-adrenoceptor agonist, isoprenaline, and the selective beta(2)-adrenoceptor agonists, salbutamol and terbutaline, inhibited the IgE-mediated release of histamine from HLMC. Terbutaline 125-136 immunoglobulin heavy constant epsilon Homo sapiens 152-155 12538816-5 2003 beta 2-AR-selective agonists salbutanol and terbutaline down-regulated IL-18-induced ICAM-1 expression on monocytes, but alpha 1-, alpha 2-, or beta1-AR agonist had no effect. Terbutaline 44-55 adrenoceptor beta 2 Homo sapiens 0-9 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 prolactin Homo sapiens 58-61 12538816-5 2003 beta 2-AR-selective agonists salbutanol and terbutaline down-regulated IL-18-induced ICAM-1 expression on monocytes, but alpha 1-, alpha 2-, or beta1-AR agonist had no effect. Terbutaline 44-55 interleukin 18 Homo sapiens 71-76 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 prolactin Homo sapiens 129-132 12538816-5 2003 beta 2-AR-selective agonists salbutanol and terbutaline down-regulated IL-18-induced ICAM-1 expression on monocytes, but alpha 1-, alpha 2-, or beta1-AR agonist had no effect. Terbutaline 44-55 intercellular adhesion molecule 1 Homo sapiens 85-91 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 186-192 12538816-6 2003 In the same manner, salbutanol and terbutaline as well as norepinephrine, epinephrine, and isoproterenol regulated the IL-18-induced cytokine production, including IL-12, tumor necrosis factor-alpha or interferon-gamma through the stimulation of beta 2-AR. Terbutaline 35-46 interleukin 18 Homo sapiens 119-124 12538816-6 2003 In the same manner, salbutanol and terbutaline as well as norepinephrine, epinephrine, and isoproterenol regulated the IL-18-induced cytokine production, including IL-12, tumor necrosis factor-alpha or interferon-gamma through the stimulation of beta 2-AR. Terbutaline 35-46 tumor necrosis factor Homo sapiens 171-198 12538816-6 2003 In the same manner, salbutanol and terbutaline as well as norepinephrine, epinephrine, and isoproterenol regulated the IL-18-induced cytokine production, including IL-12, tumor necrosis factor-alpha or interferon-gamma through the stimulation of beta 2-AR. Terbutaline 35-46 interferon gamma Homo sapiens 202-218 12538816-6 2003 In the same manner, salbutanol and terbutaline as well as norepinephrine, epinephrine, and isoproterenol regulated the IL-18-induced cytokine production, including IL-12, tumor necrosis factor-alpha or interferon-gamma through the stimulation of beta 2-AR. Terbutaline 35-46 adrenoceptor beta 2 Homo sapiens 246-255 12817706-4 2002 Terbutaline (an agonist of beta2-adrenoceptor) and dobutamine (an agonist of beta1-adrenoceptor), both are able to increase intracellular cAMP via activation of adenylate cyclase, were examined in the anesthetized rat with endotoxemia. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 27-45 12464406-4 2003 Early postnatal exposure (PN2-5) reduced DNA synthesis in early-developing brain regions of females, with sensitization of the effect upon repeated terbutaline administration; after multiple terbutaline injections, DNA content was reduced in male cerebellum. Terbutaline 148-159 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 26-31 12464406-4 2003 Early postnatal exposure (PN2-5) reduced DNA synthesis in early-developing brain regions of females, with sensitization of the effect upon repeated terbutaline administration; after multiple terbutaline injections, DNA content was reduced in male cerebellum. Terbutaline 191-202 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 26-31 12498921-2 2003 All four agonists increased right atrial adenylyl cyclase activity and contractile force, whereby increases for terbutaline, histamine and serotonin, but not for noradrenaline, were significantly larger in right atria from beta(1)-adrenoceptor antagonist-treated vs. non-beta(1)-adrenoceptor antagonist-treated patients. Terbutaline 112-123 adrenoceptor beta 1 Homo sapiens 223-243 12608646-4 2003 RESULTS: LPS activated Erk-1/2 and p38 levels, by 4.7-fold and 1.8-fold, respectively (P < 0.05), which were suppressed by terbutaline (10(-6) - 10(-8) M) in a dose dependent way. Terbutaline 126-137 mitogen activated protein kinase 3 Rattus norvegicus 23-30 12608646-4 2003 RESULTS: LPS activated Erk-1/2 and p38 levels, by 4.7-fold and 1.8-fold, respectively (P < 0.05), which were suppressed by terbutaline (10(-6) - 10(-8) M) in a dose dependent way. Terbutaline 126-137 mitogen activated protein kinase 14 Rattus norvegicus 35-38 12608646-5 2003 These inhibitory actions of terbutaline were prevented by the beta2-adrenoceptor antagonist, ICI 118,551(10(-6) M) but not by an inhibitor of the cAMP-PKA pathway, H-89 (5 x 10(-6) M). Terbutaline 28-39 adrenoceptor beta 2 Rattus norvegicus 62-80 12817706-4 2002 Terbutaline (an agonist of beta2-adrenoceptor) and dobutamine (an agonist of beta1-adrenoceptor), both are able to increase intracellular cAMP via activation of adenylate cyclase, were examined in the anesthetized rat with endotoxemia. Terbutaline 0-11 adrenoceptor beta 1 Rattus norvegicus 77-95 12817706-8 2002 In addition, both terbutaline and dobutamine reduced the plasma TNF-alpha level, but only terbutaline attenuated the aortic O2*- production in these endotoxemic rats. Terbutaline 18-29 tumor necrosis factor Rattus norvegicus 64-73 12817706-9 2002 The beneficial effect of terbutaline in endotoxemic animals was associated with a reduction in plasma TNF-alpha and aortic O2*-, but not in plasma NO. Terbutaline 25-36 tumor necrosis factor Rattus norvegicus 102-111 12452208-3 2002 AIMS AND METHODS: Our aim was to confirm that sputum and serum ECP measurements would provide a more sensitive indicator of responses to asthma treatment than eosinophil counts per se, in a randomized, placebo-controlled, crossover study of terbutaline, budesonide, and their combination in patients with chronic persistent asthma. Terbutaline 241-252 ribonuclease A family member 3 Homo sapiens 63-66 12510953-2 2002 Traditional inhaled short-acting beta2-agonists (salbutamol and terbutaline) provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli. Terbutaline 64-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 12452208-10 2002 Correlations between sputum eosinophils and ECP, and between blood eosinophils and serum ECP were greatest during treatment with placebo or terbutaline alone: budesonide weakened or abolished these relationships. Terbutaline 140-151 ribonuclease A family member 3 Homo sapiens 89-92 29492853-9 2002 The time-course of some of the cardiovascular effects of a SC dose of terbutaline in relation to terbutaline plasma concentrations was unexpected and suggests direct beta2-adrenoreceptor-mediated effects on the heart. Terbutaline 70-81 adrenoceptor beta 2 Homo sapiens 166-186 12417450-0 2002 Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls. Terbutaline 5-16 interleukin 10 Homo sapiens 50-55 12417450-0 2002 Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls. Terbutaline 5-16 tumor necrosis factor Homo sapiens 64-67 12417450-0 2002 Oral terbutaline differentially affects cytokine (IL-10, IL-12, TNF, IFNg) release in multiple sclerosis patients and controls. Terbutaline 5-16 interferon gamma Homo sapiens 69-73 12417450-5 2002 We conclude that administration of terbutaline induces anti-inflammatory (IL-10) as well as IL-12 protein production in healthy controls but not in MS patients. Terbutaline 35-46 interleukin 10 Homo sapiens 74-79 12423672-6 2002 Norepinephrine, an alpha1 agonist phenylephrine, a beta1 agonist dobutamine and terbutaline suppressed the expressions of mRNAs encoding pro-inflammatory cytokines, interleukin-6 and tumor necrosis factor alpha. Terbutaline 80-91 interleukin 6 Rattus norvegicus 165-210 12423672-7 2002 Release of tumor necrosis factor alpha and nitric oxide was suppressed by norepinephrine, phenylephrine, dobutamine and terbutaline. Terbutaline 120-131 tumor necrosis factor Rattus norvegicus 11-38 12412676-7 2002 Statistically greater increases in cardiac frequency (2.6 beats x min(-1), p=0.03) were found on terbutaline. Terbutaline 97-108 CD59 molecule (CD59 blood group) Homo sapiens 66-72 29492853-9 2002 The time-course of some of the cardiovascular effects of a SC dose of terbutaline in relation to terbutaline plasma concentrations was unexpected and suggests direct beta2-adrenoreceptor-mediated effects on the heart. Terbutaline 97-108 adrenoceptor beta 2 Homo sapiens 166-186 11818773-7 2002 RESULTS: Alveolar or intravenous lidocaine decreased alveolar fluid clearance by 50%, an effect that was reversible with the beta2 agonist, terbutaline. Terbutaline 140-151 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 125-130 12205813-4 2002 Short-acting beta 2-agonists (salbutamol or albuterol, terbutaline) are indicated for asthma attacks, as needed in chronic asthma, and for prevention of symptoms during effort. Terbutaline 55-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 11996897-1 2002 A beta-adrenergic agonist (beta-agonist), terbutaline, stimulated amiloride-sensitive Na(+) absorption in fetal rat alveolar type II epithelium, contributing to the clearance of lung fluid. Terbutaline 42-53 amyloid beta precursor protein Rattus norvegicus 0-6 12013527-5 2002 Thus, PAF increased the TPA- and terbutaline-stimulated phosphatidylcholine secretion, that are PKC and PKA activators respectively, suggesting the involvement of both protein kinases in the process. Terbutaline 33-44 PCNA clamp associated factor Rattus norvegicus 6-9 11704537-6 2001 Secretion of SP-B and SP-C was stimulated three- to fivefold by terbutaline, 5"-(N-ethylcarboxyamido)adenosine, ATP, 12-O-tetradecanoylphorbol 13-acetate, and ionomycin. Terbutaline 64-75 surfactant protein B Rattus norvegicus 13-17 14720033-1 2002 Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma. Terbutaline 80-91 adrenoceptor beta 2 Homo sapiens 0-18 14720033-1 2002 Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma. Terbutaline 80-91 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-34 11704537-6 2001 Secretion of SP-B and SP-C was stimulated three- to fivefold by terbutaline, 5"-(N-ethylcarboxyamido)adenosine, ATP, 12-O-tetradecanoylphorbol 13-acetate, and ionomycin. Terbutaline 64-75 surfactant protein C Rattus norvegicus 22-26 11718842-6 2001 When terbutaline was given on PN2-5, betaAR downregulation was obtained in brainstem, forebrain and cerebellum, but desensitization of the AC response was seen only in the forebrain; the desensitization was heterologous, reflecting decrements in total AC activity rather than specific loss of the betaAR response. Terbutaline 5-16 sodium voltage-gated channel alpha subunit 10 Rattus norvegicus 30-35 11705775-1 2001 Terbutaline, a beta(2)-adrenoceptor (beta(2)-AR) agonist, is a widely used tocolytic that also crosses the placenta to stimulate fetal beta-ARs. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 15-35 11705775-1 2001 Terbutaline, a beta(2)-adrenoceptor (beta(2)-AR) agonist, is a widely used tocolytic that also crosses the placenta to stimulate fetal beta-ARs. Terbutaline 0-11 adrenoceptor beta 2 Rattus norvegicus 37-47 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 cyclin dependent kinase 20 Homo sapiens 52-55 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 interferon induced protein 44 Homo sapiens 56-59 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 mitogen-activated protein kinase 14 Homo sapiens 61-64 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 nuclear factor kappa B subunit 1 Homo sapiens 67-77 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 nuclear factor kappa B subunit 1 Homo sapiens 79-82 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 RELA proto-oncogene, NF-kB subunit Homo sapiens 84-87 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 tumor necrosis factor Homo sapiens 94-103 11675405-9 2001 Terbutaline (10(-6) M to 10(-8) M) suppressed MAPK (p42/p44, p38), NF-kappa B (p50, p65), and TNF-alpha promoter activity in a dose-dependent way that was prevented by the beta(2)-adrenoceptor antagonist, ICI118,551. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 172-192 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 tumor necrosis factor Homo sapiens 34-43 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 adrenoceptor beta 2 Homo sapiens 113-133 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 cyclin dependent kinase 20 Homo sapiens 154-157 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 interferon induced protein 44 Homo sapiens 158-161 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 mitogen-activated protein kinase 14 Homo sapiens 163-166 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 nuclear factor kappa B subunit 1 Homo sapiens 172-182 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 nuclear factor kappa B subunit 1 Homo sapiens 184-187 11675405-12 2001 In summary, the downregulation of TNF-alpha transcription by terbutaline was mediated by an inhibitory effect of beta(2)-adrenoceptor activation on MAPK (p42/p44, p38) and NF-kappa B (p50/p65), which were exerted through a cAMP-PKA pathway and a cAMP-independent mechanism. Terbutaline 61-72 RELA proto-oncogene, NF-kB subunit Homo sapiens 188-191 11325192-2 2001 Several purported agonists, including isoproterenol, epinephrine, norepinephine, dobutamine, salbutamol, and terbutaline, exhibited dual-affinity displacement curves, which is characteristic of agonist binding to betaAR. Terbutaline 109-120 adrenoceptor beta 2 Homo sapiens 213-219 11429395-4 2001 The fat cells of Ile carriers displayed a 6 fold increase (P=0.02) in the lipolytic EC(50) of terbutaline (a selective beta(2)-adrenoceptor agonist), but no change in the lipolytic action of dobutamine (a selective beta(1)-adrenoceptor agonist), compared with the Thr carriers. Terbutaline 94-105 adrenoceptor beta 2 Homo sapiens 119-139 11256987-0 2001 beta2-Adrenoceptor desensitization in human alveolar macrophages induced by inhaled terbutaline in vivo is not counteracted by budesonide. Terbutaline 84-95 adrenoceptor beta 2 Homo sapiens 0-18 12580109-1 2001 AIM: To develop a liquid chromatography-electrospray ionization tandem mass spectrometry method for rapid analysis of terbutaline at level of 50 pg.mL-1 in human plasma. Terbutaline 118-129 L1 cell adhesion molecule Mus musculus 148-152 11509329-9 2001 The beta(2)-agonists salbutamol and terbutaline (100 microg/ml for 48 h) decreased ASF antibacterial activity by 5- to 8-fold. Terbutaline 36-47 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 11885748-2 2001 In the present study, we have investigated the structure-activity relationships of (+/-)-terbutaline and (+/-)-fenoterol as beta3-adrenoceptor agonists in the guinea pig gastric fundus. Terbutaline 83-100 beta-3 adrenergic receptor Cavia porcellus 124-142 11885748-4 2001 The combination of the selective beta1-adrenoceptor antagonist (+/-)-atenolol (100 microM), and the selective beta2-adrenoceptor antagonist (+/-)-butoxamine (100 microM), produced a 2 and 6 fold rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol respectively, without depressing the maximal responses. Terbutaline 252-269 beta-2 adrenergic receptor Cavia porcellus 110-128 11885748-6 2001 In the presence of (+/-)-atenolol and (+/-)-butoxamine, however, the non-selective beta1, beta2- and beta3-adrenoceptor antagonist (+/-)-bupranolol caused a concentration-dependent rightward shift of the concentration-response curves for (+/-)-terbutaline and (+/-)-fenoterol. Terbutaline 238-255 beta-3 adrenergic receptor Cavia porcellus 101-119 11480585-0 2001 Beta1-adrenoceptor stimulation by high-dose terbutaline downregulates terbutaline-stimulated alveolar fluid clearance in ex vivo rat lung. Terbutaline 44-55 adrenoceptor beta 1 Rattus norvegicus 0-18 11480585-0 2001 Beta1-adrenoceptor stimulation by high-dose terbutaline downregulates terbutaline-stimulated alveolar fluid clearance in ex vivo rat lung. Terbutaline 70-81 adrenoceptor beta 1 Rattus norvegicus 0-18 11284207-3 2001 In cell-attached patches formed on the epithelium, terbutaline, a beta agonist, increased the open probability (Po) of the NSC channel to 0.62 +/- 0.07 from 0.03 +/- 0.01 (mean +/- SE; n = 8) 30 min after application of terbutaline in a solution containing 1 mM Ca2+. Terbutaline 51-62 amyloid beta precursor protein Rattus norvegicus 64-70 16263481-5 2001 Beta2-agonists have been characterised into those which directly activate the receptor (salbutamol/terbutaline), those which are taken up into a membrane depot (formoterol) and those which interact with a receptor-specific, auxiliary binding site (salmeterol). Terbutaline 99-110 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-5 11284207-3 2001 In cell-attached patches formed on the epithelium, terbutaline, a beta agonist, increased the open probability (Po) of the NSC channel to 0.62 +/- 0.07 from 0.03 +/- 0.01 (mean +/- SE; n = 8) 30 min after application of terbutaline in a solution containing 1 mM Ca2+. Terbutaline 220-231 amyloid beta precursor protein Rattus norvegicus 64-70 11120594-1 2000 We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced. Terbutaline 178-189 negative elongation factor complex member C/D, Th1l Mus musculus 34-37 11172410-14 2001 Early gestational age at TO and maternal terbutaline administration adversely influenced lung growth in CDH-TO fetuses. Terbutaline 41-52 choline dehydrogenase Homo sapiens 104-107 11139781-5 2001 The beta1-adrenergic agonist dobutamine and the beta-2 agonist terbutaline also (both at 10(-5) M) significantly stimulated PYY secretion, from 29+/-1 to 79+/-12 fmol/2 min and from 19+/-1 to 73+/-13 fmol/2 min respectively (n=7, P<0.05). Terbutaline 63-74 peptide YY Rattus norvegicus 124-127 11120594-1 2000 We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced. Terbutaline 178-189 adrenergic receptor, beta 2 Mus musculus 115-122 11120594-1 2000 We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced. Terbutaline 178-189 adrenergic receptor, beta 2 Mus musculus 162-169 11120594-1 2000 We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced. Terbutaline 178-189 negative elongation factor complex member C/D, Th1l Mus musculus 240-243 11120594-2 2000 In the present study, we show that norepinephrine and terbutaline stimulate the beta2AR to decrease the level of IL-2 produced by freshly isolated murine splenic naive CD4+ T cells from either Balb/C or DO11.10 transgenic mice and activated polyclonally with anti-CD3 and anti-CD28 mAbs. Terbutaline 54-65 adrenergic receptor, beta 2 Mus musculus 80-87 11120594-2 2000 In the present study, we show that norepinephrine and terbutaline stimulate the beta2AR to decrease the level of IL-2 produced by freshly isolated murine splenic naive CD4+ T cells from either Balb/C or DO11.10 transgenic mice and activated polyclonally with anti-CD3 and anti-CD28 mAbs. Terbutaline 54-65 interleukin 2 Mus musculus 113-117 11193379-7 2000 A beta-adrenoceptor agonists (beta-agonist), procaterol, clenbuterol, fenoterol and terbutaline suppressed the production of TNF- and IL-1 beta. Terbutaline 84-95 tumor necrosis factor Homo sapiens 125-128 11193379-7 2000 A beta-adrenoceptor agonists (beta-agonist), procaterol, clenbuterol, fenoterol and terbutaline suppressed the production of TNF- and IL-1 beta. Terbutaline 84-95 interleukin 1 beta Homo sapiens 134-143 11232861-2 2001 After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged. Terbutaline 163-174 glucuronidase beta Homo sapiens 40-58 11232861-2 2001 After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged. Terbutaline 163-174 arylsulfatase A Homo sapiens 59-74 11232861-2 2001 After hydrolysis of the conjugates with beta-glucuronidase/arylsulfatase a derivatisation step with formaldehyde converts fenoterol, orciprenaline, reproterol and terbutaline to one derivative, a tetrahydroisoquinoline, while the other beta-2 agonists remain unchanged. Terbutaline 163-174 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 236-242 11219455-3 2001 Terbutaline had only a slight lipolytic effect at 10(-5) M. This low effect could be due to a lower affinity of TER than of ISO for the beta2-adrenoceptors. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 136-141 11118019-2 2000 We used microdialysis to study the in situ lipolytic effects of dobutamine (selective beta1-agonist) and terbutaline (selective beta2-agonist) on glycerol release (lipolytic index) in abdominal subcutaneous AT in 10 obese girls aged 13-17 years, BMI 38 +/- 2.1 kg/m2, and in 7 lean girls aged 11-17 years, BMI 21 +/- 1.1 kg/m2, and compared them with 10 obese women aged 21-39 years, BMI 36 +/- 1.6 kg/m2, and 10 lean women aged 18-42 years, BMI 21 +/- 0.4 kg/m2. Terbutaline 105-116 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 128-133 11120594-1 2000 We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced. Terbutaline 178-189 adrenergic receptor, beta 2 Mus musculus 87-113 10955752-12 2000 Evening peak flows were significantly higher during terbutaline treatment [mean increase 23.1 l min(-1) (95% CI = 18.8, 27.4)]. Terbutaline 52-63 CD59 molecule (CD59 blood group) Homo sapiens 96-102 11060132-4 2000 Epicardial application of angiotensin II, the selective beta2-adrenoceptor agonist terbutaline and selective alpha-adrenoceptor agonists elicited inconsistent neuronal responses. Terbutaline 83-94 beta-2 adrenergic receptor Canis lupus familiaris 56-74 11008079-9 2000 Terbutaline and dbcAMP significantly increased Na(+)/K(+)-ATPase activity in A549 cells preserved with EP4 and LPD solutions for 5 hours. Terbutaline 0-11 prostaglandin E receptor 4 Rattus norvegicus 103-106 10952688-2 2000 SR 59119A and SR 59104A and CGP 12177 (two selective agonists and a partial agonist, respectively, of the beta(3)-AR), salbutamol and terbutaline (beta(2)-AR agonists) each produced a concentration-dependent relaxation of the myometrial spontaneous contractions. Terbutaline 134-145 adrenoceptor beta 2 Homo sapiens 147-157 10878340-2 2000 Trinitrophenyl-specific B cells enriched from unimmunized mouse spleens were pre-exposed to Ag and/or the beta 2AR ligand terbutaline for 24 h before being activated by either a beta 2AR-negative Th2 cell clone or CD40 ligand/Sf9 cells and IL-4 in the presence or absence of an anti-CD86 Ab. Terbutaline 122-133 adrenergic receptor, beta 2 Mus musculus 106-114 10955752-15 2000 On ceasing terbutaline treatment there was a fall in mean morning peak flow below the baseline on the following morning of 21.6 l min(-1) (P<0.05 compared to placebo). Terbutaline 11-22 CD59 molecule (CD59 blood group) Homo sapiens 130-136 10909895-4 2000 In this report, we present evidence that terbutaline, a beta2-agonist, inhibits TNFalpha production and enhances interleukin-10 (IL-10) release in the anesthetized rat treated with LPS. Terbutaline 41-52 tumor necrosis factor Rattus norvegicus 80-88 10909895-4 2000 In this report, we present evidence that terbutaline, a beta2-agonist, inhibits TNFalpha production and enhances interleukin-10 (IL-10) release in the anesthetized rat treated with LPS. Terbutaline 41-52 interleukin 10 Rattus norvegicus 113-127 10909895-4 2000 In this report, we present evidence that terbutaline, a beta2-agonist, inhibits TNFalpha production and enhances interleukin-10 (IL-10) release in the anesthetized rat treated with LPS. Terbutaline 41-52 interleukin 10 Rattus norvegicus 129-134 10909895-5 2000 In addition, an overproduction of nitric oxide (NO, examined by its metabolites nitrite/nitrate) by inducible NO synthase (iNOS, examined by western blot analysis) is attenuated by pretreatment of LPS rats with terbutaline. Terbutaline 211-222 nitric oxide synthase 2 Rattus norvegicus 100-121 10909895-5 2000 In addition, an overproduction of nitric oxide (NO, examined by its metabolites nitrite/nitrate) by inducible NO synthase (iNOS, examined by western blot analysis) is attenuated by pretreatment of LPS rats with terbutaline. Terbutaline 211-222 nitric oxide synthase 2 Rattus norvegicus 123-127 10909895-9 2000 These findings suggest that the inhibition of TNFalpha and NO (via iNOS) production as well as the increment of IL-10 production contribute to the beneficial effect of terbutaline in animals with endotoxic shock. Terbutaline 168-179 tumor necrosis factor Rattus norvegicus 46-54 10909895-9 2000 These findings suggest that the inhibition of TNFalpha and NO (via iNOS) production as well as the increment of IL-10 production contribute to the beneficial effect of terbutaline in animals with endotoxic shock. Terbutaline 168-179 nitric oxide synthase 2 Rattus norvegicus 67-71 10909895-9 2000 These findings suggest that the inhibition of TNFalpha and NO (via iNOS) production as well as the increment of IL-10 production contribute to the beneficial effect of terbutaline in animals with endotoxic shock. Terbutaline 168-179 interleukin 10 Rattus norvegicus 112-117 10857765-1 2000 This study aimed to investigate the time-course of the effect of beta2-adrenoceptor stimulation with terbutaline on lipopolysaccharide (LPS)-induced tumour necrosis factor(TNF)-alpha production in rat mesangial cells. Terbutaline 101-112 adrenoceptor beta 2 Rattus norvegicus 65-83 10857765-1 2000 This study aimed to investigate the time-course of the effect of beta2-adrenoceptor stimulation with terbutaline on lipopolysaccharide (LPS)-induced tumour necrosis factor(TNF)-alpha production in rat mesangial cells. Terbutaline 101-112 tumor necrosis factor Rattus norvegicus 149-182 10857765-3 2000 After 1 h of incubation, terbutaline inhibited TNF-alpha protein release as well as transcription and translation of TNF-alpha and mitogen activated protein kinase (MAPK, p42/p44) activity. Terbutaline 25-36 tumor necrosis factor Rattus norvegicus 47-56 10857765-3 2000 After 1 h of incubation, terbutaline inhibited TNF-alpha protein release as well as transcription and translation of TNF-alpha and mitogen activated protein kinase (MAPK, p42/p44) activity. Terbutaline 25-36 tumor necrosis factor Rattus norvegicus 117-126 10857765-3 2000 After 1 h of incubation, terbutaline inhibited TNF-alpha protein release as well as transcription and translation of TNF-alpha and mitogen activated protein kinase (MAPK, p42/p44) activity. Terbutaline 25-36 mitogen activated protein kinase 3 Rattus norvegicus 165-169 10857765-3 2000 After 1 h of incubation, terbutaline inhibited TNF-alpha protein release as well as transcription and translation of TNF-alpha and mitogen activated protein kinase (MAPK, p42/p44) activity. Terbutaline 25-36 mitogen activated protein kinase 3 Rattus norvegicus 175-178 10857765-4 2000 At 3 h, terbutaline enhanced intracellular cAMP but suppressed TNF-alpha release and transcription. Terbutaline 8-19 tumor necrosis factor Rattus norvegicus 63-72 10690878-5 2000 The beta2-adrenergic receptor agonist terbutaline inhibits tumor necrosis factor-alpha production and enhances interleukin-10 production by monocytes. Terbutaline 38-49 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 10690878-5 2000 The beta2-adrenergic receptor agonist terbutaline inhibits tumor necrosis factor-alpha production and enhances interleukin-10 production by monocytes. Terbutaline 38-49 interleukin 10 Homo sapiens 111-125 10821420-2 2000 The stimulatory effect of lipopolysaccharide on phosphatidylcholine secretion was additive to those of terbutaline and TPA (protein kinase A and C activators respectively) and this effect was not suppressed by inhibitors of both protein kinases. Terbutaline 103-114 protein kinase cAMP-activated catalytic subunit alpha Rattus norvegicus 124-140 10229127-3 1999 Expression of alpha1b- and alpha1d-AR mRNA can be obtained by culturing freshly isolated human peripheral blood monocytes with the neuroendocrine mediators dexamethasone or the beta2-AR agonist terbutaline. Terbutaline 194-205 adrenoceptor beta 2 Homo sapiens 177-185 10629458-9 2000 Terbutaline induced similar alterations in the type-1/type-2 cytokine balance compared with EPI, indicating that the beta(2)adrenergic receptor is involved in these cytokine alterations. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 117-143 10562630-10 1999 beta-Adrenergic stimulation with terbutaline 72 h after KGF pretreatment further increased ALC to 50 +/- 7%/h (P < 0.5). Terbutaline 33-44 fibroblast growth factor 7 Rattus norvegicus 56-59 10525314-6 1999 TNF-alpha and IL-6 secretion from the cells was altered with beta(2)-adrenoceptor agonists (terbutaline, formoterol) and angiotensin II corresponding to changes of TNF-alpha and IL-6 gene transcription. Terbutaline 92-103 tumor necrosis factor Rattus norvegicus 0-9 10525314-6 1999 TNF-alpha and IL-6 secretion from the cells was altered with beta(2)-adrenoceptor agonists (terbutaline, formoterol) and angiotensin II corresponding to changes of TNF-alpha and IL-6 gene transcription. Terbutaline 92-103 interleukin 6 Rattus norvegicus 14-18 10525314-6 1999 TNF-alpha and IL-6 secretion from the cells was altered with beta(2)-adrenoceptor agonists (terbutaline, formoterol) and angiotensin II corresponding to changes of TNF-alpha and IL-6 gene transcription. Terbutaline 92-103 adrenoceptor beta 2 Rattus norvegicus 61-81 10525314-6 1999 TNF-alpha and IL-6 secretion from the cells was altered with beta(2)-adrenoceptor agonists (terbutaline, formoterol) and angiotensin II corresponding to changes of TNF-alpha and IL-6 gene transcription. Terbutaline 92-103 tumor necrosis factor Rattus norvegicus 164-173 10525314-6 1999 TNF-alpha and IL-6 secretion from the cells was altered with beta(2)-adrenoceptor agonists (terbutaline, formoterol) and angiotensin II corresponding to changes of TNF-alpha and IL-6 gene transcription. Terbutaline 92-103 interleukin 6 Rattus norvegicus 178-182 10687283-2 1999 In vivo studies were carried out to determine the extent and time-course of pulmonary tissue uptake of administered liposomes containing terbutaline sulphate(TER) on rat lungs. Terbutaline 137-157 trans-2,3-enoyl-CoA reductase Rattus norvegicus 158-161 10469353-4 1999 METHODS: IL-6 protein, mRNA, and promoter activity were measured in these cells exposed to LPS (1 microg/ml) and/or terbutaline (10(-9) to 10(-6) M). Terbutaline 116-127 interleukin 6 Homo sapiens 9-13 10469353-5 1999 Furthermore, the time course effects of terbutaline on cAMP, MAPK (p42/p44), and TNF-alpha release were evaluated in the cells. Terbutaline 40-51 tumor necrosis factor Homo sapiens 81-90 10469353-6 1999 RESULTS: Terbutaline at high concentrations (10(-6) M) significantly up-regulated IL-6 by approximately 25% (P<0.05), whereas at a lower concentration (10(-8) M), it down-regulated IL-6 production by 42% (P<0.05). Terbutaline 9-20 interleukin 6 Homo sapiens 82-86 10469353-6 1999 RESULTS: Terbutaline at high concentrations (10(-6) M) significantly up-regulated IL-6 by approximately 25% (P<0.05), whereas at a lower concentration (10(-8) M), it down-regulated IL-6 production by 42% (P<0.05). Terbutaline 9-20 interleukin 6 Homo sapiens 184-188 10469353-10 1999 The terbutaline-induced down-regulation of IL-6 gene production was mediated by an inhibitory effect of terbutaline on TNF-alpha, which was exerted through the MAPK and cAMP pathways, whereas the up-regulation appeared to be due to a direct action of intracellular cAMP. Terbutaline 4-15 interleukin 6 Homo sapiens 43-47 10469353-10 1999 The terbutaline-induced down-regulation of IL-6 gene production was mediated by an inhibitory effect of terbutaline on TNF-alpha, which was exerted through the MAPK and cAMP pathways, whereas the up-regulation appeared to be due to a direct action of intracellular cAMP. Terbutaline 4-15 tumor necrosis factor Homo sapiens 119-128 10469353-10 1999 The terbutaline-induced down-regulation of IL-6 gene production was mediated by an inhibitory effect of terbutaline on TNF-alpha, which was exerted through the MAPK and cAMP pathways, whereas the up-regulation appeared to be due to a direct action of intracellular cAMP. Terbutaline 104-115 interleukin 6 Homo sapiens 43-47 10469353-10 1999 The terbutaline-induced down-regulation of IL-6 gene production was mediated by an inhibitory effect of terbutaline on TNF-alpha, which was exerted through the MAPK and cAMP pathways, whereas the up-regulation appeared to be due to a direct action of intracellular cAMP. Terbutaline 104-115 tumor necrosis factor Homo sapiens 119-128 10446376-0 1999 Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline. Terbutaline 154-165 acetylcholinesterase Mus musculus 51-71 10446376-0 1999 Amino acid residues involved in the interaction of acetylcholinesterase and butyrylcholinesterase with the carbamates Ro 02-0683 and bambuterol, and with terbutaline. Terbutaline 154-165 butyrylcholinesterase Mus musculus 76-97 10425466-7 1999 Because terbutaline but not dobutamine or BRL 37,344 (10(-5) M) induced significant GLP-1 and PYY secretions (135+/-30 and 305+/-39 fmol/8 min respectively), isoproterenol-induced secretions are suggested to result mainly from stimulation of the beta2-isoreceptor type. Terbutaline 8-19 glucagon Rattus norvegicus 84-89 10425466-7 1999 Because terbutaline but not dobutamine or BRL 37,344 (10(-5) M) induced significant GLP-1 and PYY secretions (135+/-30 and 305+/-39 fmol/8 min respectively), isoproterenol-induced secretions are suggested to result mainly from stimulation of the beta2-isoreceptor type. Terbutaline 8-19 peptide YY Rattus norvegicus 94-97 10226872-11 1999 Tremulousness observed during the first few days of terbutaline administration disappeared after 4 to 8 days, indicating development of desensitization of beta 2-adrenoceptor-mediated noncardiovascular responses. Terbutaline 52-63 adrenoceptor beta 2 Homo sapiens 155-174 14685585-0 1998 [Intravenous terbutaline in children] OBJECTIVE: The authors describe their experience with theuse of intravenous Beta2 adrenergic (IV terbutaline) in patientsadmitted to a PICU with severe lower airway obstruction. Terbutaline 13-24 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 114-119 10226872-1 1999 In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen. Terbutaline 71-82 adrenoceptor beta 2 Homo sapiens 43-62 10226872-1 1999 In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen. Terbutaline 71-82 adrenoceptor beta 2 Homo sapiens 113-132 9843731-6 1998 beta2-Adrenoceptor stimulation with terbutaline induced a concentration-dependent increase in skeletal muscle glycerol levels and in tissue blood flow, whereas perfusion with beta1- or beta3-adrenoceptor agonists (dobutamine or CGP-12177) did not influence the glycerol concentration or blood flow. Terbutaline 36-47 adrenoceptor beta 2 Homo sapiens 0-18 14685585-0 1998 [Intravenous terbutaline in children] OBJECTIVE: The authors describe their experience with theuse of intravenous Beta2 adrenergic (IV terbutaline) in patientsadmitted to a PICU with severe lower airway obstruction. Terbutaline 135-146 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 114-119 9366411-2 1997 In the present study, we proposed that the level of beta 2AR expression on anti-CD3 mAb-activated CD4+ effector Th cells may differ from the level on resting cells, and that a change in receptor expression may alter the functional responsiveness of these cells to either the beta 2AR-selective ligand terbutaline or the sympathetic neurotransmitter norepinephrine. Terbutaline 301-312 adrenergic receptor, beta 2 Mus musculus 52-60 9876334-0 1998 Terbutaline-induced desensitization of human cardiac beta 2-adrenoceptor-mediated positive inotropic effects: attenuation by ketotifen. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 53-72 9876334-4 1998 METHODS: We investigated, in a single blinded, randomised, placebo-controlled, cross-over study of ten healthy male volunteers (mean age, 25.3 +/- 0.7 years), the effects of two weeks treatment with the beta 2-adrenoceptor agonist terbutaline (3x5 mg/day p.o.) Terbutaline 231-242 adrenoceptor beta 2 Homo sapiens 203-222 9876334-7 1998 Cardiovascular effects were assessed as isoprenaline (3.5-35 ng/kg/min)- and terbutaline (25-150 ng/kg/min)-infusion-induced increases in heart rate and systolic blood pressure, decreases in diastolic blood pressure and shortening of the systolic time intervals (STIs), heart rate corrected duration of electromechanical systole (QS2c) and pre-ejection period (PEP; as a measure of inotropism). Terbutaline 77-88 progestagen associated endometrial protein Homo sapiens 361-364 9876334-9 1998 Isoprenaline- and terbutaline-infusion caused dose-dependent increases in systolic blood pressure and heart rate, decreases in diastolic blood pressure and shortening of QS2c and PEP, whereby isoprenaline effects were more pronounced. Terbutaline 18-29 progestagen associated endometrial protein Homo sapiens 170-182 9876334-10 1998 After two weeks of treatment with terbutaline p.o., isoprenaline- and terbutaline-infusion-induced increases in heart rate, shortening of QS2c and PEP were significantly reduced whereby terbutaline-infusion effects were markedly more attenuated than isoprenaline-infusion effects. Terbutaline 34-45 progestagen associated endometrial protein Homo sapiens 147-150 9876334-10 1998 After two weeks of treatment with terbutaline p.o., isoprenaline- and terbutaline-infusion-induced increases in heart rate, shortening of QS2c and PEP were significantly reduced whereby terbutaline-infusion effects were markedly more attenuated than isoprenaline-infusion effects. Terbutaline 70-81 progestagen associated endometrial protein Homo sapiens 147-150 9876334-10 1998 After two weeks of treatment with terbutaline p.o., isoprenaline- and terbutaline-infusion-induced increases in heart rate, shortening of QS2c and PEP were significantly reduced whereby terbutaline-infusion effects were markedly more attenuated than isoprenaline-infusion effects. Terbutaline 70-81 progestagen associated endometrial protein Homo sapiens 147-150 9647274-1 1998 BACKGROUND: Various studies have demonstrated the benefits of continuous nebulization therapy for delivering aerosols of the beta2 agonists such as terbutaline sulfate or albuterol sulfate to patients with severe asthma and/or impending respiratory failure. Terbutaline 148-167 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 125-130 9643620-8 1998 A similar renal clearance of bambuterol was found during oral administration but that of terbutaline decreased (to about 120 ml min(-1)). Terbutaline 89-100 CD59 molecule (CD59 blood group) Homo sapiens 128-134 9643621-1 1998 AIMS: It has been assumed that both plasma cholinesterase (EC 3.1.1.8) and oxidative enzymes are needed for optimum formation of the bronchodilator terbutaline from its biscarbamate prodrug bambuterol. Terbutaline 148-159 butyrylcholinesterase Homo sapiens 43-57 9643621-11 1998 Nevertheless, the subjects with atypical cholinesterase were able to produce terbutaline as efficiently as normal subjects. Terbutaline 77-88 butyrylcholinesterase Homo sapiens 41-55 9432097-13 1997 We conclude that inhalation of a beta2-agonist (terbutaline) in a dose that yields significant bronchodilatation does not influence physical performance at low temperature in healthy athletes. Terbutaline 48-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 9726718-11 1998 Plasma glucose and serum insulin levels rose significantly 24 h and 48 h after terbutaline and returned to baseline after 14 d of terbutaline therapy. Terbutaline 79-90 insulin Homo sapiens 25-32 9726718-11 1998 Plasma glucose and serum insulin levels rose significantly 24 h and 48 h after terbutaline and returned to baseline after 14 d of terbutaline therapy. Terbutaline 130-141 insulin Homo sapiens 25-32 9609581-1 1998 OBJECTIVE: Terbutaline, a selective beta2-agonist, is a frequently used tocolytic known to affect maternal metabolism. Terbutaline 11-22 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 36-41 9609581-13 1998 CONCLUSION: Decreased peripheral insulin sensitivity, and to a lesser degree increased endogenous glucose production, may represent the pathophysiology of abnormal glucose tolerance observed in many women treated with oral terbutaline. Terbutaline 223-234 insulin Homo sapiens 33-40 9476903-7 1998 The combination of 12-O-tetradecanoyl-phorbol-11-acetate (TPA) and terbutaline stimulated secretion of [3H]phosphatidylcholine ([3H]PC), SP-A, and lysozyme, but not SP-D. Terbutaline 67-78 surfactant protein A1 Rattus norvegicus 137-141 9476903-7 1998 The combination of 12-O-tetradecanoyl-phorbol-11-acetate (TPA) and terbutaline stimulated secretion of [3H]phosphatidylcholine ([3H]PC), SP-A, and lysozyme, but not SP-D. Terbutaline 67-78 surfactant protein D Rattus norvegicus 165-169 9366411-8 1997 In comparison with control supernatants, the lower level of IL-2 present in terbutaline-exposed culture supernatants supported the proliferation of an IL-2-dependent Th1 clone to a lesser degree. Terbutaline 76-87 interleukin 2 Mus musculus 60-64 9366411-8 1997 In comparison with control supernatants, the lower level of IL-2 present in terbutaline-exposed culture supernatants supported the proliferation of an IL-2-dependent Th1 clone to a lesser degree. Terbutaline 76-87 interleukin 2 Mus musculus 151-155 9277405-4 1997 Gastrin release stimulated by terbutaline (beta 2-agonist) and forskolin was abolished by blockade of L-type VDCCs; the effect of 3.6 mM extracellular Ca2+ was only partially reversed. Terbutaline 30-41 gastrin Homo sapiens 0-7 9277405-4 1997 Gastrin release stimulated by terbutaline (beta 2-agonist) and forskolin was abolished by blockade of L-type VDCCs; the effect of 3.6 mM extracellular Ca2+ was only partially reversed. Terbutaline 30-41 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 43-49 9126981-4 1997 Clones of murine Th1/Th2 cells were exposed to the beta2AR agonist terbutaline before activation by Ag-presenting B cells. Terbutaline 67-78 negative elongation factor complex member C/D, Th1l Mus musculus 17-20 9250445-1 1997 OBJECTIVE: To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with IDDM. Terbutaline 201-212 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 176-181 9373782-4 1997 We assessed the effects of 2 weeks treatment with the beta 2-adrenoceptor agonist terbutaline (3 x 5 mg day-1 p.o.) Terbutaline 82-93 adrenoceptor beta 2 Homo sapiens 54-73 9279294-1 1997 OBJECTIVE: The objective of this study was to investigate the effects of bambuterol (a prodrug of the beta 2-agonist terbutaline) on lipid and lipoprotein levels in patients with hyperlipidaemia. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 102-108 9256163-4 1997 Forskolin (10 microM), an activator of adenylyl cyclase, and terbutaline (100 microM), a beta2-adrenergic agonist known to increase cAMP levels, also increased renin mRNA and prorenin release. Terbutaline 61-72 renin Homo sapiens 160-165 9256163-6 1997 Angiotensin II agonist inhibited the stimulatory effect of terbutaline on renin secretion as did the cytokines tumor necrosis factor-alpha and lipopolysaccharide plus interferon-gamma. Terbutaline 59-70 angiotensinogen Homo sapiens 0-14 9256163-6 1997 Angiotensin II agonist inhibited the stimulatory effect of terbutaline on renin secretion as did the cytokines tumor necrosis factor-alpha and lipopolysaccharide plus interferon-gamma. Terbutaline 59-70 renin Homo sapiens 74-79 9154891-11 1997 Following KGF pretreatment, uninjured lungs exported more intratracheal PBS than normal lungs following terbutaline stimulation ex vivo. Terbutaline 104-115 fibroblast growth factor 7 Rattus norvegicus 10-13 9126981-4 1997 Clones of murine Th1/Th2 cells were exposed to the beta2AR agonist terbutaline before activation by Ag-presenting B cells. Terbutaline 67-78 heart and neural crest derivatives expressed 2 Mus musculus 21-24 9126981-4 1997 Clones of murine Th1/Th2 cells were exposed to the beta2AR agonist terbutaline before activation by Ag-presenting B cells. Terbutaline 67-78 adrenergic receptor, beta 2 Mus musculus 51-58 9126981-5 1997 Terbutaline exposure of Th1 cells before activation inhibited IFN-gamma production by Th1 cells and subsequent IgG2a production by B cells. Terbutaline 0-11 negative elongation factor complex member C/D, Th1l Mus musculus 24-27 9126981-5 1997 Terbutaline exposure of Th1 cells before activation inhibited IFN-gamma production by Th1 cells and subsequent IgG2a production by B cells. Terbutaline 0-11 interferon gamma Mus musculus 62-71 9126981-5 1997 Terbutaline exposure of Th1 cells before activation inhibited IFN-gamma production by Th1 cells and subsequent IgG2a production by B cells. Terbutaline 0-11 negative elongation factor complex member C/D, Th1l Mus musculus 86-89 9126981-5 1997 Terbutaline exposure of Th1 cells before activation inhibited IFN-gamma production by Th1 cells and subsequent IgG2a production by B cells. Terbutaline 0-11 immunoglobulin heavy variable V1-9 Mus musculus 111-116 9126981-8 1997 Although baseline levels of intracellular cAMP were similar in both subsets, terbutaline induced an increase in cAMP levels in Th1 cells only. Terbutaline 77-88 negative elongation factor complex member C/D, Th1l Mus musculus 127-130 9127437-2 1997 The beta-agonists, procaterol, clenbuterol, fenoterol and terbutaline, inhibited TNF-alpha and IL-1 beta production in a concentration-dependent manner, whereas they had no effect on IL-8 production. Terbutaline 58-69 tumor necrosis factor Homo sapiens 81-90 9265155-0 1997 [Effect of the beta-2 mimetic drug terbutaline of growth hormone secretion in prepubertal asthmatic children]. Terbutaline 35-46 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 15-21 9265155-0 1997 [Effect of the beta-2 mimetic drug terbutaline of growth hormone secretion in prepubertal asthmatic children]. Terbutaline 35-46 growth hormone 1 Homo sapiens 50-64 9265155-4 1997 The purpose of our study was to find out whether the beta-2 mimetic terbutalin, often used in asthma therapy, exercises a negative influence on the spontaneous release of growth hormone in children suffering from asthma. Terbutaline 68-78 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 53-59 9265155-4 1997 The purpose of our study was to find out whether the beta-2 mimetic terbutalin, often used in asthma therapy, exercises a negative influence on the spontaneous release of growth hormone in children suffering from asthma. Terbutaline 68-78 growth hormone 1 Homo sapiens 171-185 9265155-5 1997 The growth hormone release was studied in 10 prepuberal children suffering from atopic asthma who received intravenous therapeutic doses of terbutalin: testing was done for a total period of 24 hours before and during administration. Terbutaline 140-150 growth hormone 1 Homo sapiens 4-18 9265155-6 1997 Terbutalin effected significant inhibition of growth hormone secretion merely during the waking phase (6.2 +/- 1.0 to 3.7 +/- 0.7 ng/ml), but not during the sleep phase (13.1 +/- 1.8 to 12.5 +/- 2.0 ng/ml) and the 24-hour period (11.0 +/- 1.0 to 9.8 +/- 1.5 ng/ml). Terbutaline 0-10 growth hormone 1 Homo sapiens 46-60 9265155-8 1997 These results point to a short-term inhibition of growth hormone secretion, exercised by intravenously administered terbutalin. Terbutaline 116-126 growth hormone 1 Homo sapiens 50-64 9127437-2 1997 The beta-agonists, procaterol, clenbuterol, fenoterol and terbutaline, inhibited TNF-alpha and IL-1 beta production in a concentration-dependent manner, whereas they had no effect on IL-8 production. Terbutaline 58-69 interleukin 1 beta Homo sapiens 95-104 9126197-9 1997 These results suggest that the beta 2-adrenoceptor agonist terbutaline should be effective for increasing liver blood flow and could lessen postoperative liver ischemia. Terbutaline 59-70 beta-2 adrenergic receptor Canis lupus familiaris 31-50 9002984-5 1997 The beta 3-, beta L-, and beta 2-adrenoceptor agonists BRL 37344, dobutamine, and terbutaline inhibited ob gene expression in mouse brown adipocytes differentiated in culture with EC50 values of 0.3, 1.0, and 85 nM, respectively. Terbutaline 82-93 adrenergic receptor, beta 2 Mus musculus 4-45 9126197-2 1997 This study examined the effects of the beta 2-adrenoceptor agonist, terbutaline, on liver blood flow and how these effects were influenced by surgical hepatic denervation in a conscious canine model. Terbutaline 68-79 beta-2 adrenergic receptor Canis lupus familiaris 39-58 8842454-14 1996 The beta 2-adrenoceptor agonist, terbutaline (1 mumol l-1) increased (1.53 [1.14-2.01]) and the beta-adrenoceptor antagonist, pindolol (1 mumol l-1) suppressed noradrenaline release (0.62 [0.49-0.79]) under normoxic conditions. Terbutaline 33-44 adrenoceptor beta 2 Homo sapiens 4-23 9203624-6 1997 Dobutamine and terbutaline, beta1- and beta2-adrenoceptor agonists, evoked 17- and 5-fold increases in secretion, respectively. Terbutaline 15-26 adrenoceptor beta 1 Homo sapiens 28-57 9282409-3 1997 The first beta 2-stimulants to be introduced were shorter-acting drugs such as salbutamol and terbutaline. Terbutaline 94-105 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 10-16 8899116-9 1996 Both salmeterol and terbutaline very effectively inhibited the anti-IgE-induced extravasation of alpha 2-macroglobulin into skin chambers, with a significantly more sustained effect by salmeterol. Terbutaline 20-31 alpha-2-macroglobulin Homo sapiens 97-118 8896942-1 1996 Bambuterol, a biscarbamate ester prodrug of the beta 2 adrenergic agonist terbutaline, has been approved for the treatment of asthma in 28 countries. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 8921745-0 1996 Interaction of beta 2-adrenoceptor agonists with native cyclodextrins: application to the development of chiral assays for terbutaline. Terbutaline 123-134 adrenoceptor beta 2 Homo sapiens 15-34 8921745-4 1996 Only the enantiomers of the resorcinol type beta 2-agonists terbutaline and orciprenaline were separated in the CZE and HPLC systems, suggesting the position of substituents in the aromatic ring of beta 2-agonists has a profound effect on the enantioselectivity of complexation of these drugs with beta-CD. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 44-50 8921745-4 1996 Only the enantiomers of the resorcinol type beta 2-agonists terbutaline and orciprenaline were separated in the CZE and HPLC systems, suggesting the position of substituents in the aromatic ring of beta 2-agonists has a profound effect on the enantioselectivity of complexation of these drugs with beta-CD. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 198-204 8963487-3 1996 TnT serum concentration of neonates exposed in utero to Bricanyl was not significantly higher (mean 0.12 +/- 0.20 microgram/l) in comparison with the normal cardiac troponin T level but 4 of 15 neonates had an elevated TnT concentration (above 0.1 microgram/l). Terbutaline 56-64 troponin T1, slow skeletal type Homo sapiens 0-3 8967508-3 1996 Methacholine (10(-6) M) and terbutaline (10(-6)M) increased CBF a maximum of 23.0 +/- 1.8% (P < 0.001) and 16.5 +/- 2.3% (P < 0.001). Terbutaline 28-39 nuclear transcription factor Y subunit alpha Homo sapiens 60-65 8764303-1 1996 Infusion of the beta 2-adrenoceptor agonist terbutaline will cause an activation of the Na(+)-K+ pump that leads to lowering of plasma K+ concentration and intracellular Na+ concentration. Terbutaline 44-55 adrenoceptor beta 2 Homo sapiens 16-35 8555251-3 1996 The purposes of this study were to determine if undifferentiated fetal type II cells can secrete phosphatidylcholine, to determine if terbutaline, a beta-adrenergic agonist, stimulates secretion of surfactant phospholipids by undifferentiated fetal cells and to examine the effects of differentiation on secretion of surfactant phospholipids by fetal cells. Terbutaline 134-145 amyloid beta precursor protein Homo sapiens 147-153 8902860-9 1996 Considering the general trend to noninvasive therapy in children and the more frequent adverse effects after epinephrine injection, such nebulized beta-2 agonists as terbutaline appear preferable for initial therapy of acute asthma if oxygen is supplemented to prevent possible hypoxemia. Terbutaline 166-177 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 147-153 8778469-4 1996 Because amiloride-inhibitable 22Na+ uptake reflects Na(+)-channel function, these data indicate that terbutaline may transiently upregulate Na(+)-channel function. Terbutaline 101-112 sodium voltage-gated channel alpha subunit 8 Rattus norvegicus 52-65 8778469-4 1996 Because amiloride-inhibitable 22Na+ uptake reflects Na(+)-channel function, these data indicate that terbutaline may transiently upregulate Na(+)-channel function. Terbutaline 101-112 sodium voltage-gated channel alpha subunit 8 Rattus norvegicus 140-153 8788119-1 1995 Treatment with the beta 2-adrenergic agonist terbutaline or the beta-adrenergic agonist isoproterenol suppresses experimental allergic encephalomyelitis, decreases the number of IFN gamma-producing splenic cells, and decreases the number of beta-adrenergic receptors on splenic lymphocytes in Lewis rats. Terbutaline 45-56 interferon gamma Rattus norvegicus 178-187 23888922-2 1996 On gestational day 14, acute administration of terbutaline to pregnant rats resulted in sixfold induction of c-fos mRNA within 1 h; the same increase was obtained when a membrane-permeable analogue of cAMP was given. Terbutaline 47-58 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 109-114 23888922-2 1996 On gestational day 14, acute administration of terbutaline to pregnant rats resulted in sixfold induction of c-fos mRNA within 1 h; the same increase was obtained when a membrane-permeable analogue of cAMP was given. Terbutaline 47-58 cathelicidin antimicrobial peptide Rattus norvegicus 201-205 23888922-3 1996 Treatment with dexamethasone on gestational days 11,12 and 13 produced the same increase in c-fos mRNA on gestational day 14 as had been seen with acute terbutaline or CAMP; no further increase could be obtained with acute CAMP treatment in the dexamethasone-pretreated animals. Terbutaline 153-164 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 92-97 8831799-5 1996 ER mice treated with the beta 2 adrenergic agonist terbutaline on days 4, 5 and 6 after immunization produced significantly lower numbers of IgG PFC than did saline treated controls. Terbutaline 51-62 hemoglobin, beta adult minor chain Mus musculus 25-31 7544033-4 1995 In response to terbutaline, a beta 2-selective agonist, marked stimulation of c-fos was demonstrated in the liver, which contains beta 2-receptors, on Gestational Day 20, as well as on Postnatal Days 1 and 8. Terbutaline 15-26 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 78-83 8521164-9 1995 The pA2 for the selective beta 1- and beta 2-adrenoceptor antagonists versus CGP 12177-induced lipolysis were 2 to 3 log units lower than those for the beta 1-antagonist versus dobutamine or for the beta 2-antagonist versus terbutaline. Terbutaline 224-235 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 26-32 8521164-9 1995 The pA2 for the selective beta 1- and beta 2-adrenoceptor antagonists versus CGP 12177-induced lipolysis were 2 to 3 log units lower than those for the beta 1-antagonist versus dobutamine or for the beta 2-antagonist versus terbutaline. Terbutaline 224-235 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 38-44 7544033-5 1995 In the heart, which contains predominantly beta 1-receptors, isoproterenol (a non-subtype-selective beta-agonist) was more effective that terbutaline, indicating that either receptor subtype can elicit stimulation of c-fos. Terbutaline 138-149 Fos proto-oncogene, AP-1 transcription factor subunit Rattus norvegicus 217-222 7738189-8 1995 When adipose tissue was pretreated with the beta 1/beta 2-selective adrenoceptor blocker propranolol the glycerol increasing effect of dobutamine or terbutaline was inhibited by 80-85% but the glycerol response to CGP 12177 was not influenced. Terbutaline 149-160 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 44-57 7582479-4 1995 The vasorelaxant potencies of the non-selective beta-adrenoceptor agonist, isoprenaline, the beta 1-adrenoceptor agonist, dobutamine and the beta 2-adrenoceptor agonist, terbutaline were all significantly (P < 0.05) reduced (isoprenaline, ED50 = 265 +/- 31 pmol v. 1.05 +/- 0.42 nmol; dobutamine, ED50 = 294 +/- 67 pmol v. 497 +/- 115 pmol; terbutaline, ED50 = 157 +/- 26 nmol v. 452 +/- 120 nmol) in the presence of the KATP-channel blocker, glibenclamide. Terbutaline 170-181 adrenoceptor beta 2 Rattus norvegicus 141-160 8751019-1 1995 Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 250-261 adrenoceptor beta 2 Homo sapiens 11-30 8751019-1 1995 Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 250-261 adrenoceptor beta 2 Homo sapiens 222-241 8751145-0 1995 Factors behind the functional beta 2-adrenoceptor selectivity of terbutaline. Terbutaline 65-76 adrenoceptor beta 2 Homo sapiens 30-49 7564908-5 1995 The beta 2-agonist terbutaline and salbutamol (4.10(-9) M when injected intraseptally also caused a decrease in urine flow and in renal Na+ and K+ excretion. Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 7542949-5 1994 Also the beta 2-adrenoceptor agonist terbutaline (pD2 = 8.29; Emax = 83%), the xanthine derivative theophylline (pD2 = 4.19; Emax = 100%) and the Ca2+ blocker verapamil (pD2 = 5.55; Emax = 100%) suppressed responses to non-cholinergic neurostimulation. Terbutaline 37-48 beta-2 adrenergic receptor Cavia porcellus 9-28 7889286-8 1994 The duration of beta-adrenoceptor blockade was tested by determining the adenosine 3",5"-cyclic monophosphate (cyclic AMP) production induced by terbutaline (a beta 2-adrenoceptor specific agonist). Terbutaline 145-156 adrenoceptor beta 2 Homo sapiens 160-179 7993659-0 1994 Erythropoietin (EPO) levels in fetal rats after ritodrine and terbutaline administration. Terbutaline 62-73 erythropoietin Rattus norvegicus 0-14 8058076-1 1994 BACKGROUND: In a previous study, we found that two years of treatment with an inhaled corticosteroid, budesonide, was more effective than treatment with an inhaled beta 2-agonist, terbutaline, in patients with newly diagnosed, generally mild asthma. Terbutaline 180-191 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 164-170 7993659-0 1994 Erythropoietin (EPO) levels in fetal rats after ritodrine and terbutaline administration. Terbutaline 62-73 erythropoietin Rattus norvegicus 16-19 7993659-1 1994 Beta-2 sympathomimetics, such as terbutaline, have been shown to alter erythropoietin (EPO) secretion in animal studies. Terbutaline 33-44 erythropoietin Rattus norvegicus 71-85 8059831-9 1994 CONCLUSIONS: Our data suggest that terbutaline and ritodrine are teratogenic in the chick and that these agents exert their teratogenic effects primarily through stimulation of the beta 2-adrenergic receptor. Terbutaline 35-46 adrenoceptor beta 2 Gallus gallus 181-207 7993659-1 1994 Beta-2 sympathomimetics, such as terbutaline, have been shown to alter erythropoietin (EPO) secretion in animal studies. Terbutaline 33-44 erythropoietin Rattus norvegicus 87-90 8200997-3 1994 First, an 80-fold decrease in sensitivity to the beta 2-selective agonist terbutaline (P < 0.001) which could be ascribed to a 50% reduced number of beta 2-receptors (P < 0.005) as determined with radioligand binding. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-55 7957831-3 1994 At therapeutic levels, both agents increased PMN chemotaxis to formyl-methionyl-leucyl-phenylalanine (FMLP) in a dose-dependent manner from a control value of 22.5 +/- 3.58 cells.field-1 to 26.1 +/- 4.73 cells.field-1 with 4 mg.l-1 terbutaline, and to 26.3 +/- 4.49 cells.field-1 with 20 mg.l-1 aminophylline. Terbutaline 232-243 formyl peptide receptor 1 Homo sapiens 102-106 8024220-6 1994 Challenge with the beta 2-agonist terbutaline sulfate produced an increase of mucociliary activity of 40.6% +/- 7.8% (mean +/- SEM), which is consistent with previous results in animal models. Terbutaline 34-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 19-25 8200997-3 1994 First, an 80-fold decrease in sensitivity to the beta 2-selective agonist terbutaline (P < 0.001) which could be ascribed to a 50% reduced number of beta 2-receptors (P < 0.005) as determined with radioligand binding. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 152-158 8144793-0 1994 Positive inotropic effects of the beta 2-adrenoceptor agonist terbutaline in the human heart: effects of long-term beta 1-adrenoceptor antagonist treatment. Terbutaline 62-73 adrenoceptor beta 2 Homo sapiens 34-53 8203484-6 1994 Nevertheless, a significant hyperpolarization recorded with terbutaline implied that beta 2-adrenoceptor activation stimulated the Na-K pump at rest. Terbutaline 60-71 adrenoceptor beta 2 Rattus norvegicus 85-104 8144793-6 1994 Terbutaline effects were antagonized only by the beta 2-adrenoceptor antagonist ICI 118,551, indicating that they were mediated by beta 2-adrenoceptor stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 49-68 8144793-6 1994 Terbutaline effects were antagonized only by the beta 2-adrenoceptor antagonist ICI 118,551, indicating that they were mediated by beta 2-adrenoceptor stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 131-150 8126815-2 1994 It has been suggested that terbutaline, a beta-agonist, might be beneficial in treating priapism in this setting. Terbutaline 27-38 amyloid beta precursor protein Homo sapiens 40-46 7508184-3 1994 Because terbutaline, a beta 2-agonist, increases Na+ transport by FDLE, we studied its effect and selected signal transduction mechanisms on NSC channel activity. Terbutaline 8-19 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 23-29 8143834-6 1994 Mean lung deposition of terbutaline sulphate inhaled at 57 l.min-1 was 27.0 +/- 7.7%. Terbutaline 24-44 CD59 molecule (CD59 blood group) Homo sapiens 61-66 7904614-4 1994 In contrast, hCG secretion was stimulated only by terbutaline (5-fold). Terbutaline 50-61 hypertrichosis 2 (generalised, congenital) Homo sapiens 13-16 8112441-6 1993 After treatment with bambuterol, mean morning and evening PEF (SD) were 347 (122) and 365 (121) l.min-1, respectively and 346 (121) and 365 (122) l.min-1, respectively, after treatment with terbutaline. Terbutaline 190-201 CD59 molecule (CD59 blood group) Homo sapiens 148-153 7913199-7 1994 Co-administration of methylphenidate with the mixed alpha/beta-adrenergic agonist dobutamine or with the beta 2-selective agonists metaproterenol, ritodrine or terbutaline produced a similar potentiation of toxicity. Terbutaline 160-171 hemoglobin, beta adult minor chain Mus musculus 105-111 8272370-2 1993 In the present study we have exposed intact, single fibres from a mouse muscle to the beta 2-adrenergic agonist terbutaline. Terbutaline 112-123 hemoglobin, beta adult minor chain Mus musculus 86-92 7904074-0 1993 Suppression of peptide YY-induced hyperphagia by terbutaline. Terbutaline 49-60 peptide YY Rattus norvegicus 15-25 7904074-4 1993 Terbutaline pretreatment significantly decreased feeding elicited by PYY in a dose-dependent fashion. Terbutaline 0-11 peptide YY Rattus norvegicus 69-72 8266020-2 1993 The beta-2 agonist terbutaline was given orally, 5 mg three times daily, for 10 days, and the subjects were studied before medication (basal), on days 3 and 10 during the medication, and 1 week after withdrawal of the drug. Terbutaline 19-30 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 8403793-8 1993 Sensitivity to terbutaline, a selective beta 2-adrenoceptor agonist, increased 25-fold (P = 0.01), whereas the ED50 values for dobutamine, a selective beta 1-adrenoceptor agonist, did not change significantly. Terbutaline 15-26 adrenoceptor beta 2 Homo sapiens 40-59 7901194-6 1993 Terbutaline, a partial beta 2-agonist, prevented the thrombin-induced permeability, but dobutamine, a partial beta 1-agonist, did not. Terbutaline 0-11 coagulation factor II, thrombin Bos taurus 53-61 8103495-5 1993 Terbutaline (10(-6) M) increased 3 beta-HSD mRNA, 3 beta-HSD content and progesterone production (1.5- to 3-fold), an effect which could be prevented by alprenolol. Terbutaline 0-11 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Homo sapiens 33-43 8391311-7 1993 Multiple regression analysis revealed that terbutaline sensitivity correlated inversely with total plasma triglycerides, apolipoprotein B, VLDL-C, and VLDL triglycerides (partial r from -.56 to -.42), but there was no correlation between dobutamine sensitivity and blood lipids (partial r from .05 to .18) or between receptor binding and blood lipids (partial r from .01 to .28). Terbutaline 43-54 apolipoprotein B Homo sapiens 121-137 8375242-1 1993 OBJECTIVE: To test the hypothesis that the amino acid Ala and the beta 2-adrenergic agonist terbutaline raise plasma glucose concentrations substantially, and do so through different mechanisms, in IDDM patients. Terbutaline 92-103 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 8375243-1 1993 OBJECTIVE: To test the hypothesis that, in contrast to administration of glucose or glucagon, administration of the amino acid Ala or of the beta 2-adrenergic agonist terbutaline produces sustained glucose recovery from hypoglycemia. Terbutaline 167-178 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 141-147 8392360-2 1993 A double-blind placebo-controlled study was conducted on the effects of oral terbutaline (beta 2-adrenoceptor agonist) and propranolol (beta 1 beta 2-adrenoceptor antagonist) on basal heat production of skeletal muscle, measured ex vivo by direct microcalorimetry. Terbutaline 77-88 adrenoceptor beta 2 Homo sapiens 90-109 8240692-3 1993 The patients on terbutaline therapy had a marked hyperglycemia at 11 h which remained elevated for 48 h. There was a simultaneous rise in plasma insulin and C-peptide, and a fall in plasma glucagon. Terbutaline 16-27 insulin Homo sapiens 145-152 8240692-3 1993 The patients on terbutaline therapy had a marked hyperglycemia at 11 h which remained elevated for 48 h. There was a simultaneous rise in plasma insulin and C-peptide, and a fall in plasma glucagon. Terbutaline 16-27 insulin Homo sapiens 157-166 8103495-5 1993 Terbutaline (10(-6) M) increased 3 beta-HSD mRNA, 3 beta-HSD content and progesterone production (1.5- to 3-fold), an effect which could be prevented by alprenolol. Terbutaline 0-11 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 Homo sapiens 50-60 8383517-6 1993 Terbutaline infusion induced a significant rise in plasma glucose and a fall in plasma potassium in keeping with its beta 2-adrenoceptor stimulant properties. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 117-136 8096820-7 1993 A marked insulin release following the injection of a maximal dose of the beta 2-adrenoceptor agonist, terbutaline, was accompanied by an increase (30-50%) in islet monoamine oxidase activity. Terbutaline 103-114 adrenergic receptor, beta 2 Mus musculus 74-93 8095449-3 1993 Thus, we questioned whether the beta 2-adrenergic agonist, terbutaline, would improve mucociliary clearance in patients with CF as it does in healthy subjects. Terbutaline 59-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-38 7694442-3 1993 In the isolated guinea-pig lung, spontaneous strong postmortem bronchoconstriction occurred; this had to be overcome by the beta 2-adrenoceptor agonist terbutaline. Terbutaline 152-163 beta-2 adrenergic receptor Cavia porcellus 124-143 8387193-10 1993 At 2 min after injection of different doses of glucose mixed with a maximal dose of terbutaline, the insulin secretory response was either increased (submaximal glucose dose) or unaffected (maximal dose of glucose) by the beta 2-adrenoceptor stimulator. Terbutaline 84-95 adrenergic receptor, beta 2 Mus musculus 222-241 8157045-1 1993 A double blind placebo-controlled study was conducted of the effects of oral propranolol (beta 1 beta 2-adrenoceptor antagonist) and terbutaline (beta 2-adrenoceptor agonist) on erythrocyte heat production, measured by direct microcalorimetry under static conditions at 37 degrees C and pH 7.4. Terbutaline 133-144 adrenoceptor beta 2 Homo sapiens 146-165 8420308-9 1993 CONCLUSIONS: Our data support a dose-independent, terbutaline-induced glucose intolerance mediated by glucagon and caused by diminished insulin sensitivity. Terbutaline 50-61 insulin Homo sapiens 136-143 8432621-0 1993 The beta 2-adrenergic agonist terbutaline suppresses acute passive transfer experimental autoimmune myasthenia gravis (EAMG). Terbutaline 30-41 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 4-10 8432621-1 1993 Treatment of Lewis rats with the beta 2-adrenergic agonist terbutaline suppressed clinical symptoms of acute passive transfer EAMG induced with monoclonal anti-acetylcholine receptor antibody and accelerated clinical recovery in affected animals. Terbutaline 59-70 UDP glucuronosyltransferase 1 family, polypeptide A7C Rattus norvegicus 33-39 1382419-5 1992 A beta adrenergic agonist (terbutaline, 10 microM) increased Po in cell-attached patches from almost 0 (Po less than 0.01; n = 9) to 0.39 +/- 0.09 (n = 9) and [Ca2+]i from 40 +/- 6nM (n = 9) to more than 1 microM. Terbutaline 27-38 amyloid beta precursor protein Homo sapiens 0-6 8122021-3 1993 The aim of this study is to assess the use of a beta-2-mimetic powder inhaler (Bricanyl Turbuhaler) in children presenting with an exacerbation of asthma. Terbutaline 79-98 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 1357551-8 1992 CONCLUSIONS: We observed tolerance to the nonbronchodilator actions of the inhaled beta 2-agonist terbutaline in patients with mild asthma, an effect that may be more pronounced in mast cells than in bronchial smooth muscle. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1320047-2 1992 The lipolytic sensitivity of the nonselective beta-agonists epinephrine and isoprenaline as well as the selective agonists norepinephrine (beta 1) and terbutaline (beta 2) was significantly increased 5-10 times in omental fat cells. Terbutaline 151-162 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 164-170 1358833-0 1992 Pharmacokinetic/pharmacodynamic characteristics of the beta-2-agonists terbutaline, salbutamol and fenoterol. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 55-61 1629507-0 1992 A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. Terbutaline 99-110 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1279289-0 1992 Terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function in humans: attenuation by ketotifen. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 39-58 1279289-5 1992 These parameters were assessed before and after a 14-day treatment with the beta 2-adrenoceptor agonist terbutaline (5 mg three times daily) with or without simultaneous administration of ketotifen (1 mg twice daily). Terbutaline 104-115 adrenoceptor beta 2 Homo sapiens 76-95 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 0-11 adrenoceptor beta 1 Homo sapiens 165-196 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 0-11 adrenoceptor beta 1 Homo sapiens 242-261 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 55-74 1279289-6 1992 Terbutaline desensitized all in vivo effects involving beta 2-adrenoceptors (ISO-induced decrease in DBP and increase in plasma NE and, to a minor extent, the mixed beta 1- and beta 2-adrenoceptor-mediated increase in HR), but did not affect beta 1-adrenoceptor-mediated in vivo effects; concomitant treatment of the volunteers with ketotifen markedly blunted terbutaline-induced desensitization of beta 2-adrenoceptor in vivo function. Terbutaline 360-371 adrenoceptor beta 2 Homo sapiens 55-74 1362362-3 1992 The beta 2-adrenoceptor selective compounds KWD 2026 and terbutaline were bound to two sites, one corresponding to the beta 1-adrenoceptors and the other to the beta 2-adrenoceptors. Terbutaline 57-68 beta-2 adrenergic receptor Cavia porcellus 4-23 1429916-1 1992 We compared the changes in peak expiratory flow rate (PEFR), plasma potassium and plasma glucose during and after an infusion of the beta 2-agonist, terbutaline, in seven asthmatic subjects. Terbutaline 149-160 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 133-139 1349493-8 1992 beta 2-adrenoceptor antagonism was shown by attenuation of terbutaline induced hypokalaemic, chronotropic and finger tremor responses. Terbutaline 59-70 adrenoceptor beta 2 Homo sapiens 0-19 1323000-5 1992 On the other hand, terbutaline sulfate, a full agonist to beta 2-AR, increased delta Vcfc partially in comparison with isoproterenol; 51% in NYHA I, 52% in NYHA II, 36% in NYHA III and 17% in NYHA IV. Terbutaline 19-38 adrenoceptor beta 2 Homo sapiens 58-67 1313353-3 1992 Before the other two provocations the patients had been on continuous treatment with oral terbutaline (7.5-mg slow-release pill bid) for 2 wk, which was discontinued 12 or 48 h before the allergen provocation. Terbutaline 90-101 BH3 interacting domain death agonist Homo sapiens 128-131 1576070-10 1992 Reducing the inspiratory flow to approximately 34 l min-1 produced slightly reduced side effects and lower plasma terbutaline concentrations. Terbutaline 114-125 CD59 molecule (CD59 blood group) Homo sapiens 52-57 1348869-1 1992 Short acting beta 2-agonists, such as salbutamol, fenoterol and terbutaline, are the most potent bronchodilating agents in the treatment of acute asthmatic attacks. Terbutaline 64-75 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 1550166-7 1992 The use of terbutaline by any route significantly increases the need for insulin to achieve glycemic control. Terbutaline 11-22 insulin Homo sapiens 73-80 1349258-4 1992 The same anti-LCR effect was achieved by compensating for the shorter duration of action of terbutaline with repeated drug infiltration in 12.5 micrograms doses of the weal produced by anti-IgE up to 3 1/2 hr after challenge (n = 8). Terbutaline 92-103 immunoglobulin heavy constant epsilon Homo sapiens 190-193 1541141-1 1992 The purpose of the study was to investigate whether a constant submaximal exercise challenge affected the plasma pharmacokinetics of an inhaled beta 2-adrenoceptor agonist, terbutaline sulfate. Terbutaline 173-192 adrenoceptor beta 2 Homo sapiens 144-163 1347507-0 1992 Hemodynamic effects of terbutaline, a beta 2-adrenoceptor agonist, in conscious rats with secondary biliary cirrhosis. Terbutaline 23-34 adrenoceptor beta 2 Rattus norvegicus 38-57 1347507-1 1992 The hemodynamic responses to terbutaline - a selective beta 2-adrenoceptor agonist - were studied in conscious normal rats and in conscious rats with secondary biliary cirrhosis. Terbutaline 29-40 adrenoceptor beta 2 Rattus norvegicus 55-74 1331993-1 1992 This pilot study was undertaken to characterize age-related alterations in airway and metabolic beta 2-adrenergic receptor response using terbutaline as a probe. Terbutaline 138-149 adrenoceptor beta 2 Homo sapiens 96-122 1280742-2 1992 To find out whether such "cross-regulation" between Gs protein- and Gi protein-coupled receptors can be also demonstrated in vivo in humans, we studied the effects of a 2 week treatment of eight male volunteers with the beta 2-adrenoceptor agonist terbutaline (3 x 5 mg/day) on beta 2-adrenoceptor density and Gi-protein content in lymphocytes and on alpha 2-adrenoceptor density (Gi-coupled receptors) in platelets. Terbutaline 248-259 adrenoceptor beta 2 Homo sapiens 220-239 1280742-3 1992 Terbutaline decreased the lymphocyte beta 2-adrenoceptor density by about 30%, but had no significant influence on lymphocyte Gi-protein levels (assessed by pertussis toxin-catalyzed [32P]ADP ribosylation) or on platelet alpha 2-adrenoceptor density. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 37-56 1681086-5 1991 On the other hand, isoprenaline plus a selective beta-1 receptor antagonist or the beta-2 selective adrenergic agonist terbutaline caused a constant lipolytic effect for at least 3 hr. Terbutaline 119-130 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 83-89 1591462-4 1992 Beta 2-adrenoceptor mediated changes of plasma potassium and FEV1 were related to plasma concentrations of terbutaline and racemic metoprolol. Terbutaline 107-118 adrenoceptor beta 2 Homo sapiens 0-19 1668078-0 1991 The adrenergic control of lipolysis: development of tolerance to beta-2 receptor stimulation with terbutaline. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 65-71 1718682-15 1991 The long-acting beta 2-agonists, including formoterol, represent a significant advance over current maintenance or prophylactic bronchodilator therapy with intermediate-acting beta 2-agonists such as salbutamol, fenoterol and terbutaline, predominantly because of the twice daily administration regimen. Terbutaline 226-237 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 16-22 1833216-10 1991 An ANF dose of 97 pmol kg-1 min-1 increased the aqueous humor flow by 51% in the control eye and by 19% in the terbutaline-treated eye. Terbutaline 111-122 natriuretic peptide A Homo sapiens 3-6 1867867-11 1991 Four hours after endotoxin the transferrin index was significantly higher in the controls than in the terbutaline treated group, both in the lungs and in the liver (P less than 0.01). Terbutaline 102-113 LOW QUALITY PROTEIN: serotransferrin Ovis aries 31-42 1673971-0 1991 Assessment of beta-1 selectivity of bisoprolol and atenolol by means of their influence on the lipolytic response to an infusion of terbutaline. Terbutaline 132-143 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 14-20 1672696-4 1991 The results demonstrated that epinephrine and terbutaline (a beta 2 agonist) significantly stimulated gastrin release above basal which could be blocked by the addition of propranolol (beta-adrenergic antagonist). Terbutaline 46-57 gastrin Homo sapiens 102-109 1978808-10 1990 Other beta-sympathomimetic agents such as dopamine, dobutamine, fenoterol, salbutamol, and terbutaline also stimulated myocardial G-6-PDH activity in a time- and dose-related manner. Terbutaline 91-102 glucose-6-phosphate dehydrogenase Rattus norvegicus 130-137 1758201-3 1991 PEFR increased significantly after inhaled terbutaline both with and without PEP. Terbutaline 43-54 progestagen associated endometrial protein Homo sapiens 77-80 1758201-4 1991 The mean increase in PEFR after terbutaline inhalations was significantly greater (p less than 0.0001) in the +PEP group (24 L/min) compared to the -PEP group (17 L/min). Terbutaline 32-43 progestagen associated endometrial protein Homo sapiens 111-114 2080624-5 1990 In 178 cases (98.3%) the infusion of a beta-2 adrenergic drug (hexoprenaline or terbutaline) led, without adverse effects, to the rapid resolution of the alarming findings. Terbutaline 80-91 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 39-45 2173454-11 1990 Agents that may increase cAMP levels in PMN (PTX, DBcAMP, forskolin, isobutyl methylxanthine, and terbutaline) significantly attenuate TNF-induced PMN chemiluminescence (p less than 0.05). Terbutaline 98-109 tumor necrosis factor Bos taurus 135-138 1982263-1 1990 In rat vas deferens, the beta-adrenoceptor agonists, isoprenaline, salbutamol, terbutaline and fenoterol, inhibited the contractions elicited by transmural electrical stimuli to an extent which depended on voltage magnitude. Terbutaline 79-90 arginine vasopressin Rattus norvegicus 7-10 2239124-1 1990 Bambuterol is an inactive prodrug which is enzymatically cleaved by plasma cholinesterase to yield the active compound, terbutaline. Terbutaline 120-131 butyrylcholinesterase Homo sapiens 75-89 1976296-7 1990 A beta 2-adrenergic drug (hexoprenaline or terbutaline) was infused routinely without adverse effects and with rapid resolution of the worrisome findings in 178 (98.3%) cases. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 2-8 2244449-1 1990 Bambuterol (the bisdimethylcarbamate prodrug of terbutaline) is a new bronchodilator with a prolonged duration of action due to its inhibition of plasma cholinesterase during metabolism. Terbutaline 48-59 butyrylcholinesterase Homo sapiens 153-167 1973910-0 1990 Beta 2-adrenoceptors in human lung and peripheral mononuclear leukocytes of untreated and terbutaline-treated patients. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 2103752-5 1990 This increase was not altered by pretreatment with 2 mg of propranolol intravenously, a dose which in previous studies blocked terbutaline-induced gastrin release. Terbutaline 127-138 gastrin Homo sapiens 147-154 2117390-0 1990 Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: a case report. Terbutaline 63-74 insulin Homo sapiens 26-33 2117390-2 1990 We describe diabetic ketoacidosis and transient severe insulin resistance in a woman with diabetes who was treated with subcutaneous terbutaline infusion. Terbutaline 133-144 insulin Homo sapiens 55-62 2117390-3 1990 Subcutaneous terbutaline infusion may precipitate transient insulin resistance and diabetic ketoacidosis in women with diabetes. Terbutaline 13-24 insulin Homo sapiens 60-67 1973910-11 1990 Human lung tissue is found to be less susceptible than human MNL for beta 2-adrenoceptor down-regulation by terbutaline treatment at therapeutic doses. Terbutaline 108-119 adrenoceptor beta 2 Homo sapiens 69-88 2165750-0 1990 Inhibition of anti-IgE induced skin response in normals by formoterol, a new beta 2-adrenoceptor agonist, and terbutaline. Terbutaline 110-121 immunoglobulin heavy constant epsilon Homo sapiens 19-22 1974124-3 1990 The intention of the present study was to compare formoterol and terbutaline regarding ability to inhibit immediate wheal and flare responses (WFR) to anti-human IgE with focus on the duration of anti-WFR action. Terbutaline 65-76 immunoglobulin heavy constant epsilon Homo sapiens 162-165 1974124-0 1990 Inhibition of anti-IgE induced skin response in normals by formoterol, a new beta 2-adrenoceptor agonist, and terbutaline. Terbutaline 110-121 immunoglobulin heavy constant epsilon Homo sapiens 19-22 2165750-4 1990 Anti-IgE induced an early wheal and flare reaction (WFR) followed by a progressively increasing induration, the late phase reaction (LCR), lasting greater than or equal to 24 h. Intradermal injection of formoterol 20 ng or terbutaline 500 ng 5 min before challenge gave equal inhibition of the WFR. Terbutaline 223-234 immunoglobulin heavy constant epsilon Homo sapiens 5-8 1974124-5 1990 The drugs injected intradermally 2 min prior to challenge with anti-IgE in volunteers produced a dose-dependent inhibition of the WFR in the range 1pg-100ng (formoterol) and 1ng-1 microgram (terbutaline). Terbutaline 191-202 immunoglobulin heavy constant epsilon Homo sapiens 68-71 2370646-2 1990 We have previously demonstrated, by giving an infusion of terbutaline to human volunteers, that beta 2-stimulation causes a rise in plasma glucose and a fall in plasma potassium. Terbutaline 58-69 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 96-102 1963768-8 1990 Furthermore, IP66 (10 nM) also increased, in a significant manner, the amplitude of vasodilatation elicited by the beta 2-adrenoceptor agonist terbutaline, both in rat mesenteric bed and in rat aortic strips. Terbutaline 143-154 adrenoceptor beta 2 Rattus norvegicus 115-134 2156661-2 1990 The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY (PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Terbutaline 85-96 peptide YY Canis lupus familiaris 129-132 2156661-0 1990 Terbutaline, a beta 2-adrenoreceptor agonist, inhibits gastric acid secretion and stimulates release of peptide YY and gastric inhibitory polypeptide in dogs. Terbutaline 0-11 peptide YY Canis lupus familiaris 104-114 2161747-4 1990 The accumulation of androsterone, the major androgenic steroid detected, increased 3- to 5-fold over baseline in response to treatment with hCG (1 ng/ml), an effect further optimized (2- to 4-fold) by supplementation with insulin-like growth factor-I (10 ng/ml), insulin (1 microgram/ml), terbutaline (10(-6) M), or high density lipoprotein (100 micrograms/ml). Terbutaline 289-300 glycoprotein hormones, alpha polypeptide Homo sapiens 140-143 2156661-2 1990 The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY (PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Terbutaline 85-96 GIP Canis lupus familiaris 170-173 2156661-2 1990 The purpose of this study was to examine the effect of intravenous administration of terbutaline on plasma levels of peptide YY (PYY) and gastric inhibitory polypeptide (GIP), both of which are known to inhibit gastric acid secretion. Terbutaline 85-96 peptide YY Canis lupus familiaris 117-127 2156661-5 1990 Terbutaline significantly increased plasma PYY levels, 24% in response to terbutaline at 10 micrograms/kg/hr, and 59% at 20 micrograms/kg/hr. Terbutaline 0-11 peptide YY Canis lupus familiaris 43-46 2156661-6 1990 Plasma GIP levels were also increased significantly, 24% with terbutaline at 10 micrograms/kg/hr, and 39% at 20 micrograms/kg/hr. Terbutaline 62-73 GIP Canis lupus familiaris 7-10 2156661-7 1990 Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. Terbutaline 22-33 peptide YY Canis lupus familiaris 152-155 2156661-7 1990 Our data suggest that terbutaline-induced inhibition of pentagastrin-stimulated gastric acid secretion is mediated, at least in part, by the release of PYY and GIP. Terbutaline 22-33 GIP Canis lupus familiaris 160-163 2305899-7 1990 The effect of adenosine deaminase on terbutaline-stimulated secretion was antagonized by selective adenosine A1 receptor agonists, N6-cyclopentyladenosine (CPA) and 1-deaza-2-chloro-N6-cyclopentyladenosine (DCCA). Terbutaline 37-48 adenosine deaminase Rattus norvegicus 14-33 1970632-8 1990 In comparison with their isopropyl substituted analogues the beta 2-adrenoceptor selectivity of these compounds (KWD 2026 and terbutaline) was mainly due to a change in affinity for the beta 1- and beta 2-adrenoceptors and, to a lesser degree, a change in intrinsic efficacy. Terbutaline 126-137 beta-2 adrenergic receptor Cavia porcellus 61-80 34739146-0 2021 Mechanical loading alleviated the inhibition of beta2-adrenergic receptor agonist terbutaline on bone regeneration. Terbutaline 82-93 adrenergic receptor, beta 2 Mus musculus 48-73 34739146-3 2021 Therefore, we hypothesized that precisely controlling the mechanical environment can contribute to the alleviation of the negative effects of chronic treatment with the common asthma drug terbutaline, which is a beta2-adrenergic receptor agonist that facilitates bone homeostasis and defect repair through its anabolic effect on osteogenic cells. Terbutaline 188-199 adrenergic receptor, beta 2 Mus musculus 212-237 34739146-10 2021 Periostin, which was secreted mainly by Prrx1+ osteoprogenitors and F4/80+ macrophages, was inhibited by treating the bone defect with terbutaline. Terbutaline 135-146 periostin, osteoblast specific factor Mus musculus 0-9 34739146-10 2021 Periostin, which was secreted mainly by Prrx1+ osteoprogenitors and F4/80+ macrophages, was inhibited by treating the bone defect with terbutaline. Terbutaline 135-146 paired related homeobox 1 Mus musculus 40-45 34739146-10 2021 Periostin, which was secreted mainly by Prrx1+ osteoprogenitors and F4/80+ macrophages, was inhibited by treating the bone defect with terbutaline. Terbutaline 135-146 adhesion G protein-coupled receptor E1 Mus musculus 68-73 34592235-0 2021 The interaction of a beta2 adrenoceptor agonist drug with biomimetic cell membrane models: The case of terbutaline sulphate. Terbutaline 103-123 AA2 Homo sapiens 19-26 34846077-0 2021 Terbutaline attenuates LPS-induced injury of pulmonary microvascular endothelial cells by cAMP/Epac signaling. Terbutaline 0-11 Rap guanine nucleotide exchange factor 3 Homo sapiens 95-99 34846077-2 2021 This study is intended to explore whether terbutaline can alleviate LPS-induced human pulmonary microvascular endothelial cell (HPMVEC) injury through cAMP/Epac signaling. Terbutaline 42-53 Rap guanine nucleotide exchange factor 3 Homo sapiens 156-160 34846077-6 2021 The levels of both cAMP and Epac reduced by LPS was concentration-dependently increased by terbutaline. Terbutaline 91-102 Rap guanine nucleotide exchange factor 3 Homo sapiens 28-32 34846077-8 2021 The beneficial effects of terbutaline on alleviating the inflammation and apoptosis in HPMVECs injured by LPS are mediated by cAMP/Epac signaling, and this evidence would demonstrate the potential of terbutaline in the treatment of ALI. Terbutaline 26-37 Rap guanine nucleotide exchange factor 3 Homo sapiens 131-135 34592235-1 2021 Terbutaline sulphate (TS) is a selective short-acting beta2 adrenoceptor agonist used for asthma treatment. Terbutaline 0-20 adrenoceptor beta 2 Homo sapiens 54-72 34592235-1 2021 Terbutaline sulphate (TS) is a selective short-acting beta2 adrenoceptor agonist used for asthma treatment. Terbutaline 22-24 adrenoceptor beta 2 Homo sapiens 54-72 35180545-6 2022 In this paper, a reliable resolution and determination method was presented using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for fourteen enantiomers of seven beta2-agonist racemates, clenbuterol (CLE), salbutamol (SAL), cimaterol (CIM), terbutaline (TER), clorprenaline (CLO), tulobuterol (TUL), penbuterol (PEN) in pork, beef, and lamb muscle samples. Terbutaline 253-264 ATPase H+ transporting V0 subunit a2 Homo sapiens 174-179 34909668-3 2021 Therefore, we sought to discover the effects of the beta2-adrenergic receptor agonist terbutaline on metabolism and protein synthesis in human primary skeletal muscle cells. Terbutaline 86-97 adrenoceptor beta 2 Homo sapiens 52-77 35180545-6 2022 In this paper, a reliable resolution and determination method was presented using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for fourteen enantiomers of seven beta2-agonist racemates, clenbuterol (CLE), salbutamol (SAL), cimaterol (CIM), terbutaline (TER), clorprenaline (CLO), tulobuterol (TUL), penbuterol (PEN) in pork, beef, and lamb muscle samples. Terbutaline 266-269 ATPase H+ transporting V0 subunit a2 Homo sapiens 174-179 2593433-2 1989 Terbutaline and clenbuterol, which are both selective beta 2-adrenoceptor agonists, produced a concentration-dependent decrease in contractile force of in vitro rabbit detrusor and proximal urethral smooth muscle. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 54-73 2551559-5 1989 Healthy volunteers were treated for 7 days with the beta 2-selective agonist terbutaline (5 mg t.i.d.). Terbutaline 77-88 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 52-58 35228185-4 2022 Results of bovine serum albumin denaturation assay illustrated that terbutaline inhibited 89.54+-0.46% denaturation at 6400microg/ml concentration. Terbutaline 68-79 albumin Homo sapiens 18-31 2477232-9 1989 A selective beta 2-adrenergic agonist, terbutaline, but not the beta 1-agonist dobutamine, stimulated tPA activity. Terbutaline 39-50 plasminogen activator, tissue type Rattus norvegicus 102-105 2692022-5 1989 However, those receiving terbutaline more frequently required the additional application of inhalative beta-2-sympathomimetics for respiratory distress. Terbutaline 25-36 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 103-109 2545859-0 1989 Phosphatidic acid phosphatase in neonatal rat lung: effects of prenatal dexamethasone or terbutaline treatment on basal activity and on responsiveness to beta adrenergic stimulation. Terbutaline 89-100 ubiquitin-conjugating enzyme E2D 3 Rattus norvegicus 0-29 2574736-4 1989 Glucose- and terbutaline-induced insulin secretion were inhibited by beta-endorphin at the lower dose levels of 0.25 (p less than 0.01) and 1 nmol/kg (p less than 0.05). Terbutaline 13-24 pro-opiomelanocortin-alpha Mus musculus 69-83 2574736-6 1989 In contrast, beta-endorphin at the high dose levels of 16 and 64 nmol/kg augmented the glucose- and terbutaline-induced insulin secretion (p less than 0.05). Terbutaline 100-111 pro-opiomelanocortin-alpha Mus musculus 13-27 2574736-8 1989 Met-enkephalin inhibited glucose- (p less than 0.01) and terbutaline- (p less than 0.05) induced insulin secretion at the high dose rates of 16 and 64 nmol/kg, but the peptide was without effect on carbachol-induced insulin secretion. Terbutaline 57-68 pro-opiomelanocortin-alpha Mus musculus 0-14 2573312-1 1989 Administration of the beta 2 adrenergic agonists fenoterol, salbutamol and terbutaline to volunteers significantly reduced plasma potassium concentration in a double-blind crossover study. Terbutaline 75-86 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 22-28 2810967-2 1989 Recently, pretreatment with several pulmonary vasodilators that increase cAMP levels: isoproterenol, terbutaline, theophylline, and prostacyclin, was found to reduce the severity of lung injury in animal models. Terbutaline 101-112 cathelicidin antimicrobial peptide Rattus norvegicus 73-77 2565392-1 1989 We studied the competitive interaction of terbutaline and two beta blockers, metoprolol and oxprenolol, with different cardioselectivity for the beta-2 adrenoceptor. Terbutaline 42-53 adrenoceptor beta 2 Homo sapiens 145-164 2724442-1 1989 The recent finding of terbutaline as the treatment of choice to manage intraoperative penile tumescence with the patient under anesthesia (general and regional) has prompted us to use this beta-2 agonist (5 mg. orally) for persistent penile erection and priapism resulting from injection of pharmacological agents, such as phentolamine, phenoxybenzamine and papavarine, into the penis for erectile impotence. Terbutaline 22-33 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 189-195 2472593-0 1989 Effects of prenatal terbutaline exposure on cellular development in lung and liver of neonatal rat: ornithine decarboxylase activity and macromolecules. Terbutaline 20-31 ornithine decarboxylase 1 Rattus norvegicus 100-123 2565392-2 1989 Using pharmacokinetic-dynamic modeling in nonsteady-state conditions, of the antagonism by the beta blockers of the terbutaline-induced hypokalemia, the beta blocker beta-2 selectivity was quantitated in the terms of IC50 values representing plasma concentrations resulting in half-receptor occupancy. Terbutaline 116-127 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 166-172 2747008-1 1989 Plasma potassium lowering effect of a selective beta-2 adrenergic stimulant, terbutaline sulfate (TRB) was investigated in fourteen patients with chronic renal failure (CRF) receiving maintenance hemodialysis. Terbutaline 77-96 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 2747008-1 1989 Plasma potassium lowering effect of a selective beta-2 adrenergic stimulant, terbutaline sulfate (TRB) was investigated in fourteen patients with chronic renal failure (CRF) receiving maintenance hemodialysis. Terbutaline 98-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 2747008-6 1989 Thus, a beta-2 selective adrenergic stimulant, terbutaline sulfate may be useful for acute treatment of hyperkalemia in CRF patients by way of the stimulation of potassium uptake in the cells. Terbutaline 47-66 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 8-14 2562936-9 1989 The results with atenolol pretreatment indicate that cardiac beta 1 responses are associated with the higher dose of terbutaline, either through direct beta 1 stimulation or indirectly from presynaptic beta 2 activity. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 61-67 2539393-9 1989 Terbutaline and forskolin increased SP-B mRNA but not SP-C mRNA. Terbutaline 0-11 surfactant protein B Homo sapiens 36-40 2563217-0 1989 Effects of somatostatin and oral potassium administration on terbutaline-induced hypokalemia. Terbutaline 61-72 somatostatin Homo sapiens 11-23 2563217-1 1989 Terbutaline, a beta 2-adrenergic agonist, has been shown to cause hypokalemia and an increase of plasma glucose and serum insulin concentrations. Terbutaline 0-11 insulin Homo sapiens 122-129 2563217-2 1989 We considered that terbutaline-induced hypokalemia may be due to the insulin-induced shift of potassium (K+) from the extracellular to the intracellular space. Terbutaline 19-30 insulin Homo sapiens 69-76 2563217-3 1989 If so, then inhibition of insulin secretion by somatostatin would prevent terbutaline-induced hypokalemia. Terbutaline 74-85 insulin Homo sapiens 26-33 2563217-3 1989 If so, then inhibition of insulin secretion by somatostatin would prevent terbutaline-induced hypokalemia. Terbutaline 74-85 somatostatin Homo sapiens 47-59 2563217-7 1989 Terbutaline caused a significant decrease of K+ (from 3.96 +/- 0.08 to 3.3 +/- 0.13 mmol/L +/- SEM; p less than 0.0005), accompanied by a significant increase in plasma glucose (from 83 +/- 3.6 to 101 +/- 4.4 mg/dl +/- SEM; p less than 0.01) and serum insulin concentrations (from 11.7 +/- 0.9 to 19.9 +/- 1.1 microU/ml +/- SEM; p less than 0.001), confirming earlier data. Terbutaline 0-11 insulin Homo sapiens 252-259 2563217-8 1989 Somatostatin pretreatment inhibited the terbutaline-induced hypokalemia; the small fall of K+ (from 3.7 +/- 0.08 to 3.5 +/- 0.2 mmol/L) was no longer significant. Terbutaline 40-51 somatostatin Homo sapiens 0-12 2563217-11 1989 In summary, the present findings confirm that terbutaline-induced hypokalemia is associated with increased plasma glucose and insulin levels. Terbutaline 46-57 insulin Homo sapiens 126-133 2723339-9 1989 The terbutaline-induced responses were selectively antagonized by beta 2-adrenoceptor blockade. Terbutaline 4-15 adrenoceptor beta 2 Felis catus 66-85 2562936-9 1989 The results with atenolol pretreatment indicate that cardiac beta 1 responses are associated with the higher dose of terbutaline, either through direct beta 1 stimulation or indirectly from presynaptic beta 2 activity. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 152-158 2562936-9 1989 The results with atenolol pretreatment indicate that cardiac beta 1 responses are associated with the higher dose of terbutaline, either through direct beta 1 stimulation or indirectly from presynaptic beta 2 activity. Terbutaline 117-128 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 202-208 2577692-5 1989 Increased activation of beta 2-adrenoceptors by terbutaline infusion resulted in increased FEV1 and FVC as well as beta 2-adrenoceptor mediated reflex tachycardia and skeletal muscle tremor. Terbutaline 48-59 adrenoceptor beta 2 Homo sapiens 24-43 2779705-1 1989 A case of rhabdomyolysis-induced acute renal failure secondary to overdosage with the beta 2-adrenoceptor agonist terbutaline is described. Terbutaline 114-125 adrenoceptor beta 2 Homo sapiens 86-105 2906515-3 1988 At rest the beta 2-selective adrenoceptor agonist terbutaline (10(-5) M) increased the membrane potential and [K+]i, and decreased [Na+]i when compared with control muscles. Terbutaline 50-61 hemoglobin, beta adult minor chain Mus musculus 12-18 3194412-9 1988 The content of SP-A and its mRNA was also increased by dibromo-cAMP, terbutaline, and forskolin, and effects were approximately additive with those of dexamethasone. Terbutaline 69-80 surfactant protein A1 Homo sapiens 15-19 2461609-2 1988 In vitro assessment was performed by evaluating the effect of terbutaline on 10(-8) OP-CCK stimulated amylase release of pancreatic tissue slices incubated at 37 degrees C in Krebs-bicarbonate media. Terbutaline 62-73 cholecystokinin Canis lupus familiaris 87-90 2461609-6 1988 Following the terbutaline infusion, there was also a significant decrease in OP-CCK-stimulated amylase (140.3 +/- 23.3 vs. 24.6 +/- 11.9; P less than 0.005) and bicarbonate release (.069 +/- .03 vs. .003 +/- .001; P less than 0.05). Terbutaline 14-25 cholecystokinin Canis lupus familiaris 80-83 2843407-6 1988 (-)-Norepinephrine, the unspecific beta-adrenergic agonist (-)-isoproterenol, and the beta 2-specific agonist terbutaline mimicked the effect of epinephrine on LDL-receptor activity. Terbutaline 110-121 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 86-92 2843407-6 1988 (-)-Norepinephrine, the unspecific beta-adrenergic agonist (-)-isoproterenol, and the beta 2-specific agonist terbutaline mimicked the effect of epinephrine on LDL-receptor activity. Terbutaline 110-121 low density lipoprotein receptor Homo sapiens 160-172 3415546-1 1988 A randomized, double-masked study of the effect of terbutaline sulfate, a selective beta 2-agonist, on the rate of aqueous humor formation was performed in awake and sleeping normal human subjects. Terbutaline 51-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-90 3410234-2 1988 Moreover, we hypothesized that terbutaline might inhibit food-stimulated acid secretion, as gastrin is a major mediator of food-stimulated acid secretion. Terbutaline 31-42 gastrin Homo sapiens 92-99 3410234-3 1988 Subcutaneous terbutaline (0.25 mg) reduced acid secretion during intravenous infusion of a submaximal dose of pentagastrin by 30%-40% (p less than 0.005), even though terbutaline increased serum gastrin levels (p less than 0.05). Terbutaline 13-24 gastrin Homo sapiens 115-122 3410234-4 1988 Furthermore, subcutaneous (0.25 mg) or oral (5 mg) terbutaline, given before a homogenized steak meal was infused into the stomach, lowered mean food-stimulated acid secretion rates, despite enhanced postprandial serum gastrin concentrations. Terbutaline 51-62 gastrin Homo sapiens 219-226 3410234-5 1988 Terbutaline also increased serum gastrin concentrations in patients with Zollinger-Ellison syndrome and in vagotomized individuals. Terbutaline 0-11 gastrin Homo sapiens 33-40 3244331-1 1988 The ability of the purified stereoisomers of the beta 2-receptor agonist terbutaline to block bradykinin-mediated increases in lymph flow and protein concentration was assessed in the canine forelimb perfused at constant arterial flow. Terbutaline 73-84 kininogen 1 Canis lupus familiaris 94-104 3410234-0 1988 Effect of terbutaline, a beta 2-adrenoreceptor agonist, on gastric acid secretion and serum gastrin concentrations in humans. Terbutaline 10-21 adrenoceptor beta 2 Homo sapiens 25-46 3410234-0 1988 Effect of terbutaline, a beta 2-adrenoreceptor agonist, on gastric acid secretion and serum gastrin concentrations in humans. Terbutaline 10-21 gastrin Homo sapiens 92-99 3410234-1 1988 Because beta-adrenoreceptor agonists inhibit gastrin-stimulated gastric acid secretion in animals, we postulated that the beta 2-adrenoreceptor agonist, terbutaline, would inhibit pentagastrin-stimulated acid secretion in humans. Terbutaline 153-164 gastrin Homo sapiens 45-52 3410234-1 1988 Because beta-adrenoreceptor agonists inhibit gastrin-stimulated gastric acid secretion in animals, we postulated that the beta 2-adrenoreceptor agonist, terbutaline, would inhibit pentagastrin-stimulated acid secretion in humans. Terbutaline 153-164 adrenoceptor beta 2 Homo sapiens 122-143 3169216-1 1988 In order to localize the main site of action of the beta 2-adrenoceptor selective agonist terbutaline and the beta 1-adrenoceptor selective antagonist atenolol in the airways of asthmatic patients, we compared the effects of these drugs on maximal expiratory flow-volume (MEFV) curves when breathing air and when breathing a helium-oxygen (HeO2) mixture. Terbutaline 90-101 adrenoceptor beta 2 Homo sapiens 52-71 3073804-3 1988 Compared with placebo, terbutaline produced a mean increase of 5.8 cmH2O in peak inspiratory mouth pressure and a mean increase of 5.0 cmH2O in transdiaphragmatic pressure during a maximal inspiratory manoeuvre. Terbutaline 23-34 troponin T2, cardiac type Homo sapiens 67-71 3047591-7 1988 In contrast, the insulin response to the cholinergic agonist carbachol (0.16 mumol/kg) or the beta 2-adrenoceptor agonist terbutaline (3.6 mumol/kg) was not affected by PHI. Terbutaline 122-133 adrenergic receptor, beta 2 Mus musculus 94-113 2902621-1 1988 Terbutaline, a selective beta 2-adrenoreceptor agonist, has recently been advocated as a potential agent for treating patients with pancreatic fistulae. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-46 3144513-5 1988 Blood eosinophil counts were unaffected by the challenge whereas the ECP levels were significantly reduced after the placebo challenge and when premedicated with disodium cromoglycate and terbutaline. Terbutaline 188-199 ribonuclease A family member 3 Homo sapiens 69-72 3144513-6 1988 The EPX levels stayed unaltered at the placebo challenge but were significantly reduced when the patients were premedicated with terbutaline. Terbutaline 129-140 eosinophil peroxidase Homo sapiens 4-7 3389160-0 1988 The effect of terbutaline upon myosin preparations of the human uterus. Terbutaline 14-25 myosin heavy chain 14 Homo sapiens 31-37 3389160-2 1988 Therefore the in vitro effect of terbutaline was investigated upon uterine myosin. Terbutaline 33-44 myosin heavy chain 14 Homo sapiens 75-81 3389160-3 1988 The results showed that the presence of terbutaline in the incubation medium without ATP decreased the performed (endogenous) P content of myosin slightly, whereas in the presence of ATP terbutaline facilitated release of the phosphoryl groups from myosin parallel with the increase of terbutaline concentration. Terbutaline 40-51 myosin heavy chain 14 Homo sapiens 139-145 3389160-3 1988 The results showed that the presence of terbutaline in the incubation medium without ATP decreased the performed (endogenous) P content of myosin slightly, whereas in the presence of ATP terbutaline facilitated release of the phosphoryl groups from myosin parallel with the increase of terbutaline concentration. Terbutaline 40-51 myosin heavy chain 14 Homo sapiens 249-255 3389160-3 1988 The results showed that the presence of terbutaline in the incubation medium without ATP decreased the performed (endogenous) P content of myosin slightly, whereas in the presence of ATP terbutaline facilitated release of the phosphoryl groups from myosin parallel with the increase of terbutaline concentration. Terbutaline 187-198 myosin heavy chain 14 Homo sapiens 249-255 3389160-3 1988 The results showed that the presence of terbutaline in the incubation medium without ATP decreased the performed (endogenous) P content of myosin slightly, whereas in the presence of ATP terbutaline facilitated release of the phosphoryl groups from myosin parallel with the increase of terbutaline concentration. Terbutaline 187-198 myosin heavy chain 14 Homo sapiens 249-255 3389160-4 1988 Although at low concentrations of terbutaline (in the micromolar range) a few phosphoryl groups are still incorporated in myosin, the time reaching the maximum of P incorporation was prolonged. Terbutaline 34-45 myosin heavy chain 14 Homo sapiens 122-128 2464535-7 1988 Galanin inhibited the insulin response to terbutaline by approximately 60% (p less than 0.01), but pancreastatin inhibited the insulin response to terbutaline by approximately 35% only (p less than 0.05). Terbutaline 42-53 galanin and GMAP prepropeptide Mus musculus 0-7 2464535-11 1988 The study also showed that galanin potently inhibits insulin secretion stimulated by the octapeptide of cholecystokin and by the beta 2-adrenoceptor agonist terbutaline, and that pancreastatin inhibits terbutaline-induced insulin secretion. Terbutaline 157-168 galanin and GMAP prepropeptide Mus musculus 27-34 2464535-11 1988 The study also showed that galanin potently inhibits insulin secretion stimulated by the octapeptide of cholecystokin and by the beta 2-adrenoceptor agonist terbutaline, and that pancreastatin inhibits terbutaline-induced insulin secretion. Terbutaline 157-168 adrenergic receptor, beta 2 Mus musculus 129-148 2893778-0 1987 Induction and reduction of muscle tremor upon acute and repeated administration of the beta 2-agonists terbutaline, salbutamol and tulobuterol. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 87-93 2894339-6 1987 Thus, phentolamine (2.6 mumol/kg), impaired the glucagon secretory response to the beta 2-adrenoceptor agonist terbutaline by 51% (P less than 0.01), and to the cholinergic agonist carbachol by 44% (P less than 0.02). Terbutaline 111-122 adrenergic receptor, beta 2 Mus musculus 83-102 3119689-9 1987 Single-dose pretreatment with the beta 2-agonist, terbutaline, inhibited generation of heat-labile NCA (p less than 0.001) but was without effect on LAR. Terbutaline 50-61 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 34-40 3453755-1 1987 The effect of inhaling 0.25 and 2.0 mg of terbutaline sulphate, a beta-2-stimulant, from a metered dose aerosol was studied in five asthmatic patients during two periods of five days each. Terbutaline 42-62 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 3656290-0 1987 Terbutaline treatment inhibits the hCG-induced increase in venular permeability in the rat testis. Terbutaline 0-11 hypertrichosis 2 (generalised, congenital) Homo sapiens 35-38 2887041-6 1987 Both isoproterenol and terbutaline sulfate reduced the severity of pancreatic inflammation, even when given up to 12 hours after the onset of AEP. Terbutaline 23-42 legumain Homo sapiens 142-145 3321540-3 1987 Oral terbutaline improved morning peak flow (259 v 213 l min-1) and decreased nocturnal inhaler usage (1.3 v 1.9) with no alteration in sleep quality as assessed electroencephalographically. Terbutaline 5-16 CD59 molecule (CD59 blood group) Homo sapiens 57-62 3656290-3 1987 Carbon-labelling, interstitial fluid volume and leucocyte migration were all reduced in rats treated with hCG+ terbutaline compared to the values in animals given hCG only. Terbutaline 111-122 hypertrichosis 2 (generalised, congenital) Homo sapiens 106-109 3656290-3 1987 Carbon-labelling, interstitial fluid volume and leucocyte migration were all reduced in rats treated with hCG+ terbutaline compared to the values in animals given hCG only. Terbutaline 111-122 hypertrichosis 2 (generalised, congenital) Homo sapiens 163-166 3026718-4 1987 In vivo, the beta 2-mediated plasma cyclic AMP response to isoprenaline was markedly attenuated during terbutaline treatment and was still reduced by 38% (P less than 0.05) 72 h after discontinuation of treatment. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 13-19 2886386-6 1987 Furthermore, while being without effect on baseline glucagon output, calcitonin gene-related peptide potentiated terbutaline-induced glucagon secretion more than seven-fold (p less than 0.001). Terbutaline 113-124 Calcitonin gene-related peptide Sus scrofa 69-100 3315268-8 1987 However, additional use of inhaled beta-2-mimetics because of asthmatic attacks occurred more often during terbutaline (79 times in 8/10 patients) than theophylline treatment (29 times in 5/10 patients). Terbutaline 107-118 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 35-41 2878632-2 1986 A single dose of the beta 2-agonist terbutaline (5 mg) and the beta 1 + 2-agonist orciprenaline (10 mg) did not reduce the fall in systolic pressure on standing up, despite a significant increase in both supine and standing heart rates. Terbutaline 36-47 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 21-27 3329090-7 1987 Insulin secretion stimulated by carbachol was inhibited by CGRP (P less than 0.01) but not affected by NPY, whereas terbutaline-induced insulin secretion was inhibited by both NPY (P less than 0.05) and CGRP (P less than 0.01). Terbutaline 116-127 neuropeptide Y Mus musculus 176-179 3329090-7 1987 Insulin secretion stimulated by carbachol was inhibited by CGRP (P less than 0.01) but not affected by NPY, whereas terbutaline-induced insulin secretion was inhibited by both NPY (P less than 0.05) and CGRP (P less than 0.01). Terbutaline 116-127 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 203-207 3329090-6 1987 In contrast, glucagon secretion stimulated by the beta 2-adrenoceptor agonist terbutaline was markedly inhibited by NPY already at the lower dose level (P less than 0.01) and potentiated by CGRP (P less than 0.01). Terbutaline 78-89 adrenergic receptor, beta 2 Mus musculus 50-69 3329090-6 1987 In contrast, glucagon secretion stimulated by the beta 2-adrenoceptor agonist terbutaline was markedly inhibited by NPY already at the lower dose level (P less than 0.01) and potentiated by CGRP (P less than 0.01). Terbutaline 78-89 neuropeptide Y Mus musculus 116-119 3329090-6 1987 In contrast, glucagon secretion stimulated by the beta 2-adrenoceptor agonist terbutaline was markedly inhibited by NPY already at the lower dose level (P less than 0.01) and potentiated by CGRP (P less than 0.01). Terbutaline 78-89 calcitonin/calcitonin-related polypeptide, alpha Mus musculus 190-194 2869853-8 1986 Acute or intermittent asthma should be treated first with inhaled beta 2 agonists such as albuterol or terbutaline. Terbutaline 103-114 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 66-72 2430623-2 1986 Basal release and release in response to the beta-adrenergic agonist, terbutaline and 12-O-tetradecanoylphorbol 13-acetate (TPA) were significantly decreased in the presence of substance P. Terbutaline 70-81 tachykinin precursor 1 Homo sapiens 177-188 2430623-3 1986 Inhibitory effects of substance P were noted following a 1 h exposure of primary cultures of Type II cells in vitro and persisted up to 3 h in the presence of the secretagogues, TPA and terbutaline. Terbutaline 186-197 tachykinin precursor 1 Homo sapiens 22-33 2430623-4 1986 The IC50 values for substance P inhibition of [3H]PC release were 10 microM for basal release, 40 microM for TPA-induced release and 50 microM for terbutaline-induced release. Terbutaline 147-158 tachykinin precursor 1 Homo sapiens 20-31 3096035-0 1986 Influence of terbutaline on TRH-induced prolactin and thyrotropin release in normal subjects. Terbutaline 13-24 thyrotropin releasing hormone Homo sapiens 28-31 3530592-4 1986 It was found that glipizide potentiated the IRI and C-peptide secretion in response to terbutaline (125 micrograms i.v.). Terbutaline 87-98 insulin Homo sapiens 52-61 3530592-11 1986 On the contrary, the terbutaline-induced increment in blood glucose concentration was inhibited by glipizide and the glucose elimination rate after glucose injection was slightly enhanced by glipizide; effects explained by the higher plasma insulin levels. Terbutaline 21-32 insulin Homo sapiens 241-248 2872714-9 1986 In comparison, norepinephrine stimulated AC activity to the same level as isoproterenol (three to four times basal activity) and the beta 2-selective agonist terbutaline caused some 50% of maximal AC stimulation. Terbutaline 158-169 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 133-139 2878680-5 1986 Bronchospasm induced by atenolol 50 mg and xamoterol 200 mg was completely reversed by inhalation of the beta 2-adrenoceptor agonist terbutaline to a cumulative dose of 4.0 mg. Terbutaline 133-144 adrenoceptor beta 2 Homo sapiens 105-124 3030608-2 1986 To study the mechanism behind this increase, plasma insulin, plasma C-peptide, and blood glucose responses to the beta 2-adrenoceptor agonist terbutaline were investigated in healthy humans. Terbutaline 142-153 adrenoceptor beta 2 Homo sapiens 114-133 3030608-6 1986 20 min after terbutaline injection, plasma levels of C-peptide were 0.98 +/- 0.26 nmol/l and of insulin were 0.21 +/- 0.05 nmol/l. Terbutaline 13-24 insulin Homo sapiens 96-103 3030608-7 1986 Calculations of the minute to minute increase of plasma levels of C-peptide and insulin during the 20 min after terbutaline injection, revealed that plasma insulin increased during the first 2 min by 59 +/- 8% of the increase of plasma C-peptide, and during the third and fourth min by 44 +/- 12% of the increase of plasma C-peptide; the difference being the liver extraction of insulin. Terbutaline 112-123 insulin Homo sapiens 156-163 3030608-7 1986 Calculations of the minute to minute increase of plasma levels of C-peptide and insulin during the 20 min after terbutaline injection, revealed that plasma insulin increased during the first 2 min by 59 +/- 8% of the increase of plasma C-peptide, and during the third and fourth min by 44 +/- 12% of the increase of plasma C-peptide; the difference being the liver extraction of insulin. Terbutaline 112-123 insulin Homo sapiens 156-163 3030608-8 1986 In contrast, during min 4-10 after terbutaline injection, plasma insulin levels increased more than did plasma C-peptide levels, indicating that terbutaline inhibits the liver extraction of insulin. Terbutaline 145-156 insulin Homo sapiens 65-72 3030608-8 1986 In contrast, during min 4-10 after terbutaline injection, plasma insulin levels increased more than did plasma C-peptide levels, indicating that terbutaline inhibits the liver extraction of insulin. Terbutaline 145-156 insulin Homo sapiens 190-197 2877082-5 1986 Terbutaline (10(-5) M), a relatively selective beta-2 agonist, similarly augmented the generation of cell-mediated cytotoxicity, with the increase again blocked by propranolol. Terbutaline 0-11 hemoglobin, beta adult minor chain Mus musculus 47-53 3013487-8 1986 Alternative mechanisms for the cardiac changes with terbutaline include (1) withdrawal of vagal tone, (2) decrease in afterload, and (3) stimulation of cardiac beta 2-receptors. Terbutaline 52-63 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 160-166 2869574-9 1985 Since terbutaline inhibits sigmoid and rectal motility in man during rectal distention, it is suggested that the inhibitory effect of beta-2-adrenoceptor agonists may be dependent on the mode of background stimulation of the colon. Terbutaline 6-17 adrenoceptor beta 2 Homo sapiens 134-153 2437567-2 1986 In experiments with pancreatic fistula dogs, intravenously administered terbutaline significantly reduced pancreatic juice volume, bicarbonate concentration, bicarbonate output, and protein output evoked by secretin or the octapeptide of cholecystokinin but had no effect on protein concentration. Terbutaline 72-83 SCT Canis lupus familiaris 207-215 2421600-1 1986 The site of antagonistic action on allergen-induced early skin reactions by the beta 2-agonist terbutaline was studied by light microscopy in 10 atopic subjects. Terbutaline 95-106 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-86 2866660-10 1985 Glucose (+55%) and the cholinergic agonist carbachol (+140%) displayed a potentiated insulin secretory response after phentolamine pretreatment, whereas the beta 2-adrenoceptor agonist terbutaline (-45%) had a blunted, though not abolished, insulin response. Terbutaline 185-196 adrenergic receptor, beta 2 Mus musculus 157-176 2865990-11 1985 Conjugation or COMT inactivation can take place in the gut wall (terbutaline), in lungs (isoproterenol, terbutaline, rimiterol) or by hepatic first-pass. Terbutaline 65-76 catechol-O-methyltransferase Homo sapiens 15-19 2995446-0 1985 Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-62 4042527-4 1985 A dose-response curve was then plotted after inhalation of the beta 2-adrenoceptor agonist terbutaline. Terbutaline 91-102 adrenoceptor beta 2 Homo sapiens 63-82 2995446-3 1985 Terbutaline (3 X 5 mg/d) decreased lymphocyte beta 2-adrenoceptor density by approximately 40-50%; concomitantly, lymphocyte cAMP responses to 10 microM (-)-isoprenaline were significantly reduced. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 46-65 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Terbutaline 20-31 adrenoceptor beta 2 Homo sapiens 32-51 2995446-4 1985 After withdrawal of terbutaline beta 2-adrenoceptor, density and responsiveness gradually increased, reaching predrug levels after 4 d. Prednisone (1 X 100 mg orally) accelerated beta 2-adrenoceptor recovery; only 8-10 h after administration of the steroid beta 2-adrenoceptor density and cAMP responses to (-)-isoprenaline had reached values not significantly different from pretreatment levels. Terbutaline 20-31 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-38 2995446-6 1985 Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2-adrenoceptor density and responsiveness. Terbutaline 51-62 adrenoceptor beta 2 Homo sapiens 127-146 2995446-6 1985 Furthermore, ketotifen simultaneously applied with terbutaline completely prevented terbutaline-induced decrease in lymphocyte beta 2-adrenoceptor density and responsiveness. Terbutaline 84-95 adrenoceptor beta 2 Homo sapiens 127-146 2865990-11 1985 Conjugation or COMT inactivation can take place in the gut wall (terbutaline), in lungs (isoproterenol, terbutaline, rimiterol) or by hepatic first-pass. Terbutaline 104-115 catechol-O-methyltransferase Homo sapiens 15-19 2864159-12 1985 Aerosol administration is the route of choice for beta 2-adrenergic agonists for prophylaxis of exercise-induced bronchospasm; albuterol and terbutaline provide a prolonged duration of action with excellent beta 2-adrenergic selectivity. Terbutaline 141-152 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 207-213 2864131-2 1985 Both the beta1 agonist dobutamine and the beta2 agonist terbutaline relaxed coronary arteries partially contracted by 25 mM of KCl. Terbutaline 56-67 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 42-47 2864131-3 1985 Dobutamine contracted small coronary arteries at 10(-5) M concentrations, then relaxed them at 10(-4) M. The beta1-adrenoceptor antagonist metoprolol contracted coronary arteries relaxed by either dobutamine or terbutaline, but the beta2 antagonist H35/25 did so only in high and probably nonselective concentrations. Terbutaline 211-222 adrenoceptor beta 1 Homo sapiens 109-127 2864131-8 1985 They differ from many other beta1-receptors, however, in that they are stimulated by terbutaline. Terbutaline 85-96 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 28-33 3969605-1 1985 We studied the effects of terbutaline on secretin-stimulated duodenal juice output in six healthy volunteers. Terbutaline 26-37 secretin Homo sapiens 41-49 2863289-3 1985 Thereafter, terbutaline (0.5 mg), a beta2 agonist, was administered in aerosol form at 15-minute intervals for a total of five doses. Terbutaline 12-23 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 36-41 2412749-1 1985 Immunoreactive insulin (IRI) and C-peptide secretory responses to terbutaline, glucagon, glucose and a standardized meal during continuous blood glucose monitoring were investigated in hyper- and hypothyroid patients before and after treatment. Terbutaline 66-77 insulin Homo sapiens 33-42 2412749-2 1985 The beta 2-adrenoceptor agonist terbutaline (125 micrograms IV) induced prompt IRI and C-peptide responses in hyperthyroid patients. Terbutaline 32-43 adrenoceptor beta 2 Homo sapiens 4-23 2412749-2 1985 The beta 2-adrenoceptor agonist terbutaline (125 micrograms IV) induced prompt IRI and C-peptide responses in hyperthyroid patients. Terbutaline 32-43 insulin Homo sapiens 87-96 2864777-1 1985 Exposure to the beta 2-adrenoceptor agonist terbutaline resulted in a transient stimulation of 45Ca2+ efflux from 45Ca2+ preloaded rat islets perfused in 2 mM Ca2+ and 8.3 mM glucose. Terbutaline 44-55 adrenoceptor beta 2 Rattus norvegicus 16-35 2864777-11 1985 The data suggest that the beta 2-adrenoceptor agonist terbutaline has the ability to stimulate insulin secretion in perfused rat islets, requiring extracellular Ca2+ for the full expression of its effects. Terbutaline 54-65 adrenoceptor beta 2 Rattus norvegicus 26-45 3969605-2 1985 When administered intravenously to healthy volunteers, terbutaline significantly inhibited secretin-stimulated output of duodenal juice and bicarbonate. Terbutaline 55-66 secretin Homo sapiens 91-99 2906082-4 1985 The studies described herein extend these findings to the conjunctiva, where the relatively selective beta 2-adrenoceptor agonists salbutamol and terbutaline reduced the microvascular permeability response to histamine. Terbutaline 146-157 adrenoceptor beta 2 Homo sapiens 102-121 3861138-12 1985 The hyperactivity was readily countered with the beta 2-agonist, terbutaline. Terbutaline 65-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-55 2579597-0 1985 Equivalent inhibition by terbutaline of anti-human IgE skin responses in atopic and non-atopic subjects. Terbutaline 25-36 immunoglobulin heavy constant epsilon Homo sapiens 51-54 6150925-4 1984 The beta 2-selective agonist terbutaline, eg, causes bronchodilation with less beta 1-cardiac excitation than does the beta 1-beta 2 nonselective agonist isoproterenol. Terbutaline 29-40 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 2864739-8 1985 After infusion of the beta-1 agonist prenalterol and the beta-2 selective agonist terbutaline, a profound decrease in esophageal peristaltic amplitude was seen. Terbutaline 82-93 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 6093565-3 1984 The beta-adrenergic agonists terbutaline and isoproterenol increased immunoreactive cAMP in ciliated epithelial cells of dog and cat tracheae and in both serous and mucous gland cells of cat tracheae. Terbutaline 29-40 cathelicidin antimicrobial peptide Canis lupus familiaris 84-88 6150925-4 1984 The beta 2-selective agonist terbutaline, eg, causes bronchodilation with less beta 1-cardiac excitation than does the beta 1-beta 2 nonselective agonist isoproterenol. Terbutaline 29-40 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 79-85 6149303-7 1984 The selective beta-2 adrenergic receptor agonists, salbutamol (3 X 10(-8) to 3 X 10(-7) M) and terbutaline (10(-7) to 3 X 10(-7) M), caused significantly greater enhancement of the PNS response in preparations from SHR than in those from WKY, whereas the selective beta-1 agonist, dobutamine, caused only inhibition of the PNS responses in preparations from both WKY and SHR. Terbutaline 95-106 adrenoceptor beta 2 Rattus norvegicus 14-40 6146956-4 1984 Isoprenaline, known to be a beta-adrenoceptor agonist with some alpha-adrenoceptor activity, had stimulatory and inhibitory effects, whereas the beta 2-adrenoceptor agonist, terbutaline, exhibited a pure inhibitory action. Terbutaline 174-185 adrenoceptor beta 2 Homo sapiens 145-164 6086876-2 1984 The magnitude and kinetics of the enhanced antibody response to norepinephrine alone, or to norepinephrine in the presence of phentolamine, were more closely mimicked with a beta-2 adrenoceptor agonist (terbutaline) than with a beta-1 adrenoceptor agonist (dobutamine). Terbutaline 203-214 hemoglobin, beta adult minor chain Mus musculus 174-180 6205605-0 1984 Sustained inhibition of antigen-induced histamine release from human lung by the beta 2-adrenoceptor agonist terbutaline. Terbutaline 109-120 adrenoceptor beta 2 Homo sapiens 81-100 6205605-1 1984 Antigen-induced histamine release from passively sensitized human lung tissue was inhibited in the presence of the beta 2-adrenoceptor agonist, terbutaline. Terbutaline 144-155 adrenoceptor beta 2 Homo sapiens 115-134 6086876-2 1984 The magnitude and kinetics of the enhanced antibody response to norepinephrine alone, or to norepinephrine in the presence of phentolamine, were more closely mimicked with a beta-2 adrenoceptor agonist (terbutaline) than with a beta-1 adrenoceptor agonist (dobutamine). Terbutaline 203-214 adrenergic receptor, beta 1 Mus musculus 228-247 6090153-5 1984 Naloxone moderately potentiated the insulin secretory responses to glucose and the beta 2-adrenoceptor agonist terbutaline. Terbutaline 111-122 adrenergic receptor, beta 2 Mus musculus 83-102 6364906-2 1984 This led us to study, under controlled conditions, the effects of a subcutaneous injection of 0.25 mg terbutaline sulfate on serum potassium (K+), sodium (Na+), glucose, and insulin in a group of asymptomatic asthmatics. Terbutaline 102-121 insulin Homo sapiens 174-181 6144326-5 1984 The beta 2-agonists terbutaline and salbutamol inhibited sterol synthesis by 42 and 26%, respectively, at a concentration of 0.1 mmol/l. Terbutaline 20-31 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 6364906-7 1984 Significant effects on glucose, K+, and insulin were observed as early as 15 min after terbutaline injection; serum glucose and insulin increased and remained elevated for at least 2 h. Serum K+ fell significantly, reached a peak decline of 14% from the control value at 30 min after the injection and remained decreased for a period in excess of after subcutaneous terbutaline injection should be interpreted in the light of these effects of the drug and that terbutaline should be used with caution in patients prone to hypokalemia. Terbutaline 87-98 insulin Homo sapiens 40-47 6434183-1 1984 Terbutaline sulfate, a relatively selective beta2 agonist, is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease. Terbutaline 0-19 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 44-49 6373350-1 1984 Infusion of terbutaline sulphate (0.25 mg) was followed by increases of plasma insulin and blood glucose concentrations and by a decrease in plasma potassium. Terbutaline 12-32 insulin Homo sapiens 79-86 6138106-4 1983 Subsequent treatment for 2 days with Prl, terbutaline (a beta 2-adrenergic agonist) or hCG stimulated the production of progesterone, 20 alpha-hydroxypregn-4-en-3-one (20 alpha-OH-P), pregnenolone and the activity of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD). Terbutaline 42-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 6586483-9 1984 The mean plasma concentrations of terbutaline during repeated tablet treatment were 3.4, 4.1 and 4.1 micrograms/L at 1, 2 and 4 h after administration, respectively. Terbutaline 34-45 solute carrier family 7 member 5 Homo sapiens 112-127 6188770-1 1983 Terbutaline, a preferential beta 2-adrenergic agonist, has been shown to inhibit allergen-induced histamine release in vitro. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 28-34 6138106-5 1983 In contrast, treatment with Prl or terbutaline, but not hCG, inhibited 20 alpha-hydroxysteroid dehydrogenase (20 alpha-HSD) activity by decreasing the apparent maximal velocity of the enzyme with no change in its Km value. Terbutaline 35-46 aldo-keto reductase family 1, member C3 Rattus norvegicus 71-108 6138106-5 1983 In contrast, treatment with Prl or terbutaline, but not hCG, inhibited 20 alpha-hydroxysteroid dehydrogenase (20 alpha-HSD) activity by decreasing the apparent maximal velocity of the enzyme with no change in its Km value. Terbutaline 35-46 aldo-keto reductase family 1, member C3 Rattus norvegicus 110-122 6138106-11 1983 The inhibitory effect of GnRH on Prl- or terbutaline-stimulated progesterone production appears to result from a preferential increase in 20 alpha-HSD activity, while the GnRH inhibition of hCG-stimulated progesterone production appears to result from a preferential inhibition of pregnenolone production. Terbutaline 41-52 aldo-keto reductase family 1, member C3 Rattus norvegicus 138-150 6314736-4 1983 On the other hand, the effect of terbutaline aerosol, a beta-adrenergic stimulant, on patients with chronic sinusitis was evaluated by paranasal sinus radiography. Terbutaline 33-44 amyloid beta precursor protein Homo sapiens 54-60 6134629-2 1983 The non-selective beta-adrenoceptor agonist isopropylnoradrenaline and the selective beta 2-adrenoceptor agonist terbutaline both, and with the same efficacy, enhanced radioiodine release, whereas the selective beta 1-adrenoceptor agonist prenalterol had no such effect. Terbutaline 113-124 adrenergic receptor, beta 2 Mus musculus 85-104 6134629-3 1983 The non-selective beta-adrenoceptor antagonist L-propranolol and the selective beta 2-adrenoceptor antagonist ICI 118,551 both abolished the radioiodine release induced by isopropylnoradrenaline or by terbutaline. Terbutaline 201-212 adrenergic receptor, beta 2 Mus musculus 79-98 6130662-6 1983 Prenalterol, a selective beta 1-agonist, did not stimulate cAMP accumulation, while terbutaline, a selective beta 2-agonist, exerted a potent stimulation. Terbutaline 84-95 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 109-115 6135409-4 1983 Mucin secretion was increased by H133/22, a beta 1 adrenoceptor agonist, or terbutaline, which is roughly equipotent. Terbutaline 76-87 mucin Canis lupus familiaris 0-5 6132819-5 1983 The haemodynamic effects of the terbutaline infusion can be explained by a reflex response to the vasodilatation induced by stimulation of the vascular beta 2-receptors, while the effects of prenalterol can mainly be accounted for by a direct action on beta 1-receptors in the heart. Terbutaline 32-43 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 152-158 6134281-5 1983 An 18- to 24-hr pretreatment of WT cells with terbutaline (down-regulation) led to a greater than 90% reduction of the photolabeling of both polypeptides, whereas a similar pretreatment of cyc- cells resulted in no further loss of labeled receptor than that observed after only a 15-min pretreatment with epinephrine. Terbutaline 46-57 cytochrome c, somatic Homo sapiens 189-192 6130811-3 1983 The beta(2)-adrenoceptor agonist, terbutaline (5.0 mg kg(-1)), produced a moderate increase in pineal melatonin content.2 Repeated daily administration of desmethylimipramine (10 mg kg(-1) for 10 days) and maprotiline (10 mg kg(-1) for 10 days), antidepressants predominantly inhibiting noradrenaline (NA) uptake, reduced the isoprenaline-induced increase in pineal melatonin content. Terbutaline 34-45 adrenoceptor beta 2 Rattus norvegicus 4-24 6136361-13 1983 To date, a betamimetic with selective beta 2 effects, such as terbutaline or ritodrine, is the most valuable agent for inhibition of preterm labor. Terbutaline 62-73 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 38-44 6138298-4 1983 The increase in SCC observed after terbutaline (beta 2-agonist) was similar to the increase after isoproterenol (beta 1- and beta 2-agonist). Terbutaline 35-46 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 48-54 7136993-1 1982 To assess the response of the right and left ventricles to the subcutaneous administration of terbutaline sulfate, a beta-2 selective agonist, we evaluated 14 patients with chronic obstructive pulmonary disease (COPD) with equilibrium radionuclide angiography (RNA). Terbutaline 94-113 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 117-123 6128186-3 1982 Cardioselective properties were assessed by determining the beta 1 and beta 2 adrenergic-stimulating effects of terbutaline 5 mg before and at the end of each five-day treatment period. Terbutaline 112-123 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 60-77 6128186-5 1982 Following study drug there was a 100 percent inhibition of the beta 1 terbutaline effect, and an approximate 83 percent inhibition of the beta 2 terbutaline effect. Terbutaline 145-156 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 138-144 7136993-6 1982 We conclude that in patients with COPD subcutaneous terbutaline has significant beta-1 cardiac effects; it increases the heart rate and decreases cardiac size. Terbutaline 52-63 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 80-86 6121595-5 1982 5 Since the increase in ODC activity was blocked by a beta-adrenoceptor antagonist (propranolol) and enzyme activity was stimulated by terbutaline, a beta 2-agonist, we conclude that beta 2-adrenoceptors are selectively coupled to the regulation of murine cardiac ODC activity following catecholamine stimulation. Terbutaline 135-146 hemoglobin, beta adult minor chain Mus musculus 150-156 7091211-3 1982 The adrenergic beta-receptor agonist terbutaline caused an increase in hCG secretion but did not affect hPL. Terbutaline 37-48 chorionic gonadotropin subunit beta 5 Homo sapiens 71-74 6284292-3 1982 3 In muscles obtained from terbutaline-treated animals, the effects of terbutaline and adrenaline on cyclic AMP content, active Na-K-transport and subtetanic contractions were all considerably suppressed, but insulin stimulated 22Na-efflux and affected subtetanic contractions to the same extent as in the muscles obtained from the control group. Terbutaline 27-38 insulin Sus scrofa 209-216 7042176-2 1982 Infusion of terbutaline (250 micrograms) was followed by increases in pl insulin concentration and bl glucose and by a decrease in pl K. Similar metabolic changes were seen on day 1 of oral terbutaline (5 mg x 3). Terbutaline 12-23 insulin Homo sapiens 73-80 6123517-0 1982 A time-saving method for the determination of the beta 2 sympathomimetics terbutaline, salbutamol and fenoterol. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 50-56 7096576-1 1982 Terbutaline is a selective beta 2 agonist used predominantly in the treatment of asthma. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 27-33 6121595-5 1982 5 Since the increase in ODC activity was blocked by a beta-adrenoceptor antagonist (propranolol) and enzyme activity was stimulated by terbutaline, a beta 2-agonist, we conclude that beta 2-adrenoceptors are selectively coupled to the regulation of murine cardiac ODC activity following catecholamine stimulation. Terbutaline 135-146 ornithine decarboxylase, structural 1 Mus musculus 264-267 6958476-3 1982 Group 1 was treated with corticosteroids and group 2 with corticosteroids and the beta 2-adrenergic agonist terbutaline. Terbutaline 108-119 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-88 6756931-0 1982 Ventilatory and haemodynamic effects of terbutaline infusion during beta 1-selective blockade with metoprolol and acebutolol in asthmatic patients. Terbutaline 40-51 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 68-74 6751838-3 1981 Four increasing doses of terbutaline (0.036-1.23 micrograms kg-1 min-1) were thereafter administered by intravenous infusion, starting 120 min after the tablet intake. Terbutaline 25-36 CD59 molecule (CD59 blood group) Homo sapiens 65-70 6120845-6 1982 Qualitative effects of prenalterol and terbutaline on the spontaneous contractile activity in the cat colon strip indicated that the beta 1-adrenoceptor-mediated effects may be related to inhibition of the activity in cholinergic neurons, whereas the beta 2-adrenoceptors may be acting on the smooth muscle cells per se. Terbutaline 39-50 adrenoceptor beta 1 Homo sapiens 133-152 6273481-0 1981 [Beta 1-, beta 2-effects of ritrodine and terbutaline in the treatment of preterm labor (author"s transl)]. Terbutaline 42-53 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 Homo sapiens 1-7 6273481-0 1981 [Beta 1-, beta 2-effects of ritrodine and terbutaline in the treatment of preterm labor (author"s transl)]. Terbutaline 42-53 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 10-16 6273481-3 1981 beta 2-effects of terbutaline and ritodrine in the treatment of preterm labor. Terbutaline 18-29 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 6273481-6 1981 2) The levels of c-AMP and c-GMP in the blood after administration of terbutaline or ritodrine increased and showed dose-response. Terbutaline 70-81 cathelicidin antimicrobial peptide Homo sapiens 17-32 7025578-3 1981 Contrary to these findings, the insulin response to the beta 2-adrenoceptor agonist terbutaline was potentiated, by about 75%. Terbutaline 84-95 adrenergic receptor, beta 2 Mus musculus 56-75 7282714-4 1981 On a molar basis among beta 2 agonists, terbutaline sulfate was considerably more stable than epinephrine hydrochloride or isoproterenol hydrochloride. Terbutaline 40-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 23-29 6264729-4 1981 Concentrations of c-AMP and c-GMP in the maternal, fetal cardiac tissue were in a decreasing tendency in the terbutaline group. Terbutaline 109-120 cathelicidin antimicrobial peptide Homo sapiens 18-33 6113155-2 1981 The non-selective beta-stimulator isopropylnoradrenaline and the selective beta 2-stimulator terbutaline both stimulated insulin secretion markedly, with the same efficacy and in a dose-dependent manner. Terbutaline 93-104 hemoglobin, beta adult minor chain Mus musculus 75-81 7237439-8 1981 Terbutaline, a beta 2-specific agonist, was not effective as an antidote. Terbutaline 0-11 histocompatibility 2, O region beta locus Mus musculus 13-21 7226928-1 1981 To assess the response of the left ventricle to subcutaneously administered terbutaline sulfate, a proposed beta-2 selective agonist, we evaluated 12 patients who had suffered previous myocardial infarctions using equilibrium radionuclide angiography. Terbutaline 76-95 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 108-114 6113155-5 1981 The non-selective beta-blocker propranolol and the beta 2-selective blocker ICI 188,551 inhibited terbutaline-induced insulin release markedly and at comparable low dose levels, whereas the selective beta 1-blocker metoprolol exerted this effect only at a high dose level. Terbutaline 98-109 hemoglobin, beta adult minor chain Mus musculus 51-57 7011036-4 1981 A rise in maternal plasma insulin levels occurred in all patients but was more pronounced in patients treated with terbutaline less than 25 minutes before delivery than in those treated more than 45 minutes prior to delivery. Terbutaline 115-126 insulin Homo sapiens 26-33 6264383-8 1981 The insulin secretory response to the beta 2-adrenoceptor stimulator, terbutaline, was increased after chemical sympathectomy, unaffected by adrenalectomy, and decreased after chemical sympathectomy plus adrenalectomy. Terbutaline 70-81 adrenergic receptor, beta 2 Mus musculus 38-57 6284819-2 1981 Incubation of wild type S49 cells with beta-adrenergic agonists (terbutaline or isoproterenol) inhibited ODC and SAMDC activities rapidly (less than 2 hr). Terbutaline 65-76 ornithine decarboxylase, structural 1 Mus musculus 105-108 7195156-4 1981 The immediate reaction to anti-IgE was inhibited by 3 micrograms terbutaline and 30 micrograms mepyramine (P less than 0.01) whereas 50 micrograms betamethasone had no effects. Terbutaline 65-76 immunoglobulin heavy constant epsilon Homo sapiens 31-34 7195156-11 1981 It is further suggested that terbutaline inhibits anti-IgE-mediated cutaneous reactions by inhibition of the mast cell release reaction. Terbutaline 29-40 immunoglobulin heavy constant epsilon Homo sapiens 55-58 6284819-2 1981 Incubation of wild type S49 cells with beta-adrenergic agonists (terbutaline or isoproterenol) inhibited ODC and SAMDC activities rapidly (less than 2 hr). Terbutaline 65-76 S-adenosylmethionine decarboxylase 1 Mus musculus 113-118 6258957-10 1980 "Selective" beta2-stimulants such as terbutaline or salbutamol induced no relaxation. Terbutaline 37-48 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 12-17 6255217-2 1980 Maximum urethral closure pressure was recorded before and after the administration of terbutaline, a beta-2 agonist. Terbutaline 86-97 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 101-107 6258959-0 1980 Plasma cyclic AMP levels in response to exercise and terbutaline sulphate aerosol in normal and asthmatic subjects. Terbutaline 53-73 adenine phosphoribosyltransferase Homo sapiens 14-17 6258959-7 1980 Cyclic AMP values were higher at rest and during exercise with terbutaline sulphate compared with placebo for both groups. Terbutaline 63-83 adenine phosphoribosyltransferase Homo sapiens 7-10 6113260-4 1980 2) When the progress of uterine inhibition was investigated on the basis of quantitative changes of PG and c-AMP in bath medium, it was found that both PGE1 and PGF2 alpha were significantly reduced after administration of terbutaline and indomethacin, c-AMP decreased significantly after administration of PGE1 analogue, oxytocin and PGF2 alpha. Terbutaline 223-234 cathelicidin antimicrobial peptide Rattus norvegicus 107-112 6113260-4 1980 2) When the progress of uterine inhibition was investigated on the basis of quantitative changes of PG and c-AMP in bath medium, it was found that both PGE1 and PGF2 alpha were significantly reduced after administration of terbutaline and indomethacin, c-AMP decreased significantly after administration of PGE1 analogue, oxytocin and PGF2 alpha. Terbutaline 223-234 cathelicidin antimicrobial peptide Rattus norvegicus 253-258 6113260-5 1980 The c-AMP levels increased significantly after administration of terbutaline and verapamil. Terbutaline 65-76 cathelicidin antimicrobial peptide Rattus norvegicus 4-9 6999834-2 1980 Insulin, 2.5-55 mu/ml, caused a dose-dependent depression of twitches and subtetanic concentrations of the soleus muscle similar to and additive with that produced by the beta 2-adrenoceptor agonist, terbutaline. Terbutaline 200-211 insulin Cavia porcellus 0-7 6999834-2 1980 Insulin, 2.5-55 mu/ml, caused a dose-dependent depression of twitches and subtetanic concentrations of the soleus muscle similar to and additive with that produced by the beta 2-adrenoceptor agonist, terbutaline. Terbutaline 200-211 beta-2 adrenergic receptor Cavia porcellus 171-190 498589-11 1979 Intravenous injection of the selective beta 2-adrenoceptor agonist terbutaline (0.15 mg/kg) restored the systemic arterial pressure to pre-shcok levels and partially raised the cardiac output. Terbutaline 67-78 adrenoceptor beta 2 Rattus norvegicus 39-58 7426691-7 1980 Measurement of terbutaline down to 0.1 ng ml-1 in 4 ml of plasma is possible with a coefficient of variation of 8.6%. Terbutaline 15-26 interleukin 17F Homo sapiens 42-46 34369-0 1978 Effects of terbutaline, a synthetic beta adrenoceptor agonist, on in vivo erythropoietin production. Terbutaline 11-22 erythropoietin Mus musculus 74-88 226301-5 1979 Both isoprenaline and the selective beta 2-adrenoceptor agonist terbutaline produced a concentration-dependent dilatation of liver sinusoids and slowed erythrocyte flow velocity. Terbutaline 64-75 adrenoceptor beta 2 Rattus norvegicus 36-55 434583-2 1979 Simultaneous ingestion of terbutaline and Tedral resulted in significantly greater bronchodilation than after either agent alone, which supports the concomitant use of beta-2 agonists and theophylline agents when treating patients with airflow obstruction. Terbutaline 26-37 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 168-174 517068-1 1979 The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma). Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 39-58 161461-1 1979 The acute bronchodilator effect of the beta 2-adrenoceptor agonist terbutaline was tested single-blind cross-over in out-patients with chronic obstructive airways disease (intrinsic asthma). Terbutaline 67-78 adrenoceptor beta 2 Homo sapiens 39-58 31829-3 1978 In this study the beta2 selectivity of SM 220 was poorer than that of terbutaline. Terbutaline 70-81 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 18-23 34369-1 1978 Terbutaline sulfate, a new synthetic beta2-adrenoceptor agonist, was found to produce a dose-related increase in 59Fe-incorporation into newly formed red blood cells of exhypoxic polycythemic mice. Terbutaline 0-19 adrenergic receptor, beta 2 Mus musculus 37-55 34369-5 1978 Terbutaline was found to significantly elevate plasma erythropoietin titers in rabbits while producing a slight but nonsignificant decrease in mean blood pressure. Terbutaline 0-11 erythropoietin Oryctolagus cuniculus 54-68 682845-0 1978 [Broncho-relaxing activity of Terbutaline, an aerosol of beta 2 sympathomimetic agent. Terbutaline 30-41 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 57-63 645781-1 1978 Terbutaline, a selective beta-2 adrenergic receptor stimulator, has been used to decrease myometrial activity and improve uteroplacental blood flow in 15 patients with acute intrapartum fetal distress. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-51 25467-1 1978 The development of beta2-specific sympathomimetic bronchodilators (rimiterol, salbutamol, terbutaline) has made the basic treatment of asthmatic patients more safe and effective. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 19-24 25100-4 1978 The beta1-adrenoceptor agonist, terbutaline, also stimulated amylase discharge from the parotid gland but was much less potent than H 133/22. Terbutaline 32-43 adrenoceptor beta 1 Rattus norvegicus 4-22 26113-9 1978 It is concluded that there is a small, clinically insignificant, difference in the onset of action of isoprenaline compared with that of the selective beta2-stimulating aerosol, terbutaline. Terbutaline 178-189 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 151-156 596228-0 1977 Inhibition of bradykinin induced macromolecular leakage from post-capillary venules by a beta2-adrenoreceptor stimulant, terbutaline. Terbutaline 121-132 kininogen 1 Homo sapiens 14-24 34874-3 1978 The beta-2-adrenergic drugs, salbutamol and terbutaline, had an eosinopenic effect. Terbutaline 44-55 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-10 22823-2 1977 Terbutaline, a selective beta2-adrenoceptor agonist, gave at a certain dose a more pronounced chronotropic than inotropic response, while a new beta1-selective adrenoceptor agonist (-)-H 80/62 produced the same degree of chronotropic and inotropic stimulation. Terbutaline 0-11 adrenoceptor beta 2 Homo sapiens 25-43 192771-2 1977 We applied a strong beta-2 stimulus (terbutaline, 5.0 mg orally) at weekly intervals for up to three weeks in 19 stable asthmatics and bronchitics while commencing 5.0 mg terbutaline three times daily. Terbutaline 37-48 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 20-26 20550-3 1977 The beta2-adrenergic agonists salbutamol, terbutalin, and fenoterol were considerably less effective than the naturally occurring catecholamines. Terbutaline 42-52 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 4-9 1031587-0 1976 [Functional study of the bronchodilator effect of a new beta-2-stimulant (terbutaline) administered subcutaneously]. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 56-62 319711-3 1977 However, only the newer, selective beta-2 agonists, metaproterenol and terbutaline, produced significantly prolonged action upon small as well as large airways and lung volumes. Terbutaline 71-82 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 35-41 190674-2 1977 In this study it was shown that tremor caused by terbutaline could be blocked by propranolol, a drug with both beta1- and beta2-blocking properties, but not by metoprolol, a beta1-selective antagonist. Terbutaline 49-60 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 111-127 10035-9 1976 4 beta2-Adrenoceptor selective agonists salbutamol and terbutaline were more potent in the lung strip than the trachea, suggesting beta2-adrenoceptors predominated in the lung strip. Terbutaline 55-66 adrenoceptor beta 2 Felis catus 2-20 242278-3 1975 The response to adrenaline could be blocked by phentolamine, an alpha-inhibitor, while propranolol, a beta inhibitor, had no effect.--The response to terbutaline was blocked by atropine and partly by practolol, a beta-inhibitor. Terbutaline 150-161 amyloid beta precursor protein Homo sapiens 100-106 956557-2 1976 With chronic drug administration baseline (prior to daily medication) FEV increased 19% in the terbutaline group and 3.5% in the ephedrine group. Terbutaline 95-106 FEV transcription factor, ETS family member Homo sapiens 70-73 956557-3 1976 An additional increase of FEV above baseline of 23% for terbutaline and 12% for ephedrine was noted after daily medication. Terbutaline 56-67 FEV transcription factor, ETS family member Homo sapiens 26-29 239845-3 1975 IPNE and terbutaline induced formation of colloid droplets and increased BRI levels, whereas ITP was ineffective. Terbutaline 9-20 integral membrane protein 2B Mus musculus 73-76 810302-0 1975 Evaluation of a new beta2 adrenergic receptor stimulant, terbutaline, in bronchospasm. Terbutaline 57-68 adrenoceptor beta 2 Homo sapiens 20-45 242278-3 1975 The response to adrenaline could be blocked by phentolamine, an alpha-inhibitor, while propranolol, a beta inhibitor, had no effect.--The response to terbutaline was blocked by atropine and partly by practolol, a beta-inhibitor. Terbutaline 150-161 amyloid beta precursor protein Homo sapiens 211-217 4850180-0 1974 A comparison of the beta 1 and beta 2 effects of subcutaneous isoprenaline, sulbutamol and terbutaline in adult man. Terbutaline 91-102 potassium calcium-activated channel subfamily M regulatory beta subunit 1 Homo sapiens 20-37 239414-0 1975 Evaluation of a new oral beta2-adrenoceptor stimulant bronchodilator, terbutaline. Terbutaline 70-81 adrenoceptor beta 2 Homo sapiens 25-43 1198087-2 1975 During the run-in period, as well as during the practolol period, a long-acting beta2-stimulator, terbutaline, was given in the dose of 5 mg three times daily. Terbutaline 98-109 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 80-85 1221951-0 1975 [Study of the ventilatory and cardiocirculatory effects of a new adrenergic beta-2-stimulant (terbutaline) in subjects affected by obstructive bronchial disease]. Terbutaline 94-105 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 76-82 33181580-2 2021 The aim of this study was to test if the beta2-agonist terbutaline relieves painful polyneuropathy. Terbutaline 55-66 ATPase H+ transporting V0 subunit a2 Homo sapiens 41-46 33181580-9 2021 Median score for total pain changed from NRS 6.4 to 6.1 from baseline to week 5 on terbutaline with an average effect during the treatment period as compared to placebo of 0.13 (95% CI -0.12;0.38, p = 0.32). Terbutaline 83-94 sphingolipid transporter 1 (putative) Homo sapiens 41-44 32429330-7 2020 Globally, selective beta2 adrenergic receptor agonist terbutaline decreased the innate response of monocytes from lean and obese sedentary animals, whereas exercise stimulated it. Terbutaline 54-65 adrenergic receptor, beta 2 Mus musculus 20-45 33132694-1 2020 Introduction: Salbutamol and terbutaline are short-acting beta2 adrenergic agonists that produce bronchial smooth muscle relaxation and are widely used in obstructive pulmonary diseases. Terbutaline 29-40 ATPase H+ transporting V0 subunit a2 Homo sapiens 58-63 33132694-11 2020 Conclusion: Salbutamol and terbutaline are generally well-tolerated beta2 adrenergic agonists. Terbutaline 27-38 ATPase H+ transporting V0 subunit a2 Homo sapiens 68-73 32147828-4 2020 In particular, the complex between TB enantiomers and alpha-CD was of the external type, whereas an inclusion complex was formed between TB enantiomers and beta-CD. Terbutaline 35-37 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 54-62 32147828-4 2020 In particular, the complex between TB enantiomers and alpha-CD was of the external type, whereas an inclusion complex was formed between TB enantiomers and beta-CD. Terbutaline 137-139 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 156-163 32147828-5 2020 One of the possible structures of the complex between TB and heptakis(2,3-di-O-acetyl)-beta-CD (HDA-beta-CD) was quite similar to that of TB and beta-CD, although the chiral recognition pattern and enantioselectivity of TB complexation with these two CDs were very different. Terbutaline 54-56 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 87-94 32147828-5 2020 One of the possible structures of the complex between TB and heptakis(2,3-di-O-acetyl)-beta-CD (HDA-beta-CD) was quite similar to that of TB and beta-CD, although the chiral recognition pattern and enantioselectivity of TB complexation with these two CDs were very different. Terbutaline 54-56 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 100-107 32147828-5 2020 One of the possible structures of the complex between TB and heptakis(2,3-di-O-acetyl)-beta-CD (HDA-beta-CD) was quite similar to that of TB and beta-CD, although the chiral recognition pattern and enantioselectivity of TB complexation with these two CDs were very different. Terbutaline 54-56 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 100-107 32147828-5 2020 One of the possible structures of the complex between TB and heptakis(2,3-di-O-acetyl)-beta-CD (HDA-beta-CD) was quite similar to that of TB and beta-CD, although the chiral recognition pattern and enantioselectivity of TB complexation with these two CDs were very different. Terbutaline 138-140 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 87-94 32147828-5 2020 One of the possible structures of the complex between TB and heptakis(2,3-di-O-acetyl)-beta-CD (HDA-beta-CD) was quite similar to that of TB and beta-CD, although the chiral recognition pattern and enantioselectivity of TB complexation with these two CDs were very different. Terbutaline 138-140 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 87-94 33383241-7 2021 The association constants of salbutamol, terbutaline and bambuterol to beta2-AR were calculated to be 2.02 x 104 M-1, 1.15 x 104 M-1, 1.75 x 104 M-1 by adsorption energy distribution, which were in good line with the values from frontal analysis, zonal elution and previous literatures. Terbutaline 41-52 adenosine A2a receptor Homo sapiens 71-79 32592771-0 2020 The beta2-adrenoceptor agonist bronchodilators terbutaline and orciprenaline are also weak alpha1-adrenoceptor antagonists. Terbutaline 47-58 adrenergic receptor, beta 2 Mus musculus 4-22 32592771-1 2020 Recently, the beta2-adrenoceptor agonist terbutaline was shown to have alpha1-adrenolytic activity in mouse isolated pulmonary arteries in vitro and to lower pulmonary artery pressure in anaesthetised mice. Terbutaline 41-52 adrenergic receptor, beta 2 Mus musculus 14-32 32592771-8 2020 In conclusion, our work has provided additional quantitative evidence that terbutaline and orciprenaline are weak competitive alpha1-adrenoceptor antagonists, but this additional property is probably not therapeutically important in the clinical treatment of asthma or pulmonary artery hypertension with these more potent beta2-adrenoceptor agonists. Terbutaline 75-86 adrenoceptor beta 2 Rattus norvegicus 322-340 31666899-1 2019 This study aimed to investigate the effects of beta2-agonist terbutaline sulfate (TER) at a supra-therapeutic dose (8 mg) on aerobic exercise performance. Terbutaline 61-80 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 47-52 32170888-3 2020 Therefore, the goals of this study were to determine if forearm vasodilatation to the selective beta2 AR agonist terbutaline is blunted in older postmenopausal women (59 +- 4 years) compared to young premenopausal women (27 +- 3 years) and to assess NO contribution to beta2 AR-mediated vasodilatation in both groups of women. Terbutaline 113-124 adenosine A2a receptor Homo sapiens 96-104 32170888-3 2020 Therefore, the goals of this study were to determine if forearm vasodilatation to the selective beta2 AR agonist terbutaline is blunted in older postmenopausal women (59 +- 4 years) compared to young premenopausal women (27 +- 3 years) and to assess NO contribution to beta2 AR-mediated vasodilatation in both groups of women. Terbutaline 113-124 adenosine A2a receptor Homo sapiens 269-277 31442335-2 2019 Herein, we investigated beta2 -adrenergic-induced changes in V O2max , leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2 -adrenergic agonist terbutaline with and without concurrent resistance training in young men. Terbutaline 209-220 ATPase H+ transporting V0 subunit a2 Homo sapiens 24-29 31442335-2 2019 Herein, we investigated beta2 -adrenergic-induced changes in V O2max , leg and arm composition, and muscle content of oxidative enzymes in response to treatment with the selective beta2 -adrenergic agonist terbutaline with and without concurrent resistance training in young men. Terbutaline 209-220 ATPase H+ transporting V0 subunit a2 Homo sapiens 183-188 31442335-9 2019 Accordingly, chronic treatment with the selective beta2 -adrenergic agonist terbutaline may negatively affect V O2max and iPPO in relative terms, but not in absolute. Terbutaline 76-87 ATPase H+ transporting V0 subunit a2 Homo sapiens 50-55 31717554-6 2019 Selective beta2-AR agonist terbutaline (1 microM) decreased the phagocytic and microbicide activities of macrophages from control lean and obese sedentary animals. Terbutaline 27-38 adenosine A2a receptor Mus musculus 10-18 31832629-3 2020 In this work, a novel capillary electrophoresis method using the ionic liquid 3-methyl-1-(3-sulfopropyl)-1H-imidazol-3-ium lactobionate (MSI-LA) as a chiral selector was developed for the enantioseparation of propranolol, metoprolol, bisoprolol, esmolol, atenolol, sotalol, terbutaline and clenbuterol. Terbutaline 274-285 RB binding protein 4, chromatin remodeling factor Homo sapiens 137-140 31666899-1 2019 This study aimed to investigate the effects of beta2-agonist terbutaline sulfate (TER) at a supra-therapeutic dose (8 mg) on aerobic exercise performance. Terbutaline 82-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 47-52 30834155-5 2019 Showing that both long-acting agonist (formoterol) and short-acting agonist (terbutaline) inhibited the induction of MHC protein, whereas beta2-AR antagonist (ICI-118,551) upregulated MHC expression, we clearly demonstrated that beta2-AR is involved in L6 myoblast differentiation. Terbutaline 77-88 major histocompatibility complex, class I, C Homo sapiens 117-120 31234092-1 2019 Inhaled terbutaline is commercially available beta2-agonist which consists of equivalent amount of R- and S-enantiomer. Terbutaline 8-19 hemoglobin, beta adult minor chain Mus musculus 46-51 31234092-2 2019 In this study, we aimed to investigate the effects of single enantiomers of terbutaline and its racemate in an ovalbumin (OVA)-induced mouse model of asthma via. Terbutaline 76-87 serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene Mus musculus 111-120 31015039-0 2019 Contrasting photoreactivity of beta2-adrenoceptor agonists Salbutamol and Terbutaline in the presence of humic substances. Terbutaline 74-85 adrenoceptor beta 2 Homo sapiens 31-49 31371988-8 2019 In vitro, the activation of beta2-AR by terbutaline in M2-polarized macrophages elevated the proliferative, migratory and invasive attributes of HCC cells. Terbutaline 40-51 adrenoceptor beta 2 Homo sapiens 28-36 30285125-3 2019 Design: The study was a randomized, placebo-controlled crossover trial where 10 healthy men received either infusion of beta2-agonist terbutaline (0.2 to 0.4 mg) or placebo. Terbutaline 134-145 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 120-125 30644180-8 2019 The potential signal molecules cAMP, PKA, and CREB expressions were increased after terbutaline treatment. Terbutaline 84-95 cAMP responsive element binding protein 1 Rattus norvegicus 46-50 30644180-10 2019 Inhalation of the beta2-adrenergic receptor agonist terbutaline improved lung liquid clearance. Terbutaline 52-63 adrenoceptor beta 2 Rattus norvegicus 18-43 31069746-2 2019 This chapter describes how to separate the enantiomers of three basic substances selected as model compounds, i.e., alprenolol, bupranolol, and terbutaline, using the negatively charged heptakis(2,3-di-O-acetyl-6-O-sulfo)-beta-CD (HDAS-beta-CD). Terbutaline 144-155 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 222-229 31069746-2 2019 This chapter describes how to separate the enantiomers of three basic substances selected as model compounds, i.e., alprenolol, bupranolol, and terbutaline, using the negatively charged heptakis(2,3-di-O-acetyl-6-O-sulfo)-beta-CD (HDAS-beta-CD). Terbutaline 144-155 ACD shelterin complex subunit and telomerase recruitment factor Homo sapiens 236-243 29485127-12 2018 Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect. Terbutaline 31-42 adrenergic receptor, beta 2 Mus musculus 14-22 30125791-7 2018 Independent of group, DEX and GTS-21 dose-dependently inhibited TNF-alpha and IL-10 production, whereas TERB inhibited TNF-alpha and upregulated IL-10 production. Terbutaline 104-108 tumor necrosis factor Homo sapiens 119-128 30125791-7 2018 Independent of group, DEX and GTS-21 dose-dependently inhibited TNF-alpha and IL-10 production, whereas TERB inhibited TNF-alpha and upregulated IL-10 production. Terbutaline 104-108 interleukin 10 Homo sapiens 145-150 29777633-3 2018 We investigated whether inhaled beta2 -agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Terbutaline 48-59 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 32-37 29883116-3 2018 Using adsorption energy distribution (AED) calculations, we achieved the best adsorption models for the binding of salbutamol, terbutaline, and pseudoephedrine to immobilized beta2-AR. Terbutaline 127-138 adrenoceptor beta 2 Homo sapiens 175-183 29883116-4 2018 The Langmuir model proved to be desirable for describing the adsorptions of salbutamol and terbutaline on immobilized beta2-AR, while the bi-Langmuir model was favorable to characterize the adsorption of pseudoephedrine on the receptor. Terbutaline 91-102 adrenoceptor beta 2 Homo sapiens 118-126 29295855-0 2018 The beta2 agonist terbutaline specifically decreases pulmonary arterial pressure under normoxia and hypoxia via alpha adrenoceptor antagonism. Terbutaline 18-29 hemoglobin, beta adult minor chain Mus musculus 4-9 29295855-4 2018 We found that the beta2 adrenoceptor (AR) agonists terbutaline (TER) and salbutamol induced a dose-dependent vasorelaxation in large pulmonary arteries but not aortas of mouse. Terbutaline 51-62 adrenergic receptor, beta 2 Mus musculus 18-36 29295855-10 2018 Thus, beta2 AR agonists display alpha-adrenolytic activity in pulmonary arteries ex vivo and in vivo, and may provide a novel option to reduce pulmonary arterial pressure in pulmonary hypertension.-Neumann, V., Knies, R., Seidinger, A., Simon, A., Lorenz, K., Matthey, M., Breuer, J., Wenzel, D. The beta2 agonist terbutaline specifically decreases pulmonary arterial pressure under normoxia and hypoxia via alpha adrenoceptor antagonism. Terbutaline 314-325 adrenergic receptor, beta 2 Mus musculus 6-14 29295855-10 2018 Thus, beta2 AR agonists display alpha-adrenolytic activity in pulmonary arteries ex vivo and in vivo, and may provide a novel option to reduce pulmonary arterial pressure in pulmonary hypertension.-Neumann, V., Knies, R., Seidinger, A., Simon, A., Lorenz, K., Matthey, M., Breuer, J., Wenzel, D. The beta2 agonist terbutaline specifically decreases pulmonary arterial pressure under normoxia and hypoxia via alpha adrenoceptor antagonism. Terbutaline 314-325 hemoglobin, beta adult minor chain Mus musculus 6-11 29485127-12 2018 Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect. Terbutaline 31-42 CD4 antigen Mus musculus 72-75 29485127-12 2018 Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect. Terbutaline 44-48 adrenergic receptor, beta 2 Mus musculus 14-22 29485127-12 2018 Moreover, the beta2-AR agonist terbutaline (Terb) inhibited CIA-induced CD4+ T cell proliferation and shift towards Th17 phenotype, and the protein kinase A (PKA) inhibitor H-89 abolished the agonist effect. Terbutaline 44-48 CD4 antigen Mus musculus 72-75 28346464-8 2017 In the presence of terbutaline the lipolysis rate increased two fold until the effect of endogenous insulin (p<0.001). Terbutaline 19-30 insulin Homo sapiens 100-107 28719816-0 2017 Sulfate radical induced degradation of beta2-adrenoceptor agonists salbutamol and terbutaline: Phenoxyl radical dependent mechanisms. Terbutaline 82-93 adrenoceptor beta 2 Homo sapiens 39-57 28719816-1 2017 The present study investigated the reactivity and oxidation mechanisms of salbutamol (SAL) and terbutaline (TBL), two typical beta2-adrenoceptor agonists, towards sulfate radical (SO4-) by using photo-activated persulfate (PS). Terbutaline 95-106 adrenoceptor beta 2 Homo sapiens 126-144 28719816-1 2017 The present study investigated the reactivity and oxidation mechanisms of salbutamol (SAL) and terbutaline (TBL), two typical beta2-adrenoceptor agonists, towards sulfate radical (SO4-) by using photo-activated persulfate (PS). Terbutaline 108-111 adrenoceptor beta 2 Homo sapiens 126-144 27461883-0 2017 Terbutaline: level the playing field for inhaled beta2-agonists by introducing a dosing and urine threshold. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 49-54 27461883-1 2017 Terbutaline, a short-acting beta2-agonist similar to salbutamol, is widely used in Europe in the treatment of asthma and exercise-induced bronchoconstriction. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 28-33 27461883-4 2017 It is likely that the ergogenic effects of terbutaline are class specific for all beta2-agonists. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 82-87 30460079-3 2017 injections with dobutamine (beta1-adrenergic receptor agonist) or terbutaline (beta2-adrenergic receptor agonist) caused an elevation of the blood glucose level, whereas metoprolol (beta1-adrenergic receptor antagonist) or butoxamine (beta2-adrenergic receptor antagonist) did not. Terbutaline 66-77 adrenergic receptor, beta 2 Mus musculus 79-104 30460079-3 2017 injections with dobutamine (beta1-adrenergic receptor agonist) or terbutaline (beta2-adrenergic receptor agonist) caused an elevation of the blood glucose level, whereas metoprolol (beta1-adrenergic receptor antagonist) or butoxamine (beta2-adrenergic receptor antagonist) did not. Terbutaline 66-77 adrenergic receptor, beta 2 Mus musculus 235-260 28710773-0 2017 Reciprocal modulation of helper Th1 and Th17 cells by the beta2-adrenergic receptor agonist drug terbutaline. Terbutaline 97-108 negative elongation factor complex member C/D Homo sapiens 32-35 28710773-0 2017 Reciprocal modulation of helper Th1 and Th17 cells by the beta2-adrenergic receptor agonist drug terbutaline. Terbutaline 97-108 adrenoceptor beta 2 Homo sapiens 58-83 28710773-11 2017 TERB increased IL-17A from purified Th17 cells, which argues that TERB acts directly on Th17 cells. Terbutaline 0-4 interleukin 17A Homo sapiens 15-21 28710773-11 2017 TERB increased IL-17A from purified Th17 cells, which argues that TERB acts directly on Th17 cells. Terbutaline 66-70 interleukin 17A Homo sapiens 15-21 28162907-0 2017 beta2-receptor agonists salbutamol and terbutaline attenuated cytokine production by suppressing ERK pathway through cAMP in macrophages. Terbutaline 39-50 mitogen-activated protein kinase 1 Homo sapiens 97-100 28162907-7 2017 In conclusion, we suggest that beta2-receptor agonists salbutamol and terbutaline inhibit inflammatory gene expression partly by a mechanism dependent on cAMP leading to the inhibition of ERK signaling in macrophages. Terbutaline 70-81 mitogen-activated protein kinase 1 Homo sapiens 188-191 28346464-9 2017 A similar insulin-induced decrease in lipolysis was observed for each of the norfenefrine groups and the terbutaline groups, respectively. Terbutaline 105-116 insulin Homo sapiens 10-17 26197029-1 2016 PURPOSE: The aim of the present study was to investigate the effects of the beta2-agonist terbutaline (TER) on power output and muscle metabolism during maximal sprint cycling. Terbutaline 90-101 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 76-81 28137226-10 2017 Subcutaneous and intramuscular beta2 agonists such as terbutaline and epinephrine may be considered for children with severe asthma exacerbation who have poor air entry, are uncooperative with nebulized therapy, or have poor response to nebulized therapy. Terbutaline 54-65 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 31-36 27480802-1 2016 This study investigated the effect of the beta2 receptor agonist terbutaline on the single channel activity of BKCa channel. Terbutaline 65-76 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 42-47 27840124-7 2016 Furthermore, intrathecal treatment with a selective beta2-adrenergic receptor agonist, terbutaline, but not a selective beta1-adrenergic receptor agonist, dobutamine, also significantly ameliorated neuropathic pain. Terbutaline 87-98 adrenergic receptor, beta 2 Mus musculus 52-77 26849227-0 2016 Anti-Inflammatory Effects of beta2-Receptor Agonists Salbutamol and Terbutaline Are Mediated by MKP-1. Terbutaline 68-79 dual specificity phosphatase 1 Mus musculus 96-101 26849227-4 2016 We found that beta2-receptor agonists salbutamol and terbutaline, as well as 8-Br-cAMP, increased MKP-1 expression. Terbutaline 53-64 dual specificity phosphatase 1 Mus musculus 98-103 26849227-5 2016 Salbutamol and terbutaline also inhibited p38 MAPK phosphorylation and TNF production in J774 mouse macrophages. Terbutaline 15-26 mitogen-activated protein kinase 14 Mus musculus 42-45 26002106-3 2015 The results of the zonal elution showed that clorprenaline, clenbuterol, methoxyphenamine, salbutamol, terbutaline, tulobuterol and bambuterol have only one type of binding site on immobilised beta2-AR, while nonlinear chromatography confirmed the existence of at least two types of binding sites between beta2-AR and clorprenaline, clenbuterol and bambuterol. Terbutaline 103-114 adrenoceptor beta 2 Homo sapiens 193-201 26426856-9 2015 The beta2-adrenoceptor agonist terbutaline was sufficient to enhance the skin expression of TNF-alpha and IL-1beta and to increase 5-HT-induced scratching in naive rats. Terbutaline 31-42 adrenoceptor beta 2 Rattus norvegicus 4-22 26426856-9 2015 The beta2-adrenoceptor agonist terbutaline was sufficient to enhance the skin expression of TNF-alpha and IL-1beta and to increase 5-HT-induced scratching in naive rats. Terbutaline 31-42 tumor necrosis factor Rattus norvegicus 92-101 26426856-9 2015 The beta2-adrenoceptor agonist terbutaline was sufficient to enhance the skin expression of TNF-alpha and IL-1beta and to increase 5-HT-induced scratching in naive rats. Terbutaline 31-42 interleukin 1 beta Rattus norvegicus 106-114 26002106-3 2015 The results of the zonal elution showed that clorprenaline, clenbuterol, methoxyphenamine, salbutamol, terbutaline, tulobuterol and bambuterol have only one type of binding site on immobilised beta2-AR, while nonlinear chromatography confirmed the existence of at least two types of binding sites between beta2-AR and clorprenaline, clenbuterol and bambuterol. Terbutaline 103-114 adrenoceptor beta 2 Homo sapiens 305-313 25175747-5 2014 Specific uptake of cimetidine, acyclovir, metformin, and terbutaline was observed in human embryonic kidney 293 cells transfected with murine Oct1 or Oct2. Terbutaline 57-68 solute carrier family 22 (organic cation transporter), member 1 Mus musculus 142-146 26634602-2 2015 beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. Terbutaline 139-150 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-6 26634602-2 2015 beta;2-agonists can be broadly classified according to their duration of action: short-acting beta2-agonists (SABAs), including albuterol, terbutaline and fenoterol, have pharmacodynamics halflives between 2 and 6 h and long-acting beta2-agonists (LABAs), including salmeterol and formoterol, require twice daily treatment. Terbutaline 139-150 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 94-99 25240148-6 2014 Terbutaline suppressed T cell proliferation and IL-6 production and increased AOE activities involving ERK, PKA, PKC, and NF-kappaB pathways and NO production. Terbutaline 0-11 interleukin 6 Homo sapiens 48-52 25240148-6 2014 Terbutaline suppressed T cell proliferation and IL-6 production and increased AOE activities involving ERK, PKA, PKC, and NF-kappaB pathways and NO production. Terbutaline 0-11 mitogen-activated protein kinase 1 Homo sapiens 103-106 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 22-33 interleukin 6 Homo sapiens 96-100 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 22-33 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 113-118 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 22-33 cAMP responsive element binding protein 1 Homo sapiens 125-129 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 43-54 interleukin 6 Homo sapiens 96-100 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 43-54 eukaryotic translation initiation factor 2 alpha kinase 3 Homo sapiens 113-118 25240148-8 2014 E2 in the presence of terbutaline reversed terbutaline-induced effects on T cell proliferation, IL-6 production, p-ERK and p-CREB expression, AOE activities, NO production, and NF-kappaB expression. Terbutaline 43-54 cAMP responsive element binding protein 1 Homo sapiens 125-129 25739475-7 2015 Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, suggests that the effect of terbutaline is mediated by activation of beta2-adrenergic receptors. Terbutaline 97-108 adrenoceptor beta 2, surface b Danio rerio 19-44 24725067-0 2015 The beta2 -adrenoceptor agonist terbutaline recovers rat pharyngeal dilator muscle force decline during severe hypoxia. Terbutaline 32-43 adrenoceptor beta 2 Rattus norvegicus 4-23 24725067-4 2015 AIM: We tested the hypothesis that the beta(2) -adrenoceptor agonist terbutaline improves rat sternohyoid muscle performance especially during hypoxic stress. Terbutaline 69-80 adrenoceptor beta 2 Rattus norvegicus 39-60 24725067-9 2015 CONCLUSION: The beta(2) -adrenoceptor agonist terbutaline completely recovers hypoxic depression of upper airway muscle force. Terbutaline 46-57 adrenoceptor beta 2 Rattus norvegicus 16-37 25344552-6 2014 Non-fatigued MVCs were 6 +- 3 and 6 +- 2% higher (P < 0.05) with terbutaline than placebo in EXP1 and EXP2, respectively. Terbutaline 68-79 exportin 1 Homo sapiens 96-100 25344552-6 2014 Non-fatigued MVCs were 6 +- 3 and 6 +- 2% higher (P < 0.05) with terbutaline than placebo in EXP1 and EXP2, respectively. Terbutaline 68-79 chromosome segregation 1 like Homo sapiens 105-109 25161169-8 2014 The potency and the maximal effect of the beta2-adrenoceptor agonist terbutaline were lower in Pnmt-KO than in wild-type (WT) mice. Terbutaline 69-80 adrenergic receptor, beta 2 Mus musculus 42-60 25161169-8 2014 The potency and the maximal effect of the beta2-adrenoceptor agonist terbutaline were lower in Pnmt-KO than in wild-type (WT) mice. Terbutaline 69-80 phenylethanolamine-N-methyltransferase Mus musculus 95-99 25175747-5 2014 Specific uptake of cimetidine, acyclovir, metformin, and terbutaline was observed in human embryonic kidney 293 cells transfected with murine Oct1 or Oct2. Terbutaline 57-68 POU domain, class 2, transcription factor 2 Mus musculus 150-154 24633512-3 2014 Using His-tagged beta2-adrenoceptor (beta2-AR) as a probe, we developed a new mathematical model to elucidate the interactions between the receptor and five ligands (methoxyphenamine, terbutaline, salbutamol, tulobuterol and fenoterol). Terbutaline 184-195 adrenoceptor beta 2 Homo sapiens 17-35 25157248-6 2014 We report that in spleen, mesenteric (MLN) and draining lymph node (DLN) cells, TERB reduces proliferation, an effect independent of IL-2. Terbutaline 80-84 interleukin 2 Rattus norvegicus 133-137 25157248-10 2014 In MLN cells, TERB or PHEN lowers MLN cell secretion of TNF-alpha or IL-10, respectively. Terbutaline 14-18 tumor necrosis factor Rattus norvegicus 56-65 25157248-10 2014 In MLN cells, TERB or PHEN lowers MLN cell secretion of TNF-alpha or IL-10, respectively. Terbutaline 14-18 interleukin 10 Rattus norvegicus 69-74 24780318-2 2014 We investigated whether an antioxidant (tocopherol) can reduce the effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 77-88 adrenoceptor beta 2 Rattus norvegicus 92-118 24780318-2 2014 We investigated whether an antioxidant (tocopherol) can reduce the effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 77-88 adrenoceptor beta 2 Rattus norvegicus 120-128 24341818-4 2014 This review found that administration of beta2-agonist bronchodilators via dry powder inhalers (formoterol, salbutamol, terbutaline and budesonide/formoterol) was effective during severe asthma worsening and acute asthma attacks, and was as effective as established therapies with a pressurized metered-dose inhaler with or without a spacer, or nebulization. Terbutaline 120-131 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 41-46 24361988-11 2014 Direct stimulation of beta2 adrenoceptors appears sufficient to relieve allodynia, as shown with chronic terbutaline treatment. Terbutaline 105-116 hemoglobin, beta adult minor chain Mus musculus 22-27 23899894-3 2014 This study explored central and peripheral neuromuscular adjustments of the quadriceps induced by beta2-agonist terbutaline after fatiguing exercise. Terbutaline 112-123 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 98-103 25470978-2 2014 We investigated whether an antioxidant (limonene) can reduce the beta-mimetic effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 88-99 adrenoceptor beta 2 Rattus norvegicus 103-129 25470978-2 2014 We investigated whether an antioxidant (limonene) can reduce the beta-mimetic effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 88-99 adrenoceptor beta 2 Rattus norvegicus 131-139 25508605-2 2014 We investigated whether an antioxidant (limonene) can reduce the beta-mimetic effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 88-99 adrenoceptor beta 2 Rattus norvegicus 103-129 25508605-2 2014 We investigated whether an antioxidant (limonene) can reduce the beta-mimetic effect of terbutaline in beta-2-adrenergic receptor (beta2-AR)-regulated smooth muscles. Terbutaline 88-99 adrenoceptor beta 2 Rattus norvegicus 131-139 23505234-11 2014 alpha- And beta-adrenergic agonists show no influence on expression levels of IL-7R on activated B cells; however, intracellular IL-7R downstream signalling is abrogated via the beta2-adreonceptor (beta2AR) agonist terbutaline. Terbutaline 215-226 interleukin 7 receptor Homo sapiens 129-134 23505234-11 2014 alpha- And beta-adrenergic agonists show no influence on expression levels of IL-7R on activated B cells; however, intracellular IL-7R downstream signalling is abrogated via the beta2-adreonceptor (beta2AR) agonist terbutaline. Terbutaline 215-226 adrenoceptor beta 2 Homo sapiens 178-196 23505234-11 2014 alpha- And beta-adrenergic agonists show no influence on expression levels of IL-7R on activated B cells; however, intracellular IL-7R downstream signalling is abrogated via the beta2-adreonceptor (beta2AR) agonist terbutaline. Terbutaline 215-226 adrenoceptor beta 2 Homo sapiens 198-205 23978467-10 2013 This indirect anti-TNFalpha action was observed with the tricyclic antidepressant nortriptyline, the selective serotonin and noradrenaline reuptake inhibitor venlafaxine and the beta2-AR agonist terbutaline. Terbutaline 195-206 tumor necrosis factor Mus musculus 19-27 23978467-10 2013 This indirect anti-TNFalpha action was observed with the tricyclic antidepressant nortriptyline, the selective serotonin and noradrenaline reuptake inhibitor venlafaxine and the beta2-AR agonist terbutaline. Terbutaline 195-206 adrenergic receptor, beta 2 Mus musculus 178-186 23473506-4 2013 3 cm teico-CSP resulted to be effective for the on-line pre-concentration, before the separation, of acebutolol, alprenolol, nadolol, oxprenolol and terbutaline with limit of detection at levels of few ng/mL. Terbutaline 149-160 DnaJ heat shock protein family (Hsp40) member C5 Homo sapiens 11-14 24030662-2 2013 In animals, the short-acting beta2-agonist terbutaline has been shown to reduce dry airflow-induced bronchoconstriction and the associated shedding of airway epithelial cells. Terbutaline 43-54 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 29-34 24030662-9 2013 EVH caused an increase in urinary excretion of CC16 in both conditions (P < 0.001), and terbutaline significantly reduced this rise (pre- to postchallenge CC16 increase 416 +- 495 pg/mumol creatinine after placebo vs. 315 +- 523 pg/mumol creatinine after terbutaline, P = 0.016). Terbutaline 91-102 secretoglobin family 1A member 1 Homo sapiens 158-162 24088990-13 2013 Thus, AQP1 and AQP5 expression is differentially regulated following exposure to LPS, the beta2 adrenoreceptor agonist terbutaline, and cAMP. Terbutaline 119-130 aquaporin 1 (Colton blood group) Homo sapiens 6-10 24088990-13 2013 Thus, AQP1 and AQP5 expression is differentially regulated following exposure to LPS, the beta2 adrenoreceptor agonist terbutaline, and cAMP. Terbutaline 119-130 aquaporin 5 Homo sapiens 15-19 24088990-13 2013 Thus, AQP1 and AQP5 expression is differentially regulated following exposure to LPS, the beta2 adrenoreceptor agonist terbutaline, and cAMP. Terbutaline 119-130 adrenoceptor beta 2 Homo sapiens 90-110 23299764-3 2013 This study investigated central and peripheral neuromuscular adjustments induced by beta(2)-agonist terbutaline on a predominantly slow human muscle, the soleus. Terbutaline 100-111 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 84-90 24088990-0 2013 Aquaporin 1 and 5 expression evoked by the beta2 adrenoreceptor agonist terbutaline and lipopolysaccharide in mice and in the human monocytic cell line THP-1 is differentially regulated. Terbutaline 72-83 aquaporin 1 Mus musculus 0-17 24088990-0 2013 Aquaporin 1 and 5 expression evoked by the beta2 adrenoreceptor agonist terbutaline and lipopolysaccharide in mice and in the human monocytic cell line THP-1 is differentially regulated. Terbutaline 72-83 adrenergic receptor, beta 2 Mus musculus 43-63 24088990-4 2013 Furthermore, we tested the hypothesis that the beta2 adrenoreceptor agonist terbutaline or its downstream effector cyclic adenosine monophosphate (cAMP) mitigates LPS-evoked changes of AQP expression. Terbutaline 76-87 adrenoceptor beta 2 Homo sapiens 47-67 24088990-11 2013 Terbutaline increased AQP1 mRNA expression twice (P = 0.0005) but not AQP5 mRNA expression. Terbutaline 0-11 aquaporin 1 (Colton blood group) Homo sapiens 22-26 23718987-10 2013 Based on these in vitro results, we returned to animal testing and observed that the selective beta2-AR antagonist butoxamine reduced nociceptive sensitization in the CRPS model, and that local injection of the selective beta2-AR agonist terbutaline resulted in mechanical allodynia and the production of IL-6 in the cells of the skin. Terbutaline 238-249 adrenoceptor beta 2 Rattus norvegicus 221-229 23718987-10 2013 Based on these in vitro results, we returned to animal testing and observed that the selective beta2-AR antagonist butoxamine reduced nociceptive sensitization in the CRPS model, and that local injection of the selective beta2-AR agonist terbutaline resulted in mechanical allodynia and the production of IL-6 in the cells of the skin. Terbutaline 238-249 interleukin 6 Rattus norvegicus 305-309 23633340-16 2013 Withdrawals due to adverse events were more common in people treated with SiT (OR 2.85; 95% CI 1.89 to 4.30, moderate quality evidence due to risk of detection bias).Three studies including 4209 adults compared SiT with higher dose budesonide maintenance and terbutaline for symptom relief. Terbutaline 259-270 signaling threshold regulating transmembrane adaptor 1 Homo sapiens 74-77 23348973-4 2013 Traditional inhaled short-acting beta2-agonists albuterol, fenoterol, and terbutaline provide rapid as-needed symptom relief and short-term prophylactic protection against bronchoconstriction induced by exercise or other stimuli. Terbutaline 74-85 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 33-38 23539880-1 2013 Beta2-adrenergic agonist medications such as albuterol and terbutaline are often prescribed during pregnancy to treat conditions such as asthma, pulmonary disease, preterm labor, or acute non-reassuring fetal heart rate abnormalities during labor. Terbutaline 59-70 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 0-5 23548654-7 2013 Terbutaline is a beta-2 agonist available in oral dosage form. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 17-23 22817559-2 2012 One of these structurally related bronchodilators is terbutaline; it is administered as a prodrug, bambuterol, and is metabolized (bioconverted) into terbutaline by butyrylcholinesterase (BChE). Terbutaline 53-64 butyrylcholinesterase Homo sapiens 165-186 22813780-1 2013 Terbutaline, a beta2-adrenoceptor agonist, is used off-label for long-term management of preterm labor; such use is associated with increased risk of neurodevelopmental disorders, including autism spectrum disorders. Terbutaline 0-11 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 15-20 22813780-7 2013 Thus, terbutaline, operating through trophic interactions with beta2-adrenoceptors, impairs development of noradrenergic projections in a manner similar to that previously reported for its effects on the same neurotransmitter systems in the immature cerebellum. Terbutaline 6-17 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 63-68 22742717-6 2012 Increases in HR, CO, and SV with terbutaline were greater for those homozygous for the beta2 Glu27 allele than those with >=1 Gln27 allele (change in HR 13.7 vs 4.8 beats/min, p = 0.048; change in CO 3.1 vs 1.6 L/min, p = 0.034; change in SV 28.3 vs 14.8 ml, p = 0.045). Terbutaline 33-44 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 87-92 22842339-1 2012 BACKGROUND: Short-acting beta2-agonists like salbutamol and terbutaline are used as rescue medications for acute bronchoconstriction and relief of symptoms due to their rapid onset of action. Terbutaline 60-71 potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens 25-30 22817559-2 2012 One of these structurally related bronchodilators is terbutaline; it is administered as a prodrug, bambuterol, and is metabolized (bioconverted) into terbutaline by butyrylcholinesterase (BChE). Terbutaline 53-64 butyrylcholinesterase Homo sapiens 188-192 22817559-2 2012 One of these structurally related bronchodilators is terbutaline; it is administered as a prodrug, bambuterol, and is metabolized (bioconverted) into terbutaline by butyrylcholinesterase (BChE). Terbutaline 150-161 butyrylcholinesterase Homo sapiens 165-186 22817559-2 2012 One of these structurally related bronchodilators is terbutaline; it is administered as a prodrug, bambuterol, and is metabolized (bioconverted) into terbutaline by butyrylcholinesterase (BChE). Terbutaline 150-161 butyrylcholinesterase Homo sapiens 188-192